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 Abstract 
 
 System xc- (Sxc-) is a cellular antiporter that links the import of L-cystine with the 
export of L-glutamate. In the central nervous system (CNS), this export contributes to 
the ambient glutamate levels found in the synaptic cleft. To wit, a 50% reduction in 
extracellular glutamate has been demonstrated in animals null for the substrate-specific 
light chain, xCT. Moreover, in most tissues, including the CNS, cystine import through 
Sxc- is necessary for the synthesis and maintenance of glutathione (GSH) levels. Given 
that either a reduction in ambient glutamate levels and/or a redox imbalance involving 
GSH have been reported to affect synaptic strength and intrinsic neuronal excitability, 
the main focus of this dissertation was to elucidate whether Sxc- signaling contributes to 
brain excitatory/inhibitory (E/I) balance in vivo. Using chemoconvulsants to uncover 
excitability changes in SLC7A11sut/sut mice — mice that are null for Sxc- because of a 
spontaneous mutation in exon 12 of SLC7A11 — we uncovered a sex-independent 
alteration in neuronal excitability. Specifically, we found that both female and male 
SLC7A11sut/sut mice had lower convulsive seizure thresholds than their wild-type 
(SLC7A11+/+) littermates after acute challenge with two pharmacologically distinct 
chemoconvulsants: the glutamate receptor agonist, kainic acid (KA), or the GABAA 
receptor antagonist, pentylenetetrazole (PTZ). Paradoxically, after repeated 
repeated/chronic administration of the same chemoconvulsants, SLC7A11sut/sut mice 
exhibit signs of hypo-excitability, a response polar opposite to that which occurs in 
SLC7A11+/+ littermate controls. Whether the aberrant neuronal excitability in 
SLC7A11sut/sut mice occurred in association with alterations in brain morphology – at the 
gross, cellular, and sub-cellular level – or with alterations in redox balance or plasma 
 membrane protein expression levels, was also investigated. Overall, our data 
demonstrate that neuronal excitability in SLC7A11sut/sut mice provoked by 
chemoconvulsant challenge deviates from that of SLC7A11+/+ littermates in a complex 
manner that differs in sign depending on the chemoconvulsant dosing paradigm 
employed. Moreover, mutations in Sxc- trigger sex-dependent changes in redox status, 
brain morphology, and plasma membrane protein expression, any or all of which could 
contribute to the observed E/I imbalance in SLC7A11sut/sut mice. 
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Chapter 1: Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
1.1 Overview  
In several brain disorders including autism, stroke, and epilepsy an imbalance 
between the excitatory and inhibitory (E/I) neurotransmitter systems exists. 
Understanding fully the cellular and molecular processes that underlie normal, 
physiological synaptic transmission is the first step in determining how such aberrations 
might be countered to provide affected individuals with E/I imbalance symptomatic 
relief. This dissertation focuses on the role of the cystine/glutamate antiporter System 
xc- (Sxc-) ─ which exports glutamate and imports cystine, the latter of which is the rate-
limiting substrate for the synthesis of the thiol antioxidant glutathione ─ in maintenance 
of E/I balance. 
 
1.2 The cystine/glutamate antiporter System xc- (Sxc-) 
Sxc- was first described in 1980 by Bannai and Kitamura who demonstrated that 
the Na+-independent uptake of cystine into cultured human diploid fibroblasts was 
inhibited by glutamate (and vice versa) (Bannai & Kitamura 1980). Sxc- is an amino acid 
antiporter that imports L-cystine and exports L-glutamate in a Na+-independent, Cl--
dependent, 1:1 stoichiometric ratio (Bannai 1986, Bannai & Kitamura 1980). 
Cystine/glutamate exchange is electroneutral, with transport limited to the anionic form 
of these amino acids. The direction of exchange is determined by the substrate 
concentration gradient and is independent of membrane potential (Bannai 1986). 
Though Sxc- is capable of transporting either amino acid in either direction, rapid 
kinetics of excitatory amino acid transport (EAAT) systems and intracellular reductases 
maintain relatively low levels of extracellular glutamate and intracellular cystine, 
respectively, whereas intracellular glutamate levels are typically in the millimolar range, 
 3 
conferring the aforementioned directionality of transport (Bannai & Kitamura 1980, Hertz 
et al 1988).  
 
1.2.1 Sxc- structure  
Identification of Sxc- by expression cloning revealed it is a heteromeric amino 
acid transporter (HAT) and therefore composed of a light chain and a heavy chain 
covalently linked through a disulfide bridge (Sato et al 1999). The light (catalytic) chains 
of HATs, also known as glycoprotein-associated amino acid transporters (gpaATs), are 
members of the solute carrier 7 (SLC7) family and confer their substrate specificity 
(Verrey et al 2004). HAT light chains must associate with a glycoprotein heavy chain of 
the SLC3 family in order to allow for surface expression (Verrey et al 2004). With 
respect to Sxc- the gpaAT light chain is xCT, encoded by the solute carrier gene 
SLC7A11, and the heavy chain is 4f2hc (4f2 cell-surface antigen heavy chain, also 
known as cluster of differentiation 98 [CD98]), encoded by SLC3A2 (Bassi et al 2001, 
Sato et al 1999). While xCT is specific to Sxc-, 4f2hc forms a heterodimer with at least 
five other gpaAT light chains within the HAT family (Verrey et al 2004).  
In humans, the SLC7A11 gene is located on chromosome 4q28-31, producing a 
40 kDa protein of a predicted 501 amino acids (Bassi et al 2001). The encoded xCT 
protein shares 93-96% similarity and 89% identity to mouse xCT protein, which is a 
predicted 502 amino acids (Bassi et al 2001, Sato et al 1999). The mouse SL7A11 gene 
maps on chromosome 3 (Lane 1988). As with other proteins of the HAT family, xCT has 
12 putative transmembrane domains and is thus highly hydrophobic (Gasol et al 2004). 
Both the N- and C-termini are intracellularly localized, and there is a reentrant loop 
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between transmembrane domains 2 and 3 (Gasol et al 2004). This reentrant loop is 
believed to be a site of substrate binding, as biotinylation of His110 at the apex of loops 2 
and 3 does not occur in the presence of cystine, glutamate, or the non-transportable 
Sxc- inhibitor, (s)-4-carboxyphenylglycine (4-CPG) (Gasol et al 2004). Another potential 
substrate binding site is near Cys327 in the middle of the eighth transmembrane domain; 
in a study by Jimenez-Vidal and colleagues, the authors proposed a scenario whereby 
small side-chains at this position are permissive to substrate binding and translocation 
whereas bulky amino acids inflict steric hindrance to transporter activity (Jiménez-Vidal 
et al 2004). More recently, precrystallization screening of xCT bacterial orthologs and 
subsequent identification of a representative amino acid, polyamine, and organocation 
(APC) transporter revealed greater insight into HAT structure (Shaffer et al 2009). 
Further substrate permeation residues were identified including human xCT residue 
Arg135, suggested to be a binding-site of the substrate’s g-carboxylate entity (Shaffer et 
al 2009). Using the crystal structure of this APC transporter, Bridges et al proposed a 
novel three-dimensional representation of xCT protein structure using protein threading 
of human xCT (Fig. 1.1) (Bridges et al 2012b). 
The SLC3A2 gene encoding the type II membrane glycoprotein 4f2hc is located 
on chromosome 11q12-13 in humans (chromosome 19 in mouse) and produces a »94 
kDa glycosylated protein (72 kDa unglycosylated) of approximately 526-529 amino 
acids in humans (Francke et al 1983, Lumadue et al 1987, Quackenbush et al 1987). 
This protein shares 75% amino acid identity with mouse 4f2hc, which has a predicted 
526 amino acids (Parmacek et al 1989). Mouse 4f2hc consists of a 428 amino acid  
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Figure 1.1 xCT homology model 
xCT homology model depicting xCT protein in its inwardly-facing Apo form as proposed 
by Bridges et al 2012. The human xCT protein sequence was threaded over the crystal 
structure of a bacterial xCT homolog, ApcT (Shaffer et al 2009). Each helical ribbon 
represents a transmembrane domain of xCT, while the white thread demonstrates the 
ApcT structure. The truncated N and C termini are depicted by light pink and red 
spheres, respectively. Yellow spheres depict the conserved cysteine residue (Cys158), 
located between pore loops three and four of the xCT protein, that forms a bond with 
4f2hc. Adapted from (Bridges et al 2012b).  
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extracellular C-terminal domain, a 23 amino acid transmembrane domain, and a 75 
amino acid N-terminal cytoplasmic domain (Parmacek et al 1989). The bulky C-terminus 
is heavily glycosylated, with nine potential N-linked glycosylation sites in mouse and 
four such sites in human (Parmacek et al 1989). Northern blot analysis has revealed 
that 4f2hc is ubiquitously expressed in mouse, with highest levels of expression found in 
kidney, lung, spleen, testis, and brain (Parmacek et al 1989). It is involved in a diverse 
array of biological processes including integrin signaling, cell adhesion, and cell 
activation and proliferation (Bron et al 1986, Fenczik et al 1997, Nguyen et al 2008). 
The latter role is supported by evidence that its expression is induced upon fibroblast 
activation and maintained at high expression levels throughout the cell cycle (Parmacek 
et al 1989). Given that 4f2hc is abundantly expressed throughout the body, Sxc- 
transport activity is tied to the expression and availability of the light-chain subunit xCT 
(Verrey et al 2004).  
  Multiple studies have confirmed that xCT forms a disulfide bridge with 4f2hc at a 
single, conserved cysteine residue (Cys158) located between pore loops three and four 
of the xCT protein (Bassi et al 2001, Bridges et al 2012b, Sato et al 1999). Experiments 
using cysteine-to-serine mutagenesis or reducing agents with 4f2hc/HAT dimers 
suggest that this light-chain residue interacts with Cys109 of 4f2hc (Estévez et al 1998, 
Torrents et al 1998). Intriguingly, the functional role of this covalent linkage remains 
elusive. This cys-cys interaction is not required to induce transporter activity in at least 
one other HAT; cysteine-to-serine mutagenesis at the disulfide bridge in LAT1, an 
aromatic and branched-chain amino acid HAT, results in functional transport activity in 
both Xenopus oocytes and mammalian cells (Nakamura et al 1999, Wagner et al 2000). 
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Whether the same is true for the xCT/4f2hc disulfide bridge remains to be investigated. 
Furthermore, exactly how 4f2hc interacts with xCT is unknown, though it too may share 
similar characteristics with other HATs. In the case of LAT2, a neutral amino acid 
transporter, the 4f2hc ectodomain interacts with its extracellular loops, covering the 
extracellular surface of the light chain protein and increasing transporter stability (Rosell 
et al 2014).  
As mentioned previously, 4f2hc can interact with five other gpaAT light-chains at 
Cys109 besides xCT; LAT1 (SLC7A5) (Kanai et al 1998, Mastroberardino et al 1998), LAT2 
(SLC7A8) (Pineda et al 1999, Rossier et al 1999, Segawa et al 1999), system asc1 (small 
neutral amino acid transporter, SLC7A10) (Fukasawa et al 2000), and the cationic amino 
acid transporters y+LAT1 (SLC7A7) and y+LAT2 (SLC7A6) (Pfeiffer et al 1999, Torrents et 
al 1998) [for detailed reviews see (Palacín et al 2005, Verrey et al 2004)]. All 4f2hc-
associated light-chains require the heavy chain to translocate to the plasma cell 
membrane and induce transporter activity. With respect to Sxc-, this was demonstrated 
in Xenopus oocytes whereby co-injection of xCT and 4f2hc cRNA induced transport of 
L-glutamate and L-cystine and resulted in expression of xCT at the oocyte plasma 
membrane (Bassi et al 2001, Sato et al 1999). In contrast, injection of xCT or 4f2hc 
alone did not induce transport activity, with the former scenario resulting in intracellular 
retention of xCT (Bassi et al 2001, Sato et al 1999). Induction of cystine/glutamate 
exchange can also be induced by co-injection of mouse, but not human, cRNA for xCT 
and rBAT, a heavy chain with significant homology to 4f2hc (Bassi et al 2001, Wang et 
al 2003). Whether xCT associates with rBAT in vivo has yet to be ascertained.  
 
 8 
1.2.2 Sxc- expression  
Expression of xCT mRNA and protein have been detected throughout the body 
suggesting that Sxc- plays a role in maintaining cellular health in a variety of biological 
processes. Northern blot and quantitative polymerase chain reaction (PCR) analyses 
have revealed widespread xCT mRNA expression in the pancreas, intestine, ovary, 
spleen, and stomach (Bassi et al 2001, Dave et al 2004). Using an xCT specific 
antibody confirmed by xCT siRNA knockdown in HT22 cells, Burdo and colleagues also 
demonstrated xCT protein expression in kidney (Burdo et al 2006).  
Within the mouse central nervous system (CNS), in situ hybridization studies 
have revealed xCT mRNA expression at the brain/cerebral spinal fluid (CSF) borders 
including the cerebral ventricles, meninges, and circumventricular organs such as the 
area postrema and subfornical organ (Sato et al 2002). Furthermore, robust expression 
of xCT mRNA was found in most major brain regions including in the cerebral cortex, 
putamen, and medulla, with xCT protein detected in cortex, hippocampus, and striatum 
(Sato et al 2002, Shih et al 2006). Weak xCT mRNA expression was found in the 
choroid plexus, thalamus, cerebellum, brainstem, and nucleus of the solitary tract, with 
no expression detected in mouse brain vasculature (Sato et al 2002). Interestingly, xCT 
protein is present in human brain vasculature, suggesting that cystine/glutamate 
exchange across the blood brain barrier may be species specific (Burdo et al 2006).  
Despite the scarcity of reliable antibodies against xCT protein – largely owing to 
its hydrophobicity bestowed by its 12 transmembrane domains – the cell-type specificity 
of xCT expression in the CNS is becoming increasingly better understood. While Sxc- is 
expressed in cultured microglia (Jackman et al 2010, Piani & Fontana 1994), neurons 
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(Burdo et al 2006, Dun et al 2006, Jackman et al 2010, Murphy et al 1990), and the 
HT22 neuronal cell line (Lewerenz et al 2003), there is a growing consensus that 
astrocytes are the primary cell types expressing Sxc- in the mature brain in vivo (Fig. 
1.2). Nearly 20 years ago, Pow and colleagues elucidated the cell-type specificity of Sxc- 
activity using an antibody against the xCT substrate inhibitor, a-aminoadipate, in rat 
brain slice (Pow 2001). Substrate accumulation occurred in glia – specifically Bergmann 
glia, radial glia, and astrocytes – and was conspicuously absent from neurons and 
oligodendrocytes (Pow 2001). Furthermore, rodent astrocytes in cell culture express 
xCT, as do human glioma cell lines (Bender et al 2000, Burdo et al 2006, Cho & Bannai 
1990, Gochenauer & Robinson 2001, Pow 2001, Ye & Sontheimer 1999), and 
transcriptome data from both human and mouse cortex indicates that xCT is enriched in 
astrocytes as compared to other parenchymal cells (Zhang et al 2014, Zhang et al 
2016b). More recently, Ottestad-Hansen and colleagues engineered an xCT specific 
antibody and determined that Sxc- is expressed throughout the adult mouse brain 
parenchyma in a subpopulation of astrocytes – but not any other cell type investigated 
including neurons, microglia, and oligodendrocytes (Ottestad-Hansen et al 2018). 
Confirming in situ studies, xCT labeling was found concentrated at the 
brain/blood/cerebral spinal fluid periphery, as well as in most major brain regions 
including cortex, thalamus, hypothalamus, striatum, and hippocampus – where labeling 
intensity was greatest in the molecular layer of the dentate gyrus and the stratum 
lacunosum moleculare (Ottestad-Hansen et al 2018). Finally, the concentration of xCT 
protein was estimated to be comparable to that of EAAT3 (0.013 mg/g hippocampal  
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Figure 1.2 Sxc- is predominantly localized to CNS astrocytes 
(A) An antibody against the xCT substrate inhibitor, a-aminoadipate, demonstrated that 
a-aminoadipate uptake occurred mainly in Muller glia cells (M) and was excluded from 
synaptic terminals in the outer (OPL) and inner (IPL) plexiform layers of rat retina. (B) 
Mouse cortical transcriptome data from the Barres lab indicates that astrocytes are the 
predominant cell types expressing SLC7A11 in mouse cortex (OPC: oligodendrocyte 
precursor cell; FPKM: Fragments Per Kilobase of transcript per Million mapped reads). 
(C) Ottestad-Hansen and colleagues observed that xCT expression (red) exclusively co-
localized with a subset of GFAP (green) expressing astrocytes in CA1 hippocampus 
(shown) and throughout the CNS (not shown).  Figures adapted from [A (Pow 2001), B 
(Zhang et al 2014), and C (Ottestad-Hansen et al 2018)].   
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tissue), suggesting that xCT abundance is sufficient to contribute to brain function 
(Holmseth et al 2012, Ottestad-Hansen et al 2018). 
 
1.2.3. Sxc- function 
1.2.3.1 Use of xCT null mice to characterize Sxc- function in vivo 
Insight into the in vivo contribution of Sxc- signaling has been possible due to the 
use of genetic xCT loss of function mouse models. Sato and colleagues genetically 
engineered the first global xCT knock-out (xCT-/-) mouse on the C57BL/6 background by 
removing the ATG start codon in exon 1 of SLC7A11 (Sato et al 2005). These mice lack 
glutamate-sensitive cystine uptake as well as xCT transcript and protein in all tissues 
examined, including in brain and thymus where constitutive expression is normally 
observed (McCullagh & Featherstone 2014, Sato et al 2005). xCT-/- mice, however, 
were healthy in appearance, fertile, and all of the major organs examined – including 
the kidney, pancreas, lung, liver, and brain – had no apparent abnormalities (Sato et al 
2005). A second xCT loss of function mouse was engineered by inducing an in-frame 
TGA stop codon in exon 10 of SLC7A11 in C57BL/6 mice using N-ethyl-N-nitrosourea 
(ENU) mutagenesis (Nabeyama et al 2010). Finally, a spontaneous mutation in 
SLC7A11 gave rise to the subtle gray (sut) mutant mice on the C3H/HeSnJ background, 
henceforth referred to as the SLC7A11sut/sut mice  (Chintala et al 2005). The 
SLC7A11sut/sut mice have a large deletion (481,280 base pairs) that extends from intron 
11 to exon 12 and into the SLC7A11 intergenic region neighboring the Pcdh18 gene, 
resulting in a new stop codon in exon 12’ (Chintala et al 2005). Important for this 
dissertation, no xCT protein or transcript have been detected in the brains of 
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SLC7A11sut/sut mice (Chintala et al 2005, McCullagh & Featherstone 2014). These mice 
are fertile and healthy in appearance (Hewett lab unpublished observations). 
SLC7A11sut/sut mice have a subtle gray coat color, which is a result of decreased 
pheomelanin (red/yellow) pigment production due to reduced Sxc--mediated cystine 
import into melanocytes (Chintala et al 2005). Interestingly, Shih et al found that 
SLC7A11sut/sut mice exhibit gross brain atrophy by 13 weeks of age compared to wild-
type C3H/HeSnJ mice maintained on a separate, homozygous background as 
demonstrated by a reduction in hemisphere and striatal area, cortical thinning, and 
ventricular enlargement (Shih et al 2006). However, the observed neurodegeneration in 
this particular SLC7A11sut/sut sub-strain may be attributable to genetic drift from the 
authors wild-type colony as a result of maintaining homozygous colonies (Henderson 
1997, Masel 2011). Indeed, SLC7A11sut/sut mice derived from heterozygous breeding 
units do not exhibit gross brain atrophy when compared to wild-type littermate controls 
(Chapter 2), suggesting the phenotype reported by Shih et al is not exclusively due to 
loss of the SLC7A11 gene. 
  
1.2.3.2 Cellular cystine supplier 
Sxc--mediated cystine import is fundamental in maintaining the extracellular and 
intracellular redox balance as it provides the rate-limiting substrate (cysteine) for the 
biosynthesis of the thiol antioxidant glutathione (GSH; g-glutamylcysteinylglycine) (Sato 
et al 1998) and it facilitates the cysteine/cystine redox coupling across the cell plasma 
membrane (Banjac et al 2008). Once transported intracellularly, cystine is rapidly 
reduced into two cysteine molecules that can be incorporated in proteins, GSH, or 
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exported via the neutral alanine-serine-cysteine transporters (system ASC) in 
maintenance of the cystine/cysteine redox couple (Banjac et al 2008, Sato et al 1998). 
It should be noted that cells throughout the body can accumulate cyst(e)ine via 
several alternative mechanisms. De novo cysteine synthesis from methionine via the 
transsulfuration pathway represents a mechanism by which cells can obtain cysteine, 
and evidence suggests this pathway may be particularly active in supplying cysteine for 
GSH synthesis under conditions of oxidative stress or when Sxc- transport is limited 
(McBean 2012). In addition, several cystine transporters are expressed throughout the 
body, including system b0,+ and the aspartate/glutamate transporter 1 (AGT1), 
responsible for cystine reabsorption in the renal proximal tubules (Fernández et al 2002, 
Nagamori et al 2016). In the CNS, other known cysteine transporters include system 
XAG- transporters EAAT2 and EAAT3, expressed in astrocytes and/or neurons (Chen & 
Swanson 2003, Watts et al 2014), the ASC transporters 1 and 2, predominantly 
expressed in astrocytes (Fernández et al 2005, Fotiadis et al 2013, Nagamori et al 
2016), the aromatic preferring amino acid transporter (ArpAT) (Fernández et al 2005), 
the system A Na+-coupled neutral amino acid transporters 1 and 2 (SNAT1 and SNAT2) 
(Mackenzie & Erickson 2004), and the neurotransmitter transporter 4 (NTT4) (Zaia & 
Reimer 2009).  
Despite the prevalence of cyst(e)ine transporters, GSH synthesis in CNS 
astrocytes is tightly linked to Sxc--mediated cystine import. In fact, in their seminal 
characterization of Sxc--mediated cystine/glutamate exchange, Bannai and Kitamura 
demonstrated that approximately 15% of Sxc--mediated cystine import is incorporated 
into GSH within five minutes of transport (Bannai & Kitamura 1980). This is further 
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exemplified by evidence demonstrating enhanced Sxc- activity occurs in association with 
increases in GSH (Hosoya et al 2002, Sasaki et al 2002), and that inhibition of Sxc- 
diminishes intracellular GSH stores (Kato et al 1992, Sagara et al 1996).  
GSH synthesis takes places intracellularly in the cytosol in a two-step reaction 
(Fig. 1.3) (Meister 1974). In the first step, glutamate and the rate-limiting substrate 
cysteine are used to form the dipeptide g-glutamylcysteinyl in a reaction catalyzed by g-
glutamylcysteinyl synthetase (glutamate-cysteine ligase). In the second step, 
glutathione synthetase catalyzes the formation of g-glutamylcysteinylglycine (GSH) from 
g-glutamylcysteinyl and glycine; with the final product (GSH) capable of feedback 
inhibiting g-glutamylcysteinyl synthetase (step one) (Meister 1974, Richman & Meister 
1975).  In fulfillment of its role as an antioxidant, GSH either directly detoxifies radicals 
or serves as a cofactor for the antioxidant enzyme glutathione peroxidase in the 
reduction of peroxides (Chance et al 1979, Saez et al 1990, Winterbourn & Metodiewa 
1994). In either case, GSH oxidation results in a glutathione disulfide (GSSG) product, 
which itself is a substrate for glutathione reductase in a reaction that regenerates GSH 
[reviewed in (Dringen et al 2000)]. In this way, GSH molecules synthesized 
intracellularly and used for detoxification are recycled. Conversely, GSH molecules 
used as a substrate for intracellular glutathione-S-transferases (GST) lower the 
intracellular GSH concentration, as does GSH export [reviewed in (Dringen et al 2000)].  
In the CNS, increased astrocyte GSH production is intimately linked to decreased 
oxidative stress susceptibility in neurons (Gegg et al 2005). Interestingly, astrocytes 
export 10% of their GSH per hour (Minich et al 2006). Once extracellular, GSH may 
serve as a substrate for the ectoenzyme g-glutamyl transpeptidase (gGT) and its  
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Figure 1.3 GSH metabolism and transport 
Astrocyte Sxc- imports cystine (C-C) which, once intracellular, is rapidly reduced to 
cysteine (Cys). Glutamate-cysteine ligase (GCL; also known as γ-glutamylcysteinyl 
synthetase) catalyzes the formation of glutamate (Glu) and Cys to γ-glutamylcysteine 
(Cys-Glu). Glycine (Gly) is added to the dipeptide by GSH synthetase (GS) to form the 
tripeptide glutathione (GSH). Astrocytic export of GSH is facilitated through the 
multidrug resistance protein 1 (MRP-1) transporter. Once extracellular, GSH is cleaved 
by γ-glutamyltransferase (γ-GT) into cysteinylglycine (Cys-Gly). Aminopeptidase N (AP-
N) promotes further breakdown of cysteinylglycine into glycine and cysteine. Cysteine is 
taken up into neurons via EAATs (E), where it is metabolized into GSH. Alternatively, 
the extracellular oxidation of cysteine into cystine promotes Sxc--mediated uptake into 
astrocytes. Adapted from (Bridges et al 2012a). 
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product, cysteinylglycine (CysGly), can serve as a GSH precursor (Taniguchi & Ikeda 
1998). Neurons express an ectopeptidase of their own (aminopeptidase N) which allows 
them to utilize CysGly by taking up its constituent amino acids (cysteine and glycine) to 
be used for GSH synthesis intracellularly (Dringen et al 2001). Thus, astrocytic GSH 
production is not only used as a cell-autonomous thiol antioxidant, but its export confers 
protection to neurons as well. Apart from its role as an antioxidant, GSH is perhaps the 
most important cellular thiol that participates in signal transduction and regulates cellular 
metabolism and proliferation, gene expression, cytokine and growth factor production, 
and the function of proteins with redox-modification residues (Dringen 2000, Klatt & 
Lamas 2000, Poot et al 1995, Shih et al 2006, Stamler & Hausladen 1998).  
Since astrocytes derive the majority of their cystine from Sxc- transport, and 
cyst(e)ine is the rate-limiting substrate in the synthesis of GSH and forms a redox 
couple (cysteine/cystine) on its own, it follows that Sxc- is involved in maintaining redox 
balance in vivo. Indeed, male xCT-deficient mice on a C57BL/6 background have a 
plasma redox imbalance characterized by elevated CySS and decreased GSH levels as 
compared to wild-type control animals (Sato et al 2005). Intriguingly, male xCT null mice 
on this same background do not have a hippocampal or striatal redox imbalance as 
evidenced by lack of oxidative stress markers and similar GSH levels as compared to 
wild-type controls (De Bundel et al 2011, Massie et al 2011b).  Furthermore, the 
striatum of male xCT null mice have similar expression levels of oxidative stress-related 
markers HO-1, HNE, and NT as compared to wild-type controls following a 6-
hydroxydopamine (6-OHDA) injection (Massie et al 2011b). Whether a compensatory 
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expression of other cysteine transporters in xCT null mice explains their lack of brain 
redox imbalance is not known.  
 
1.2.3.3 Regulation of ambient extracellular glutamate levels  
Evidence from xCT null animals has demonstrated that Sxc--derived glutamate 
contributes to the extracellular glutamate pool that bathes the CNS in vivo. In male       
xCT-/- mice, extracellular glutamate levels are decreased by »40% in the hippocampus 
and »70% in the striatum as compared to wild-type C57BL/6 controls (De Bundel et al 
2011, Massie et al 2011b). Similarly, in male SLC7A11sut/sut mice, extracellular 
glutamate levels are decreased in the striatum by »50% as compared to wild-type 
C3H/HeSnJ mice (McCullagh & Featherstone 2014). Interestingly, extracellular 
glutamate levels in male SLC7A11sut/sut cerebellum are comparable to wild-type 
controls, suggesting that the contribution of Sxc- to ambient glutamate occurs in a brain 
region-dependent manner (McCullagh & Featherstone 2014). These findings are in line 
with results from the Danbolt lab showing relatively weak cerebellar xCT expression 
levels as compared to forebrain (Ottestad-Hansen et al 2018). Of note, the one study 
that investigated extracellular glutamate levels in both male and female Sxc- null mice 
found that male, but not female, SLC7A11sut/sut mice have decreased extracellular 
glutamate levels in the striatum as compared to wild-type sex-matched controls (Borra 
et al 2014). Interestingly, the authors did find a »70% decrease in striatal extracellular 
glutamate levels in wild-type females versus males, giving rise to the idea that there are 
sex-differences in glutamate physiology and perhaps, Sxc--mediated glutamate release 
(Borra et al 2014).    
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Regulation of ambient extracellular glutamate levels by Sxc- is conserved across 
species. In Drosophila, genetic disruption of the xCT homolog, genderblind, results in a 
»50% reduction in hemolymph glutamate levels (Augustin et al 2007, Piyankarage et al 
2008). Furthermore, reverse dialysis of the xCT pharmacological inhibitors homocysteic 
acid or (S)-4-carboxyphenylglycine (CPG) leads to a 60% decrease in extracellular 
glutamate levels in rat striatum (Baker et al 2002). 
The role of ambient glutamate appears to be multifaceted (section 1.3.3.2), and 
several mechanistic studies have shed light on whether Sxc--derived glutamate 
contributes to physiological neural transmission. In genderblind mutants, Augustin and 
colleagues demonstrated that a reduction in glutamate levels occurs in association with 
increased ionotropic glutamate receptor immunoreactivity and enhanced spontaneous 
excitatory junction current amplitudes at the neuromuscular junction (NMJ) (Augustin et 
al 2007). Moreover, bathing wild-type larval NMJs in abnormally low levels of glutamate 
was sufficient to phenocopy glutamate receptor expression levels in genderblind 
mutants (Augustin et al 2007). More recently, this same group confirmed Sxc--derived 
glutamate controls synaptic strength at the mouse hippocampal CA3-CA1 synapse by 
demonstrating that slices derived from male xCT-/- mice have enhanced AMPA receptor 
immunoreactivity and spontaneous and evoked excitatory postsynaptic currents 
(EPSCs) in  CA1 as compared to wild-type control slices (Williams & Featherstone 
2014). Similar to their studies in Drosophila, the authors phenocopied their xCT-/- 
electrophysiology findings by incubating wild-type slices in Glu-free artificial 
cerebrospinal fluid or by using the Sxc- inhibitor (S)-4-carboxyphenylglycine (4-CPG), 
providing evidence that glutamate released via Sxc- modulates synaptic strength 
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(Williams & Featherstone 2014). Finally, Sxc--derived glutamate negatively modulates 
release of synaptic glutamate and dopamine in the nucleus accumbens and striatum, 
respectively, by exerting glutamatergic tone on group II metabotropic glutamate 
receptors in male rats (Baker et al 2002, Moran et al 2005). Thus, evidence across 
multiple species suggests that Sxc--derived ambient glutamate contributes to the 
delicate balance between excitatory and inhibitory neurotransmission (E/I balance) that 
exists in the CNS.  
 
1.2.4 Role of Sxc- in CNS function  
While Sxc- signaling has been implicated in a number of disorders and disease 
states associated with a primary or secondary excitatory/inhibitory (E/I) imbalance 
including multiple sclerosis (Domercq et al 2007, Evonuk et al 2015, Pampliega et al 
2011), amyotrophic lateral sclerosis (Albano et al 2013, Mesci et al 2014), Huntington’s 
disease (Frederick et al 2014), Alzheimer’s disease (Barger & Basile 2001, Qin et al 
2006, Zhang et al 2016a), Parkinson’s disease (Bentea et al 2015b, Massie et al 2011b, 
Massie et al 2008), cerebral ischemia (Fogal et al 2007, Soria et al 2014), addiction 
(Baker et al 2003, Knackstedt et al 2010, Moran et al 2005), epilepsy (Lewerenz et al 
2014, Takaki et al 2008), and glioblastoma multiforme (Chung et al 2005, Takeuchi et al 
2012, Ye et al 1999, Ye & Sontheimer 1999) and its associated epileptiform activity 
(Buckingham et al 2011, Robert et al 2015), a growing body of evidence suggests that 
Sxc- may also contribute to physiological brain E/I balance. Behaviorally, male xCT-/- 
mice demonstrate decreased spatial working memory as determined by reduced 
alternations in the three-arm spontaneous alternation task compared to wild-type 
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controls, and similar deficits were found in male and female SLC7A11sut/sut mice (De 
Bundel et al 2011, McCullagh & Featherstone 2014). Furthermore, male SLC7A11sut/sut 
mice have impaired long-term memory in a hippocampal and amygdala-dependent fear 
conditioning task as well as in a hippocampal-dependent passive avoidance task (Li et 
al 2012). Given the memory deficits across several distinct tasks, it is perhaps 
unsurprising that long-term potentiation at the CA1-Schaeffer collateral synapse is also 
reduced in male SLC7A11sut/sut mice (Li et al 2012).  
In assays of anxiety, male xCT-/- mice have a decreased latency to eat in a 
novelty suppressed eating paradigm and spend an increased amount of time in an open 
field or in the lighted portion of a light/dark box as compared to wild-type littermates 
(Bentea et al 2015a). These results suggest that Sxc- increases behavioral anxiety. In 
addition, xCT-/- mice demonstrate increased climbing behavior and decreased 
immobility in the forced swim and tail suspension tests as compared to wild-type 
littermate controls, suggesting that xCT-/- mice have less behavioral despair as 
compared to wild-type controls (Bentea et al 2015a). Of note, motor activity and visual 
acuity is normal in xCT-/- and SLC7A11sut/sut mutants, suggesting that these are unlikely 
confounds in any of the aforementioned behavioral paradigms (Bentea et al 2015a, 
McCullagh & Featherstone 2014). 
Despite xCT-/- mice demonstrating enhanced spontaneous and evoked EPSCs at 
the hippocampal CA3-CA1 synapse (discussed above), De Bundel and colleagues have 
demonstrated that male xCT-/- mice have an apparent increase in seizure threshold 
upon acute stimulation with the chemoconvulsants kainic acid, NMDA, or pilocarpine 
(De Bundel et al 2011, Williams & Featherstone 2014). Specifically, male xCT-/- mice 
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require a higher dose of kainic acid or pilocarpine, delivered via intravenous infusion, to 
induce seizure activity as compared to wild-type controls (De Bundel et al 2011). 
Furthermore, xCT-/- mice have a decreased incidence of mortality and increased latency 
to convulsive seizure upon administration of a single intraperitoneal dose of NMDA as 
compared to wild-type mice (De Bundel et al 2011). The increase in seizure threshold in 
xCT-/- mice in vivo is in stark contrast to their enhanced excitability in ex vivo slice 
(Williams & Featherstone 2014), suggesting a complex regulation of E/I balance by Sxc- 
in vivo. Moreover, these results are also in contrast to findings reported in this 
dissertation demonstrating a sex-independent decrease in seizure threshold in 
SLC7A11sut/sut mice as compared to SLC7A11+/+ sex-matched littermate controls in 
response to an acute dose of two pharmacologically distinct chemoconvulsants, 
pentylenetetrazole (Chapter 2, Fig. 2.9) or kainic acid (Chapter 4, Fig. 4.1).  
 
1.3 Excitatory/inhibitory (E/I) balance in the brain 
Effective communication between cells in the CNS requires a balance between 
excitatory and inhibitory neural transmission. This balance is established during 
development and maintained throughout adulthood (Turrigiano & Nelson 2004). At the 
network level, the E/I balance refers to the innumerable inhibitory and excitatory 
neurons that together, maintain a stable circuit [reviewed in (Gao & Penzes 2015, 
Nelson & Valakh 2015)]. At the cellular level, E/I balance is influenced by the intrinsic 
membrane excitability and synaptic strength controlling the overall output – or firing 
probability – of a given neuron (Beck & Yaari 2008, Megıas et al 2001, Pratt & 
Aizenman 2007, Turrigiano et al 1998). Importantly, the physiological E/I balance 
 22 
provides a stable substrate upon which the information transfer underlying learning and 
memory formation can occur (Cannon 1932, Zhou & Yu 2018).   
Of particular interest to this dissertation is the balance between excitatory 
glutamatergic and inhibitory GABAergic neural transmission – including the synthesis, 
release, and uptake of these neurotransmitters, as well as the myriad receptors upon 
which they exert their influence. Functional alterations at excitatory or inhibitory 
synapses have been implicated in numerous neurodevelopmental disorders (Gao & 
Penzes 2015, Nelson & Valakh 2015) and disease states (Foerster et al 2013, Fritschy 
2008, Lai et al 2014, Ren et al 2018, Snyder et al 2005), and as such, understanding all 
factors that contribute to maintenance of E/I balance is integral in developing novel 
therapeutic targets to provide symptomatic relief. In this section, factors driving normal 
glutamatergic or GABAergic neural transmission, as well as modulators of E/I balance, 
including those influenced by Sxc- transport, are discussed. 
 
1.3.1 Inhibitory GABAergic neural transmission  
GABA (g-aminobutyric acid) is the major inhibitory neurotransmitter in the CNS. 
Originally classified as a glutamatergic neuromodulator, evidence demonstrating that it 
is present in large concentrations in the mammalian brain and that ionotophoretic 
application to cortex is sufficient to inhibit cell firing paved the way for its classification 
as an inhibitory neurotransmitter (Awapara et al 1950, Elliott 1965, Krnjević & Phillis 
1963, Krnjević & Whittaker 1965). Additionally, GABA signaling regulates proliferation of 
neural progenitors and neuronal development (Ge et al 2007, Platel et al 2010).  
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GABA synthesis and packaging: GABA is predominantly synthesized from 
glutamate via one of two molecularly distinct enzymes – glutamate decarboxylase 65 
(GAD65) or GAD67 – using pyridoxal 5’-phosphate as a cofactor. The subcellular 
distribution of the two GAD enzymes differs. GAD65 is primarily located in nerve 
terminals and thus produces GABA for neurotransmission (Martin & Rimvall 1993, 
Waagepetersen et al 1999). GAD67 is distributed uniformly throughout neurons and 
provides GABA to fulfill non-neurotransmitter roles such as redox regulation and 
developmental synaptogenesis (Lamigeon et al 2001, Martin & Rimvall 1993, 
Waagepetersen et al 1999). Approximately 50% of GAD exists in its inactive, 
apoenzyme form; this is thought to function as a reserve for when enhanced GABA 
synthesis is required (Itoh & Uchimura 1981, Miller et al 1980). Alternatively, GABA can 
be synthesized directly from glutamine derived from the Kreb’s cycle via 2-oxoglutarate 
and glutamate (Waagepetersen et al 1998, Westergaard et al 1995). Following its 
synthesis, GABA is transported into synaptic vesicles via vesicular GABA transporters 
(VGATs) in a process dependent on both the membrane potential and the proton 
gradient (Chaudhry et al 1998, McIntire et al 1997). Interestingly, glycine is a shared 
substrate for VGATs, and as such, glycine is co-released at certain GABAergic 
synapses (Wojcik et al 2006). 
GABA signaling: Upon depolarization of the GABAergic nerve terminal, a rise in 
intracellular calcium levels stimulates exocytosis of GABA-containing vesicles (Chen et 
al 2017). In the synaptic cleft, GABA can activate one of three major GABA receptors 
(GABARs): the ionotropic GABAAR and GABACR as well as the G-protein coupled 
metabotropic GABABR [for review see (Bormann 2000)].   
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The GABAAR and GABACR are pentameric ligand-gated ion channels that 
mediate the majority of fast synaptic inhibition [for review see (Bormann 2000)]. As the 
potassium/chloride (K+/Cl-) cotransporter (KCC2) maintains relatively low intracellular Cl- 
levels in mature neurons, GABA binding to either ionotropic receptor facilitates a Cl- 
influx and bicarbonate (HCO3-) efflux leading to a net hyperpolarization (Rivera et al 
1999). Each receptor is composed of five subunits: there are 18 GABAAR subunits (a1-
6, b1-4, g1-4, d, e, p, and q) and three GABACR subunits (r1-3) [(Bonnert et al 1999, 
Hedblom & Kirkness 1997) and reviewed in (Macdonald & Olsen 1994, Zhang et al 
2001)]. While GABAARs must contain at least three subunits (including an obligatory a 
and b subunit) and are expressed throughout the brain, GABACRs are only composed of 
r subunits and are predominantly expressed in the vertebrate retina (Bormann 2000, 
Bormann & Feigenspan 1995). Despite structural dissimilarities, both GABAA and 
GABAC receptors allow for Cl- influx upon ligand binding. However, GABACRs are more 
sensitive to GABA and have a smaller single channel conductance compared to 
GABAARs (major conductance state of 1–5 pS versus »30 pS) (Chang & Weiss 1999, 
Karim et al 2013, Wotring et al 1999, Zhang et al 2001). Pharmacologically, GABAARs 
are positively modulated by benzodiazepines and barbiturates via binding sites at their 
subunit interfaces (Chiara et al 2013, Macdonald & Olsen 1994, Pritchett et al 1989). 
Moreover, GABAARs are selectively inhibited by the competitive antagonist bicuculline 
(Andrews & Johnston 1979). In contrast, GABACRs are benzodiazepine, barbiturate, 
and bicuculline insensitive (Bormann & Feigenspan 1995).   
The GABABR is a G-protein coupled metabotropic receptor capable of 
modulating synaptic transmission through its intracellular effector systems (Padgett & 
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Slesinger 2010). Each receptor is a heterodimer consisting of a GABAB1 subunit – of 
which there are A and B isoforms – and a GABAB2 subunit [reviewed in (Heaney & 
Kinney 2016)]. GABABR activation results in a bicuculline-insensitive GABAergic current 
that is modulated by the GABABR selective agonist baclofen (Bowery et al 1979). 
Moreover, GABABR activation is negatively coupled to adenylate cyclase and therefore 
has an overall inhibitory effect, with presynaptic activation inhibiting neurotransmitter 
release and postsynaptic activation increasing the K+ conductance responsible for long-
lasting inhibitory postsynaptic potentials (IPSPs) (Kabashima et al 1997, Pérez-Garci et 
al 2006, Sakaba & Neher 2003).  
GABA uptake: GABA released into the synaptic cleft is cleared by GABA 
transporters expressed on both neurons and astrocytes. There are four known high-
affinity GABA transporters, all of which belong to the SLC6 family: GABA transporter 1-3 
(GAT1-3), and the betaine-GABA transporter (BGT1) (Guastella et al 1990, Liu et al 
1993, Lopez-Corcuera et al 1992, Radian et al 1986, Yamauchi et al 1992). All 
transporters are Na+ and Cl- coupled, with reported Km values of 8 µM (GAT1), 18 µM 
(GAT2), 0.8 µM (GAT3), and 80 µM (BGT1) (Liu et al 1993, Liu et al 1992, Lopez-
Corcuera et al 1992). In the CNS, GAT1 is localized to both neurons and astrocytes 
whereas GAT3 is selectively expressed in astrocytes (Minelli et al 1995, Minelli et al 
1996). In contrast, GAT2 and BGT1 are largely excluded from the brain, except for the 
encompassing leptomeninges and blood vessels, but are predominantly expressed in 
the kidney and liver (Zhou et al 2012, Zhou et al 2011). In the brain, GABA taken up by 
neurons can be directly packaged into vesicles for neurotransmission (Coulter & Eid 
2012, Eulenburg & Gomeza 2010). Alternatively, in a process known as the GABA 
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shunt, GABA taken up by neurons or astrocytes can replenish TCA cycle intermediates 
via its catabolism into succinate by GABA-transaminase (GABA-T) and succinic 
semialdehyde dehydrogenase (SSADH) (Bak et al 2006, Fonnum & Fyske 2000).  
 
1.3.2 Excitatory glutamatergic neural transmission 
Glutamate is the most abundant excitatory amino acid neurotransmitter in the 
vertebrate nervous system (Fonnum 1984, Ottersen & Storm-Mathisen 1984). The first 
evidence of its role as an excitatory neurotransmitter came from the seminal discovery 
that direct application of glutamate to neural tissue resulted in epileptic seizure activity 
(Hayashi 1952, Hayashi 1954, Okamoto 1951). Its presence in concentrations three- to 
four-fold greater than aspartate, glutamine, or taurine – the next three most abundant 
amino acids in brain – also provided suggestion that it had specialized functions apart 
from serving as an amino acid building block (McGeer et al 1978). Later work 
established that glutamate fulfills the criteria for classification as a neurotransmitter: it is 
localized to nerve terminals, it is released from a neuron upon stimulation, it is capable 
of activating its cognate receptors, direct application of glutamate mimics neuronal 
stimulation, and mechanisms exist to rapidly terminate its action (Fonnum 1984, 
Watkins & Evans 1981). In addition to its role as the major excitatory neurotransmitter in 
the brain, glutamate is a precursor for GABA and other various Krebs cycle 
intermediates and it is involved in the regulation of ammonia levels and osmotic balance 
(McGeer et al 1978, Roberts & Frankel 1950, Weil-Malherbe 1950). Furthermore, 
glutamate is involved in the synthesis of fatty acids, proteins, and peptides, including 
glutathione (Meister 1979). 
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Approximately 80-90% of neurons, and the same proportion of central synapses, 
are glutamatergic (Braitenberg & Schüz 2013, Ottersen & Storm-Mathisen 1984). Given 
its ubiquitous CNS localization, it is unsurprising that glutamate signaling is involved in a 
diverse array of brain functions including sensory transduction, motor coordination, and 
cognitive processes such as learning and memory [for review see (Hassel & Dingledine 
2012)]. However, high fidelity glutamatergic transmission requires a stable substrate – 
efficient glutamate release and uptake, as well as low ambient extracellular glutamate 
concentrations – and it follows that alterations in such are associated with neurological 
disorders and disease states. For example, hypo-glutamatergic signaling is implicated in 
the cognitive deficits associated with schizophrenia (Moghaddam & Javitt 2012). 
Moreover, excessive glutamate release and prolonged activation of its receptors can 
lead to seizures and neuronal cell death via excitotoxicity (Choi 1992, Nadler et al 1978, 
Olney 1969). Thus, it is essential that the release and uptake of glutamate be tightly 
regulated.  
Glutamate synthesis and packaging: Neurons synthesize glutamate via the 
hydrolysis of glutamine to glutamate and ammonia, catalyzed by the phosphate-
dependent mitochondrial enzyme glutaminase (Errera & Greenstein 1949baker, Laake 
et al 1999). Alternatively, glutamate can be rapidly transaminated from a-ketoglutarate, 
a key intermediate in the Kreb’s cycle, via the enzyme glutamate dehydrogenase (Peng 
et al 1993). Finally, glutamate can be directly transported from the extracellular space 
into neurons through Na+-dependent EAATs (Danbolt et al 2016). In its final form, 
glutamate is transported into synaptic vesicles via vesicular glutamate transporters, of 
which there are three mammalian isoforms (VGLUT1-3 encoded by the genes 
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SLC17A6-8), to a maximum glutamate concentration of approximately 70-210 mM per 
vesicle (Burger et al 1989, Omote et al 2011, Riveros et al 1986). Accumulation of 
glutamate via VGLUTs is chloride-dependent and driven by both the membrane 
potential and an electrochemical gradient of H+ ions established by the V-ATPase (Naito 
& Ueda 1985, Omote et al 2011).  
Glutamate release: Upon depolarization of nerve terminals, increasing 
intracellular calcium levels stimulate vesicular fusion with the presynaptic membrane, 
allowing for glutamate molecules to be released into the synaptic cleft (Fernandez-
Chacon et al 2001, Geppert et al 1994). Though vesicular-mediated neuronal glutamate 
release mediates the majority of fast excitatory neurotransmission, glutamate can also 
be released by neurons and/or astrocytes via several other mechanisms. In both cell 
types, calcium-independent glutamate release can occur via EAAT reversal, especially 
under pathological conditions such as cerebral ischemia wherein the Na+ and K+ 
gradients across the plasma cell membrane are reduced (Longuemare & Swanson 
1995, Nicholls & Attwell 1990, Szatkowski et al 1990). In an attempt to achieve volume 
homeostasis under hypo-osmotic conditions, neurons and astrocytes may release 
anions, including glutamate, through volume-regulation anion channels (VRACs) 
(Kimelberg et al 1990, Mongin & Orlov 2001). Additionally, astrocytic hemichannels – 
when left unopposed versus aligned with a hemichannel on a neighboring astrocyte to 
allow for intercellular gap junction-mediated transport – are independently functional 
and can efflux glutamate and other amino acids (Ye et al 2003). This mechanism of 
glutamate release may be functional under conditions of metabolic inhibition when 
hemichannels appear to open (Contreras et al 2002, John et al 1999), though some 
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evidence also indicates hemichannels are open physiologically (Bruzzone et al 2001, 
Kamermans et al 2001, Plotkin & Bellido 2001, Quist et al 2000). Furthermore, P2X7 
receptor-associated ion channels are capable of glutamate efflux upon ligand binding 
(Duan et al 2003). Moreover, calcium-dependent vesicular glutamate release from 
astrocytes has been demonstrated, and is supported by evidence that G-protein 
coupled receptor activation, and the ensuing rise in intracellular calcium levels, 
culminate in glutamate release (Bezzi et al 1998, Parpura et al 1994). This release 
mechanism is further substantiated by astrocytic expression of exocytotic machinery 
including cellubrevin, synaptobrevin II, syntaxin, vesicular soluble N-ethylmaleimide-
sensitive factor attachment protein receptors (SNAREs), and VGLUTs (Bezzi et al 2004, 
Parpura et al 1995, Schwarz et al 2017). However, opposing evidence indicates lack of 
metabotropic glutamate receptors in adult astrocytes suggesting that vesicular-mediated 
glutamate release may be a developmental phenomenon (Sun et al 2013). Moreover, 
astrocyte transcriptome analyses and more recent immunohistochemical data 
demonstrate a paucity of VGLUT expression (Barres 2008, Cahoy et al 2008, Li et al 
2013, Zhang et al 2014) and as such, whether this route of glutamate release exists in 
vivo is hotly debated (for dual perspective reviews see (Fiacco & McCarthy 2018, 
Savtchouk & Volterra 2018)). Finally, of particular interest to this dissertation, glutamate 
release occurs via Sxc--mediated cystine/glutamate exchange (Bannai & Kitamura 
1980). Route of release notwithstanding, once released into the synaptic cleft or 
extracellular space, glutamate binds to its cognate receptors and/or is taken up by 
EAATs.  
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Glutamate receptors: Two distinct classes of glutamate receptors exist within the 
CNS, ionotropic (iGluR) and metabotropic (mGluR) [for reviews see (Niswender & Conn 
2010, Traynelis et al 2010)]. Canonical iGluRs are integral membrane cation channels 
capable of mediating rapid synaptic transmission and can be further classified into three 
subtypes based upon structure and agonist pharmacology: a-amino-3-hydroxy-5-
methyl-4-isoxazole propionic acid receptors (AMPARs), kainic acid receptors (kainate, 
KARs), and N-methyl-D-aspartate receptors (NMDARs) [for review see (Traynelis et al 
2010)]. Glutamate delta receptors (d1 and d2) are a fourth iGluR subtype, which have 
been classified as such solely upon sequence homology as they are not gated by 
glutamate (Lomeli et al 1993, Yamazaki et al 1992). Instead, endogenous ligands for 
these receptors include D-serine and glycine (Naur et al 2007). The eight mGluR 
subtypes function as G-protein coupled receptors and can be broadly classified into 
three subcategories based upon sequence homology, pharmacology, and second 
messenger systems (Pin & Acher 2002).  
Tetrameric AMPARs are assembled using combinations of subunits GluA1-4, 
with forebrain receptors containing predominantly GluA1/GluA2 and GluA2/GluA3 
subunits (Craig et al 1993). Upon glutamate binding, the opening of the ion-channel 
pore allows for Na+ influx and K+ efflux, facilitating postsynaptic membrane 
depolarization with rapid onset and desensitization kinetics (Jones & Westbrook 1996). 
RNA editing of the GluA2 subunit (Q/R edit) is prevalent in the adult brain, and this 
feature bestows calcium-impermeability to the pore channel (Greger et al 2003). 
However, the presence of unedited GluA2 subunits and/or GluA2-lacking AMPARs 
allow for AMPA-mediated calcium influx; the latter receptors have been demonstrated to 
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play a role in plasticity, including in the stabilization of long-term potentiation (Plant et al 
2006, Yang et al 2010). AMPARs are enriched at glutamatergic synapses, and dendritic 
spine morphology correlates with the number of synaptic AMPARs (Kasai et al 2003, 
Matsuzaki et al 2001). Their dynamic trafficking to and from the postsynaptic 
membrane, often via lateral diffusion from extrasynaptic sites, are key determinants of 
synaptic strength (Lüscher et al 1999).  
KARs are tetrameric receptors composed of a combination of the subunits 
GluK1-5. These subunits have heterogeneous expression patterns and, although 
expressed throughout the CNS, predominant localization has been demonstrated in the 
hippocampus (GluK2, GluK3, GluK4, GluK5) and cerebellum (GluK1, GluK2, GluK5) 
(Porter et al 1997). In addition to agonist binding, KARs require external monovalent 
cations and anions at binding sites on the GluK1-5 subunits to allow for pore opening 
(Bowie 2002, Paternain et al 2003). Similar to AMPARs, Q/R editing within subunits 
GluK5-6 bestows calcium-impermeability (Köhler et al 1993, Sommer et al 1991). At the 
postsynaptic membrane, KAR activation enhances excitation, albeit via a slower and 
smaller excitatory postsynaptic current than AMPAR activation (Castillo et al 1997, 
Frerking et al 1998). Presynaptically, KAR activation induces depression of inhibition 
(Rodríguez-Moreno et al 1997, Sloviter & Damiano 1981), thought to occur via a 
noncanonical metabotropic route of KAR signaling (Rodríguez-Moreno & Lerma 1998). 
Moreover, presynaptic KAR activation can modulate glutamate release, with facilitation 
or depression of release at the mossy fiber-CA3 and CA3-CA1 hippocampal synapses 
dependent upon agonist concentration (Chittajallu et al 1996, Frerking et al 2001, 
Schmitz et al 2000).  
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NMDARs are distinct from the aforementioned iGluRs in that they exhibit high 
calcium permeability (in addition to fluxing Na+ and K+) and mediate the slow 
component of excitatory synaptic currents, thus allowing for temporal summation 
(Schiller & Schiller 2001). NMDARs function as coincidence detectors: channel opening 
is dependent upon the binding of glutamate and glycine along with membrane 
depolarization to relieve a voltage-dependent magnesium (Mg2+) block (Mayer et al 
1984). Much like AMPARs and KARs, the tetrameric assembly of GluN1, GluN2A-D, 
and/or GluN3A-B subunits dictates their physiology [reviewed in (Sanz-Clemente et al 
2013)]. GluN1 and GluN2 subunits are required for receptor function as they contain the 
glutamate and glycine binding sites, respectively, while receptors containing a GluN3 
subunit are calcium impermeable (Kew et al 2000, Laube et al 1997, Matsuda et al 
2002, Nishi et al 2001). Given their calcium conductance, NMDARs play a role in the 
expression of activity-dependent plasticity and multiple lines of evidence suggests that 
NMDAR trafficking contributes to both Hebbian (long-term potentiation and depression) 
and homeostatic forms of plasticity as well (Hunt & Castillo 2012, Pérez-Otaño & Ehlers 
2005).  
G-protein coupled mGluRs are classified into three groups based on agonist 
pharmacology and intracellular second messenger cascades [for reviews see 
(Niswender & Conn 2010, Pin & Acher 2002)]. Group I (mGluR 1 and mGluR5) 
receptors are coupled to phospholipase C and generally lead to increases in protein 
phosphorylation and activation of calcium binding proteins. Group II (mGluR2 and 
mGluR3) and III (mGluR4 and mGluR6-8) receptors are negatively coupled to adenylate 
cyclase, decreasing cAMP production and protein phosphorylation. In the CNS, the 
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physiological role of mGluR signaling is varied, ranging from positive and negative 
facilitation of presynaptic neurotransmitter release to inhibition of postsynaptic calcium 
channels (Pin & Acher 2002).  
Glutamate uptake: Extracellular glutamate is taken up by EAATs in an 
electrogenic process driven by the import of 3Na+ and 1H+ coupled to the export of 1K+ 
(Barbour et al 1991, Kanner & Schuldiner 1987, Levy et al 1998, Nicholls & Attwell 
1990, Zerangue & Kavanaugh 1996). Transport also occurs with an uncoupled Cl- 
gradient (Bergles et al 2002, Wadiche et al 1995). Rapid glutamate uptake by the 
EAATs is necessary to prevent overactivation of glutamate receptors and excitotoxic 
cell death. There are five mammalian EAAT transporters that differ in their cellular and 
regional distribution, all of which belong to the SLC1 (high affinity glutamate and neutral 
amino acid) family of transporters (Hediger et al 2013). Found throughout the brain are 
EAAT1 (GLAST) (Storck et al 1992, Tanaka 1993), localized exclusively on astrocytes 
(Lehre et al 1995), EAAT2 (GLT-1) (Danbolt et al 1990), localized predominately to 
astrocytes but also located on some neuronal axon terminals (Chen et al 2004, Furness 
et al 2008, Zhou et al 2018), and EAAT3 (EAAC1) (Bjørjås et al 1996, Kanai & Hediger 
1992), localized to neuronal somata and dendrites (Holmseth et al 2012, Rothstein et al 
1994).  EAAT4 is found primarily in cerebellar Purkinje cells (Fairman et al 1995, Itoh et 
al 1997), but also astrocytes (Hu et al 2003), whereas EAAT5 is restricted to retinal 
bipolar and photoreceptor neurons (Arriza et al 1997). Despite redundant functional 
activity among the EAATs, the vast majority (»95%) of extracellular glutamate uptake is 
performed by EAAT2 (Danbolt et al 1992, Haugeto et al 1996, Otis & Kavanaugh 2000). 
Indeed, genetic deletion of EAAT2 in mice results in spontaneous epileptiform activity 
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by three weeks of age (Tanaka et al 1997), and spontaneous electrographic seizures 
and increased mortality have been reported in astrocytic (but not neuronal) EAAT2 
conditional knock-out mice (Petr et al 2015). Once taken up into astrocytes, glutamate 
can be released via one of the aforementioned mechanisms, including Sxc-, or it can be 
incorporated into proteins, metabolized via the Kreb’s cycle, or converted to glutamine 
via the enzyme glutamine synthetase (Erecińska & Silver 1990, Krebs 1935). The 
transport of glutamine from astrocytes into neurons via sodium-coupled neutral amino 
acid transporters (SNATs) or other glutamine transporters is thought to provide the 
majority of glutamate precursor to neuronal terminals (Jenstad et al 2008, Mackenzie & 
Erickson 2004, Solbu et al 2010). Together, neuronal glutamate release, its astrocytic 
uptake and conversion to glutamine, and its subsequent transport to neurons for 
glutamate or GABA synthesis is referred to as the glutamine-glutamate (GABA) shuttle 
(Hertz 2013).   
 
1.3.3 Modulators of E/I Balance  
Other than fast inhibitory or excitatory synaptic transmission, a comprehensive 
understanding of mechanisms underlying brain E/I balance includes the effects exerted 
by neuromodulators. These include substances such as brain derived neurotrophic 
factor (BDNF) and adenosine, as well as a cell type of particular interest to this 
dissertation, astrocytes. Interestingly, astrocytes can release soluble factors, such as 
glypicans, tumor necrosis factor-a (TNFa), and secreted protein acidic and rich in 
cysteine (SPARC), that influence synaptogenesis and synaptic activity (Allen et al 2012, 
Jones et al 2011, Stellwagen & Malenka 2006). Moreover, the glutamate-glutamine 
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cycle, maintained by astrocytes, controls synaptic strength during period of intense 
neuronal activity (Tani et al 2014). Of interest to this dissertation is how the 
intracellular/extracellular redox environment and ambient extracellular glutamate levels 
– two parameters maintained in part by astrocytes and influenced by Sxc- signaling – 
contribute to E/I balance.  
 
1.3.3.1 Redox status 
Numerous lines of evidence suggest that redox status influences the E/I balance. 
For instance, a redox imbalance is associated with impaired neuronal synaptic plasticity 
(Almaguer-Melian et al 2000, Robillard et al 2011), with effects of such on seizure 
activity reported (Jiang et al 2000, Liang & Patel 2004). However, the exact mechanism 
by which redox signaling influences E/I balance is unclear, with reports of increased 
(Liang & Patel 2004) or decreased (Jiang et al 2000) seizure activity in mice under 
oxidative stress. Moreover, compounds with antioxidant properties (vitamin C, 
superoxide dismutase [SOD], melatonin, and N-acetylcysteine) have been 
demonstrated to reduce seizures and seizure-induced cell death in several animal 
models of epilepsy (MacGregor et al 1996, Rong et al 1999, Tan et al 1998, Zaeri 
2015). Interestingly, both glutamate transporters and the NMDAR possess redox-
sensing properties that regulate their activity (Aizenman et al 1989, Köhr et al 1994, 
Sullivan et al 1994, Trotti et al 1997), suggesting that a redox imbalance can modulate 
E/I balance through influencing glutamatergic neural transmission.  
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1.3.3.2 Ambient extracellular glutamate 
Despite the efficient glutamate uptake mechanisms described earlier, there is a 
pool of ambient extracellular glutamate that bathes the CNS in vivo. Estimates of the 
ambient extracellular glutamate concentration range from 25-90 nM as determined by 
electrophysiological measurement of tonic NMDAR activity in acute brain slices 
(Benveniste et al 1984, Cavelier & Attwell 2005, Herman & Jahr 2007, Meur et al 2007) 
to 0.2-35 µM as measured by in vivo microdialysis (Baker et al 2003, Dash et al 2009, 
De Bundel et al 2011, Massie et al 2011b). Some reports postulate that the discrepancy 
in ambient glutamate concentrations could reflect compartmentalization within distinct 
synaptic (nM) and extrasynaptic (µM) glutamate compartments (Baker et al 2002, 
Moussawi et al 2011). Another possibility for the discordant measurements in ambient 
glutamate is that in vivo microdialysis studies are typically performed in adult mice 
whereas acute slice experiments are performed using young rodents (postnatal day 11-
19), a point in development when glutamate transporters, including Sxc-, are not yet fully 
expressed (Kugler & Schleyer 2004, La Bella et al 2007). However, the two 
aforementioned theories were recently refuted by work demonstrating that ambient 
glutamate levels in acute brain slices are »25 nM throughout the brain in both young 
(postnatal day 15-22) and old (8-12 week old) rats, indicating a distinct lack of 
compartmentalization and age-related differences in rat (Chiu & Jahr 2017). Finally, 
micromolar glutamate levels as measured by in vivo microdialysis could be an artifact of 
tissue damage inflicted by the sampling probe, thus rendering the adjacent neuropil 
metabolically impaired (Sun et al 2014).  
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Despite conflicting reports over the precise concentration of extracellular 
glutamate, evidence suggests that ambient levels are sufficient to influence E/I balance. 
For instance, tonic activation of NMDARs by glutamate of non-vesicular origin (Ca2+-
independent, tetrodotoxin-insensitive) regulates the intrinsic excitability and 
synchronization of hippocampal pyramidal and granule cells (Angulo et al 2004, 
Cavelier & Attwell 2005, Dalby & Mody 2003, Jabaudon et al 1999, Meur et al 2007, 
Sah et al 1989). Moreover, tonic exposure to micromolar levels of glutamate has been 
demonstrated to cause steady-state glutamate receptor desensitization and 
suppression of synaptic strength (Augustin et al 2007, Williams & Featherstone 2014, 
Zorumski et al 1996). Other evidence points to a role for ambient glutamate in 
depolarization induced suppression of inhibition (DSI) of inhibitory interneurons through 
its activation of pyramidal cell mGluRs in the hippocampus (Varma et al 2001). Finally, a 
developmental role for ambient glutamate in E/I circuit formation has been suggested, 
with reports indicating it can regulate cellular differentiation and migration (LoTurco et al 
1991, LoTurco et al 1995, Manent et al 2005, Nguyen et al 2001).  
 
1.3.4 Use of chemoconvulsants to investigate E/I balance in vivo 
Experimentally, baseline E/I balance can be measured using brain slice or in vivo 
electrophysiological recordings. Alternatively, the use of pharmacological agents to 
stimulate or inhibit excitatory and/or inhibitory signaling can be used to uncover an E/I 
imbalance that may not be apparent physiologically. Pertinent to the studies performed 
in this dissertation, the chemoconvulsants pentylenetetrazole (PTZ) and kainic acid (KA) 
will be discussed. As potent chemoconvulsants, PTZ and KA are capable of eliciting 
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seizures, which is a brain state characterized by abnormally excessive or synchronous 
neuronal activity (Fisher et al 2005). The aberrant electrical activity induced by a seizure 
can be recorded via electroencephalography; it also manifests as behavioral motor 
changes ranging from immobility to generalized convulsive seizures involving clonic 
limb movements. Thus, by using frank motor seizures as a behavioral readout, 
chemoconvulsant-induced brain excitation is readily observable.    
 
1.3.4.1 Pentylenetetrazole (PTZ) 
PTZ was first characterized as an inhibitor of GABARs in 1978 (Macdonald & 
Barker 1978). Several years later,  radioligand studies determined its site of action to be 
at the picrotoxin binding site within the GABAAR channel pore (Ramanjaneyulu & Ticku 
1984, Squires et al 1984). A more recent report by Huang and colleagues indicated that 
PTZ and picrotoxin share common but not identical domains of action, as the PTZ 
antagonized-GABAAR current occurs exclusively through competitive inhibition whereas 
picrotoxin displays both non-competitive and competitive inhibition of GABAARs (Huang 
et al 2001). Following its synthesis in 1924, PTZ was initially used as a cardiovascular 
and respiratory stimulant (Haury 1939). In a line of investigation stemming from his 
postmortem neuropathological observations of decreased gliosis in schizophrenic tissue 
versus enhanced gliosis in epileptic tissue, Meduna began using PTZ in 1934 as a 
therapeutic treatment to induce epileptic activity in schizophrenic individuals in an 
attempt to stimulate gliosis (Meduna 1932, Meduna 1935). Eventually, PTZ was 
replaced with electroconvulsive therapy as the therapeutic stimulant of choice in mood 
disorders and schizophrenia (Bini 1938).  
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PTZ administration in laboratory animals is traditionally used to experimentally 
test the efficacy of anti-seizure drugs in response to seizure activity (Swinyard 1949). 
Alternatively, it can be used in rodents to explore their seizure threshold, or the innate 
balance between excitation and inhibition that influences seizure susceptibility 
(Steppuhn & Turski 1993). Finally, PTZ can be used as a chemical kindling agent to 
model epileptogenesis – which is the process by which a normal brain network develops 
spontaneous recurrent seizures (i.e. epilepsy) over time. The kindling phenomenon 
occurs via a gradual sensitization of neuronal circuitry to repeated application of a low 
intensity stimulus (Goddard 1967). A similar period of sensitization is thought to occur 
during the latent period of acquired epilepsies, which are a group of diseases 
characterized by spontaneous seizures resulting from an antecedent CNS injury and 
ensuing latent, seizure-free period (Braunwald et al 2001, Victor & Ropper 2002). Thus, 
kindling serves as a model of acquired epilepsies, and understanding the cellular and 
molecular mechanisms facilitating this period of sensitization is integral in developing 
therapeutic targets to thwart their progression  (Jensen 2009). Moreover, given that 
kindling induces synaptic changes over time it is, at its core, a plasticity model. In fact, 
kindling shares common mechanisms with long-term potentiation (LTP) (Cain 1989, 
Goddard & Douglas 1975) and as such, it can be used to study how E/I balance evolves 
during plastic sensitization of neuronal circuitry.   
Though strain differences exist with regards to seizure presentation, in general, 
within tens of seconds of receiving a systemic dose of PTZ rodents will socially isolate 
themselves, becoming distinctly hypomobile and unresponsive (Kosobud et al 1992). 
These seizures can evolve into myoclonic muscle jerks, indicative of increased 
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synchronous neuronal activity in the motor cortex. Depending on the dose of PTZ (sub-
convulsive vs. convulsive), seizure severity can further progress into a generalized 
convulsive episode involving forelimb and/or hindlimb clonus. This progression of 
seizure activity – from behavioral immobility and facial automatisms, to forelimb clonic 
movements and generalized convulsions –  was first characterized by Ronald Racine 
(Racine 1972). 
In the seminal kindling studies performed by Goddard, the stimulus was a sub-
convulsive threshold electrical current, delivered daily via depth electrodes implanted in 
rat amygdala (Goddard 1967). Several years later, several studies pioneered the use of 
PTZ as a chemical kindling agent (Ito et al 1977, Mason & Cooper 1972). In this model, 
a low dose of PTZ is administered daily via systemic injections. Over time, an initially 
sub-convulsant dose will evoke behavioral convulsions, at which point an animal is 
considered to be “kindled” (Dennison et al 1995, Wada et al 1974), an effect generally 
viewed as being permanent. It should be noted that the kindling phenomenon is not 
specific to rodents, rather, it has been demonstrated in every species tested, from frog 
to humans, where a similar seizure progression was observed in response to brain 
tumors (McNamara 1986, Morrell 1985).  
 
1.3.4.2 Kainic Acid (KA) 
The excitatory agent KA was first isolated by Murakami and colleagues from the 
red seaweed Digenea simplex (Murakami et al 1953). Soon after, it was found that 
microiontophoretic administration to cortical neurons resulted in prolonged spike 
discharges (Shinozaki 1978, Shinozaki & Konishi 1970), followed next by the 
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observation that parenteral KA delivery resulted in excitotoxic, depolarization-induced 
cell death (Olney et al 1974). In its seminal use as a chemoconvulsant, Lagowska and 
Ben-Ari discovered that KA administration in the amygdala produced prolonged, 
recurrent convulsive seizures (status epilepticus), heralding its use in epilepsy research 
(Ben-Ari & Lagowska 1978). Indeed, KA induces excitatory activity as it exhibits affinity 
for both AMPARs as well as its own cognate receptors, bindings to KARs containing the 
GluK1-2 and GluK5-7 subunits with high-affinity (Vincent & Mulle 2009). Within minutes 
of systemic KA administration, animals become immobile and/or hypermobile – 
including unilateral rotations and/or pacing – which can further progress to displays of 
myoclonic twitching, kyphotic rearing, and paw clonus associated with rearing [personal 
observations and (Ben-Ari 2012, McKhann II et al 2003)]. Depending on the dose, these 
seizures can evolve into generalized convulsions and “popcorn” like violent jumping that 
in some instances culminates in death [personal observations and (Ben-Ari 2012, 
McKhann II et al 2003)]. Following KA administration, early activation of the 
hippocampus and amygdala, two brain regions with a particularly low seizure threshold, 
is observed via EEG recording (Ben-Ari 2012). Postmortem analysis of KA-treated 
animals reveals extensive cell loss in hippocampal CA3, a region particularly vulnerable 
to KA-induced excitation, in part, due to a high density of KARs and excitatory recurrent 
collaterals that, once synchronous, propagate to other structures within the limbic 
system and brain (Ben-Ari 2012, Ben-Ari & Cossart 2000, Miles & Wong 1983, 
Robinson & Deadwyler 1981, Vincent & Mulle 2009, Westbrook & Lothman 1983). 
Finally, the KA-induced model of status epilepticus represents a model of acquired 
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epilepsy as animals can develop spontaneous seizures several weeks to months 
following the initiation of seizure activity (Ben-Ari 2012).  
 
1.3.5 Current need for understanding E/I balance  
An E/I imbalance has been implicated in numerous neurological disorders and 
disease states. For instance, dysfunction of GABAergic signaling, glutamatergic 
signaling, or both has been implicated in the etiology of autism spectrum disorders 
(ASD), anxiety, depression, intellectual disability, cerebral ischemia, traumatic brain 
injury, schizophrenia, and epilepsy (Coghlan et al 2012, Luscher & Fuchs 2015, 
Meldrum 1994, Moghaddam & Javitt 2012, Olsen & Avoli 1997). This is exemplified by 
ASDs and schizophrenia which, despite varied genetic etiologies, both present with 
similar E/I deficits including NMDAR hypofunction (Akbarian et al 1996, Blundell et al 
2010, Duffney et al 2013, Gao & Penzes 2015, Maliszewska-Cyna et al 2010, Morris et 
al 2005). In fact, an emerging hypothesis is that a shared pathophysiological E/I 
imbalance underlies similar social and cognitive behavioral phenotypes in ASD and 
schizophrenia (Gao & Penzes 2015). Furthermore, while dozens of disease associated 
genes have been implicated in epilepsy (Poduri & Lowenstein 2011), behavioral 
presentation of spontaneous seizures – the hallmark of epilepsy diseases – are thought 
to be a result of commonalities in GABAergic hypofunction and/or glutamatergic 
hyperfunction (Bradford 1995). Given the prevalence of disorders and disease states 
associated with an E/I imbalance, it is necessary to fully understand all cellular and 
molecular processes that underlie normal, physiological E/I transmission in order to 
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develop novel therapeutic options to provide individuals with an E/I imbalance 
symptomatic relief. 
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1.4 Specific Aims  
Numerous studies demonstrate that Sxc- is an important contributor to the 
ambient extracellular glutamate levels that bathe the central nervous system in vivo 
(Augustin et al 2007, Baker et al 2002, Bannai 1986, De Bundel et al 2011, Massie et al 
2011a, Melendez et al 2005). Moreover, Sxc--mediated cystine import provides cells 
with the rate-limiting substrate (cysteine) of the major cellular antioxidant glutathione; it 
also forms a redox couple on its own (Banjac et al 2008, Dringen 2000). Given that 
glutamate signaling and cellular redox status both influence neuronal excitability, the 
objective of this dissertation was to determine whether endogenous Sxc- signaling 
contributes to E/I balance in vivo and if so, to investigate the mechanism(s) underlying 
its contribution. 
 
1.4.1 Specific Aim 1 
Experiments were designed to determine whether Sxc- contributes to the E/I 
balance in vivo using the acute-PTZ seizure threshold test (Chapter 2). Female 
and male mice that harbor a spontaneous mutation in Sxc- (SLC7A11sut/sut mice) were 
used to assess the contribution of endogenous Sxc- signaling in acute seizures induced 
indirectly by disinhibition achieved via administration of the GABAA receptor antagonist 
PTZ. Moreover, experiments in this aim characterized naïve SLC7A11sut/sut mice by 
exploring the extent to which loss of Sxc- affected brain morphometry at the gross and 
cellular level.   
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1.4.2 Specific Aim 2 
Experiments were designed to determine whether Sxc- signaling affects synaptic 
plasticity assessed using the PTZ-kindling model of epileptogenesis (Chapter 3). 
Whether endogenous Sxc- signaling contributed to epileptogenesis was assessed by 
comparing PTZ-kindling acquisition between male SLC7A11sut/sut and SLC7A11+/+ 
littermates. Furthermore, experiments in this aim addressed whether observed changes 
in PTZ-kindling were associated with morphological changes implicated in 
epileptogenesis, with changes in brain redox status, and/or with changes in plasma 
membrane protein expression.  
 
1.4.3 Specific Aim 3 
Experiments were designed to determine whether Sxc- signaling regulates E/I 
balance using both the acute-KA seizure threshold test and the elevated KA 
dosing model of status epilepticus (Chapter 4). To explore whether results found in 
chapters two and/or three were model-dependent, this specific aim used a 
pharmacologically distinct chemoconvulsant, KA, to directly elicit excitation in vivo in two 
different dosing paradigms.  
Aim 3.1: Female and male SLC7A11sut/sut and SLC7A11+/+ littermates were used 
to assess the contribution of endogenous Sxc- signaling to acute seizures 
induced by KA. 
Aim 3.2: Whether endogenous Sxc- signaling contributed to the incidence of 
status epilepticus elicited using an elevated KA dosing paradigm was assessed 
using female and male SLC7A11sut/sut and SLC7A11+/+ littermates. Furthermore, 
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the contribution of endogenous Sxc- signaling to repeated KA dosing-induced cell 
death and KA-mediated changes in glutamate or GABA receptor plasma 
membrane protein expression levels was investigated.    
 
 
1.5 Significance  
A variety of neurological disorders and disease states are afflicted by an E/I 
imbalance (Section 1.3.5). In order to develop therapeutic targets for disease states 
resulting from an E/I imbalance, including epilepsy, we must first fully understand the 
cellular and molecular processes that underlie normal, physiological transmission. 
Towards this end, the results presented herein provide the first evidence that 
physiological Sxc- function maintains E/I balance in vivo in both female and male mice. 
Additionally, evidence is presented implicating Sxc- in epileptogenesis. As such, the 
work presented in this thesis may pave the way for the development of therapeutic 
targets to combat an E/I imbalance.   
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Chapter 2: Sex-dependent alterations in neuronal morphometry occur 
in association with altered E/I balance in system xc- null mice 
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2.1 Summary  
Despite evidence that the cystine/glutamate antiporter Sxc- contributes to ambient 
extracellular glutamate levels and redox status, its contribution to physiological brain 
function in vivo remains incompletely defined. As such, the present study investigated 
whether and how Sxc- contributes to morphological parameters implicated in E/I 
balance, as well as, whether it contributes to acute seizure activity elicited by the 
chemoconvulsant PTZ. Gross brain and cellular morphology were explored using 
thionin or Golgi-Cox staining, respectively, in female and male SLC7A11+/+ and 
SLC7A11sut/sut mice. Furthermore, littermate mice were administered an acute dose of 
PTZ (i.p.) and seizure severity was scored using a five-point behavioral scale. Our 
results demonstrate that loss of Sxc- signaling results in sex-dependent brain 
morphological alterations at the gross, cellular, and sub-cellular level. Specifically, 
female SLC7A11sut/sut mice have decreased corpus callosum thickness, soma size, and 
dendritic spine head widths as compared to SLC7A11+/+ sex-matched littermate 
controls. Conversely, male SLC7A11sut/sut mice have enhanced dendritic complexity and 
dendritic spine head widths as compared to SLC7A11+/+ sex-matched littermate 
controls. Interestingly, these sex-dependent morphological alterations occur in 
association with a sex-independent enhancement of neuronal excitability, exemplified 
by a decreased convulsive seizure threshold upon administration of an acute dose of 
PTZ. This study provides the first evidence that Sxc- signaling regulates brain 
morphology in a sex-dependent manner, and that loss of Sxc- disrupts E/I balance in the 
acute PTZ seizure threshold test.  
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2.2 Introduction  
System xc- (Sxc-) is an amino acid antiporter that couples the import of L-cystine 
(CySS) with the export of L-glutamate (Glu) with 1:1 stoichiometry (Bannai 1986, Bannai 
& Kitamura 1980). Sxc- is a heterodimer composed of a light chain (xCT, encoded by 
SLC7A11) that confers substrate specificity linked via a disulfide bridge to a heavy chain 
(4f2hc or CD98, encoded by SLC3A2) that traffics xCT to the plasma membrane (Bassi 
et al 2001, Sato et al 1999, Verrey et al 2004). Within the central nervous system 
(CNS), transcriptome and immunohistochemical analyses conclude that Sxc- is 
predominantly localized to astrocytes (Ottestad-Hansen et al 2018, Pow 2001, Zhang et 
al 2014).  
Evidence from xCT mutants indicates that Sxc--mediated glutamate release 
accounts for >50% of the ambient extracellular glutamate pool that bathes the CNS in 
vivo (Augustin et al 2007, De Bundel et al 2011). This pool of glutamate is largely 
regulated by glial transporters, and multiple studies suggest it plays a role in maintaining 
physiological excitatory/inhibitory (E/I) balance. For example, glial-derived ambient 
glutamate can modulate neuronal Kv2.1 channels, whose somatodendritic location and 
delayed-rectifier K+ current exert a strong influence on action potential initiation 
(Mulholland et al 2008, Murakoshi & Trimmer 1999). Moreover, tonic activation of 
NMDA receptors by ambient glutamate regulates the intrinsic excitability and 
synchronization of hippocampal pyramidal and granule cells (Angulo et al 2004, 
Cavelier et al 2005, Dalby & Mody 2003, Meur et al 2007, Sah et al 1989). Other 
evidence points to a role for ambient glutamate in depolarization induced suppression of 
inhibition (DSI) of inhibitory interneurons through its activation of pyramidal cell 
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metabotropic glutamate receptors (mGluRs) in the hippocampus (Varma et al 2001). 
Pertinently, studies performed in xCT mutants have demonstrated that genetic deletion 
of xCT results in increased (200-300%) postsynaptic glutamate receptors in Drosophila, 
and male transgenic xCT null mice have enhanced AMPA receptor surface expression 
and larger evoked and spontaneous EPSCs in ex vivo slice (Augustin et al 2007, 
Williams & Featherstone 2014). Although the magnitude of EPSCs is positively 
correlated with morphological parameters, such as dendritic complexity (Klenowski et al 
2016) and dendritic spine geometry (Matsuzaki et al 2001), whether mice null for Sxc- 
have cellular morphological alterations is not known.  
Sxc- also contributes to the intracellular/extracellular redox homeostasis; CySS 
import through Sxc- is necessary for the synthesis and maintenance of the cellular 
antioxidant glutathione (GSH) and contributes to the cysteine/cystine (Cys/CySS) redox 
cycle across the cell plasma membrane (Banjac et al 2008, Sato et al 2005). 
Interestingly, cellular redox status influences the E/I balance in part because glutamate 
receptors (NMDA) and transporters are susceptible to redox modification; disulfide 
reduction potentiates NMDA mediated currents and increases glutamate uptake 
whereas thiol oxidation does the opposite (Aizenman et al 1989, Köhr et al 1994, 
Sullivan et al 1994, Trotti et al 1997). Additionally, GSH participates in signal 
transduction and regulates gene expression, cellular metabolism, and cell proliferation 
(Lu 2009, Wu et al 2004). Moreover, GSH deficiency in excitatory amino acid 
transporter 3 (EAAT3/EAAC1) null mice (Aoyama et al 2006), as well as 
pharmacologically induced GSH deficiency in rats (Jain et al 1991), occurs in 
association with brain tissue atrophy, suggesting that decreased GSH levels induces 
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neurodegeneration. However, exactly how redox balance influences excitability in vivo 
appears to be complex; mice deficient in glutathione peroxidase, with elevated brain 
oxidative stress levels, display less seizure activity following KA administration whereas 
manganese superoxide dismutase (SOD+/-) mice with chronic mitochondrial oxidative 
stress have increased seizure severity (Jiang et al 2000, Liang & Patel 2004). 
Pertinently, male and female transgenic xCT null mice have elevated levels of plasma 
CySS (Sato et al 2005). However, male transgenic xCT null mice have normal levels of 
hippocampal GSH and are resistant to seizures elicited by intravenous infusion of three 
pharmacologically distinct chemoconvulsant – pilocarpine, NMDA, or KA (De Bundel et 
al 2011).  
Taking an in vivo approach, we investigated whether female and male Sxc- null 
(SLC7A11sut/sut; sut/sut) mice have alterations in brain excitability as compared to wild-
type littermate control mice. Given that changes in synaptic efficacy and redox balance 
are associated with changes in brain morphology, we investigated whether alterations in 
such occurred in SLC7A11sut/sut mice. Herein, we demonstrate that sex-dependent 
changes in neuronal morphology occur in association with a sex-independent increase 
in susceptibility to PTZ-evoked convulsive seizures in SLC7A11sut/sut mice. These 
results indicate that Sxc- signaling contributes to the endogenous network activity that 
maintains E/I balance in vivo. 
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2.3 Materials and Methods  
2.3.1 Animals 
Mice were bred and maintained in the AALAC accredited Laboratory Animal 
Resource facility of Syracuse University on a 12 hr light/dark schedule (7am/7pm). 
Standard mouse chow and water were provided ad libitum. Wild-type (SLC7A11+/+) and 
xCT mutant (SLC7A11sut/sut) littermates for studies were derived from heterozygous 
(SLC7A11+/sut) breeding units (F1) that were obtained by crossing SLC7A11sut/sut male 
mice [Jackson Laboratories (JAX) Stock #001310] with SLC7A11+/+ female C3H/HeSnJ 
mice (JAX, Stock #000661). F2 SLC7A11+/sut progeny were also used as breeding units 
for studies. Genotyping was performed via PCR analysis of tail genomic DNA samples: 
+/+ primers, 5'- GAA GTG CTC CGT GAA GAA GG -3' (forward), 5'- ATC TCA ATC 
CTG GGC AGA TG -3' (reverse); sut/sut primers, 5'- CCA CTG TTG TAG GTC AGC 
TTA GG -3’ (forward), 5'- CAG GAC CTG TGA ATA TGA TAG GG -3' (reverse). Mice 
were segregated by sex at weaning and SLC7A11+/+ and SLC7A11sut/sut housed two to 
four per cage. Experiments were carried out on female and male mice 8-12 weeks of 
age in accordance with the National Institutes of Health guidelines for the use of 
experimental animals as approved by the Institutional Animal Care and Use Committee 
of Syracuse University. These breeding and housing strategies were employed to 
control for environmental differences, genetic background influences, and genetic drift 
(Barnwell et al 2009, Pick & Little 1965). 
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2.3.2 Gross Brain Morphology Measurements 
Brains were harvested from naïve 12 week old SLC7A11+/+ and SLC7A11sut/sut 
littermates and snap-frozen on dry ice in Optimal Cutting Temperature (O.C.T) 
compound (Tissue-Tek, Torrance, CA). Frozen sections (coronal, 40 µm) were cut on a 
cryostat at 80 µm intervals, mounted on SuperFrost Plus slides (Fisher Scientific, 
Houston, TX), and thionin-stained as we previously describe (Chowdhury et al 2018). 
ImageJ Software (version 1.47v or 1.51n; National Institutes of Health, Bethesda, MD, 
RRID: SCR_003070) was used to make gross brain morphological measurements on 
scanned images (Epson 3170; 720 dpi) of slices at +1.1, -0.1, -0.94, -1.46, and -2.54 
mm relative to bregma  by three individuals blind to genotype. Mean cortical width was 
obtained by averaging six non-overlapping, straight tool measurements taken from the 
apex of the corpus callosum to the pial layer in the somatosensory cortex (3 each 
bilaterally). Mean corpus callosum width was obtained by averaging three non-
overlapping, straight tool measurements taken from the base to the apex of the corpus 
callosum at the midline.  Mean ventricular, striatal, hemispheric, and corpus callosum 
areas were determined by averaging user-defined pixel volumes using the free hand 
tool taken of the respective regions measured three times bilaterally (six in total) or 
three times total for structures decussating the midline (corpus callosum). In all cases, 
data are expressed as the mean ± SEM of measurements obtained from animals in the 
respective genotype derived from the mean calculated from three individual raters blind 
to experimental conditions.  
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2.3.3 Cellular Morphological Measurements  
2.3.3.1. Golgi-Cox Staining 
Brains from naïve SLC7A11+/+ and SLC7A11sut/sut littermates were Golgi-Cox 
stained using the FD Rapid Golgi Stain Kit (FD Neuro Technologies, Inc., Baltimore, 
MD) as per manufacturer’s instructions. Following removal from the cranium, brains 
were immediately rinsed in deionized (DI) water, placed in a proprietary impregnation 
solution (Solution A plus B) containing potassium dichromate, potassium chromate, and 
mercuric chloride, and stored at room temperature for 14 days in the dark. Brains were 
then transferred to a sucrose solution (Solution C) for 3 days followed by rapid freezing 
on dry ice. Frozen brain were cut serially (≈ +2.46 – -2.30 mm posterior to bregma) into 
140 µm coronal sections, mounted on gelatin-coated slides (FD Neuro Technologies, 
Inc., Baltimore, MD), air dried at room temperature for 2 days in the dark. Sections were 
Golgi-Cox stained as per manufacturer’s instructions (FD Rapid Golgi Stain Kit). Briefly, 
sections were initially rinsed 2x with DI water (4 min each) then placed in a solution 
containing silver nitrate (Solution D plus E) for 10 min. Slides were rinsed in DI water 2x 
for 4 min each followed by serial dehydration in absolute ethanol (50%, 75%, 95%, 
100%, 100%, 100%, 100%; 4 min each). Ethanol was cleared with xylene (3x for 4 min 
each), after which coverslips were mounted using Permount mounting media.   
2.3.3.2 Dendritic Morphology and Soma Area Analysis 
Photomicrographs of Golgi-Cox stained layer V pyramidal cells in the primary 
motor cortex (PM1) were obtained with a Nikon eclipse Ni-U upright microscope with 
motorized stage at 20x magnification. Neurons whose cell body and dendrites were 
completely impregnated and visible within the plane(s) of focus were selected for 
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analysis. Neurons were reconstructed with Adobe Illustrator. The complexity of dendritic 
arborization in reconstructed neuronal drawings was quantified (Image J) using Sholl 
analysis as described (Sholl 1953). Briefly, the number of dendrites intersecting 
concentric circles of a gradually increasing radius from the centroid of the soma were 
calculated. The soma cross-sectional area was quantified using the polygon tool in 
Image J. The number and length of primary, secondary, tertiary, apical, and basal 
dendrites were also determined using Neuron J. Experimenters blind to genotype 
performed the image acquisition and analyses. Six to 11 neurons from 3-5 
mice/genotype/sex were analyzed; data are expressed as the mean ± SEM of all 
measurements obtained.  
2.3.3.3 Spine Morphometric and Density Analysis: 
Photomicrographs of Golgi-Cox stained secondary apical dendrites on layer V 
pyramidal cells in the PM1 were obtained with a Nikon eclipse Ni-U upright microscope 
with motorized stage at 60x magnification. Neurons whose cell body and dendrites were 
completely impregnated and were visible within the plane(s) of focus were selected for 
analysis. Spine morphometric analysis was carried out as described (Risher et al 2014). 
In brief, Z-stack sections were analyzed using RECONSTRUCT software by measuring 
the length and head width of all protrusions (spines) along the dendritic segment of 
interest. The spine density was determined by calculating the number of protrusions/µm 
of dendrite. The length-to-width ratios (LWR) of individual spines were calculated in 
Microsoft Excel and used for hierarchical classification into the following categories: 
branched (entered manually by experimenter), filopodia (length > 2µm), mushroom 
(width > 0.6 µm), long thin (length > 1µm), thin (LWR > 1), and stubby (LWR ≤ 1). All 
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image acquisition and analyses were performed by experimenters blinded to genotype. 
Eight-nine neurons from three mice/genotype/sex were analyzed; data are expressed 
as the mean ± SEM of all measurements obtained. 
 
2.3.4 PTZ dosing paradigm  
Five days prior to each study, SLC7A11+/+ or SLC7A11sut/sut mice were 
acclimated to handling by performing mock daily intraperitoneal (i.p.) injections which 
consisted of inverting the mouse and rubbing its abdomen. Prior to each experiment, 
mice were brought into the procedure room, weighed, and allowed to acclimatize for at 
least one hour. PTZ (Sigma Chemical Co., St. Louis, MO) was dissolved in saline, filter 
sterilized, and administered i.p. in a volume of 10 ml/kg body weight. Mice were injected 
with a single dose of PTZ. Doses were chosen following initial dose ranging studies in 
female and male SLC7A11+/+ or SLC7A11sut/sut mice to determine the PTZ seizure 
threshold for each strain (Supplementary Fig. S1) (Kosobud et al 1992). Following each 
injection, mice were observed for acute behavioral seizures over the next 30 min. The 
time and severity of behavioral seizures (see Table 2.1 below) were scored and 
recorded for each mouse by an observer blinded to genotype to ensure unbiased 
scoring. The percentage of animals exhibiting convulsive seizures was determined by 
dividing the number of animals with a maximum seizure score of 3 or 4 by the total 
number of animals injected.  
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2.3.5 Statistical analysis 
All statistical analyses were performed using GraphPad Prism (Version 6.0.1, 
Graphpad Software, Inc., La Jolla, CA). Brain morphological parameters, including 
areas, lengths, and widths, were compared using two-way ANOVA. Prior to parametric 
analysis, count or percentage data were log (y = log(y)) or arcsine (y = 
arcsine[sqrt(y/100)] transformed, respectively. Seizure severity was compared using a 
Mann-Whitney U test, whereas proportions indicating the percent of mice convulsing 
were compared using a Fisher’s exact test. In all cases, significance was set at p < 
0.05.  
 
 
 
 
 
 
 
 
 
 
 
 58 
Table 2.1: Descriptive PTZ-induced Seizure Scoring System 
Seizure 
Score 
Abbreviated 
Description 
Detailed 
Description 
0 Normal behavior 
Frequent ambulation/exploration, sniffing, rearing, peer 
interactions, grooming, eating, digging, climbing are 
common. 
1 
Hypomobility 
and hypoactivity 
Mice will socially isolate self and disregard peers; body 
will be positioned close to bottom of cage. The overall 
behavioral picture will be dominated by bouts (>10 sec 
in duration) of staring and motionlessness that may be 
interrupted by brief sniffing or ambulation. 
2 
 
Repeated 
myoclonus 
 
Animal exhibits at least two isolated myoclonic 
seizures typically involving axial muscles, commonly 
seen as neck flexion. Straub tail (dorsiflexion) is also 
common, as is an increase in locomotor activity 
(compared to score 1). 
3 
 
Convulsive 
seizure with intact 
righting reflex 
Clonic seizures involve forelimbs and neck while the 
animal assumes an upright posture using hind limbs to 
support body weight. 
4 
 
Convulsive 
seizure with loss 
of righting reflex 
 
Clonic seizures involve both forelimbs and hind limbs 
preventing the maintenance of upright posture. 
Infrequently, these seizures can be associated with 
violent running and jumping episodes and tonic hind 
limb extension. 
Table adapted from descriptions in (Ferraro et al 1999, Pitkanen 2006, Racine 1972).  
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2.4 Results  
 
Gross morphometric analysis of SLC7A11+/+ and SLC7A11sut/sut mice 
Mice null for the neuronal cysteine uptake transporter EAAT3 (EAAC1) exhibit 
gross brain atrophy in association with decreased GSH levels (Aoyama et al 2006). 
Whether loss of the predominant cyst(e)ine supplier in astrocytes, Sxc-, similarly 
influences brain morphology was explored. Though quantification of female brain 
hemisphere area using coronal sections spanning +1.1 to -2.54 bregma revealed a 
slight decrease in overall brain size in SLC7A11sut/sut mice as compared SLC7A11+/+ 
sex-matched littermate controls, this effect was not statistically significant (Fig. 2.1B; p = 
0.2520; repeated measures two-way ANOVA). Similarly, SLC7A11sut/sut females showed 
a slight, but not significant, decrease in cortical area (Fig. 2.1C; p = 0.2472), striatal 
area (Fig. 2.1D; p = 0.5675), and corpus callosum area (Fig. 2.1F; p = 0.0739), while 
their lateral ventricle area was indistinguishable from SLC7A11+/+ littermates (Fig. 2.1E; 
p = 0.2941; repeated measures two-way ANOVA). However, a significant reduction in 
corpus callosum thickness was detected in SLC7A11sut/sut female as compared to 
SLC7A11+/+ littermates (Fig. 2.1G; p = 0.0399; repeated measures two-way ANOVA). 
Interestingly, these findings were sex-dependent, as male SLC7A11sut/sut mouse brains 
were virtually indistinguishable from their SLC7A11+/+ sex-matched littermate controls 
with respect to not only corpus callosum thickness, but also hemisphere area, cortical 
thickness, striatal area, lateral ventricle area, and corpus callosum area (Fig. 2.2). 
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Figure 2.1 Comparison of gross brain morphology between female SLC7A11+/+ 
and SLC7A11sut/sut mice 
Gross brain morphological measurements were made on thionin-stained coronal brain 
sections from 12 week old naïve female SLC7A11+/+ (+/+) (n = 4) and SLC7A11sut/sut 
(sut/sut) (n = 4) littermates. Sections of 40 μm thickness were imaged using an Epson 
Digital Scanner at 720 dpi. Digitized images were processed and quantified using NIH 
Image J software. 
A) Representative thionin-stained coronal sections spanning +1.1 to -2.54 anterior to 
posterior from bregma from +/+ and sut/sut mice derived from sut/+ breeders.  
B-E) Quantification of (B) hemispheric area, (C) cortical width, (D) striatal area, (E) lateral 
ventricle area, (F) corpus callosum area, and (G) corpus callosum width from +/+ and 
sut/sut mice was performed over 3-5 coronal sections as described in Materials and 
Methods. Data are expressed as the mean ± SEM width (mm) or area (mm2). No significant 
difference between +/+ and sut/sut mice was observed in hemispheric area (B; p = 0.2520), 
cortical thickness (C; p = 0.2472), striatal area (D; p = 0.5675), lateral ventricle area (E; p = 
0.2941), or corpus callosum area (F; p = 0.0739) as determined by repeated measures two-
way ANOVA. *Corpus callosum width is significantly decreased in sut/sut as compared to 
+/+ littermates (G; p = 0.0399, repeated measures two-way ANOVA). 
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Figure 2.2 Comparison of gross brain morphology between male SLC7A11+/+ and 
SLC7A11sut/sut mice 
Gross brain morphological measurements were made on thionin-stained coronal brain 
sections from 12 week old naïve male SLC7A11+/+ (+/+) (n = 7) and SLC7A11sut/sut 
(sut/sut) (n = 8) littermates. Sections of 40 μm thickness were imaged using an Epson 
Digital Scanner at 720 dpi. Digitized images were processed and quantified using NIH 
Image J software. 
A) Representative thionin-stained coronal sections spanning +1.1 to -2.54 anterior to 
posterior from bregma from +/+ and sut/sut mice derived from sut/+ breeders.  
B-E) Quantification of (B) hemispheric area, (C) cortical width, (D) striatal area, (E) 
lateral ventricle area, (F) corpus callosum area, and (G) corpus callosum width from +/+ 
and sut/sut mice was performed over 3-5 coronal sections as described in Materials and 
Methods. Data are expressed as the mean ± SEM width (mm) or area (mm2). No 
significant difference between +/+ and sut/sut mice was observed in hemispheric area 
(B; p = 0.3061), cortical thickness (C; p = 0.6010), striatal area (D; p = 0.7010), lateral 
ventricle area (E; p = 0.7990), corpus callosum area (F; p = 0.6587), or corpus callosum 
width (G; p = 0.6321) as determined using repeated measures two-way ANOVA. 
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Quantification of primary motor cortex layer V pyramidal cells in SLC7A11+/+ and 
SLC7A11sut/sut mice 
The dendritic tree complexity of cortical layer V excitatory pyramidal cells can 
influence their stereotypical repetitive spike bursting train firing pattern and thus E/I 
balance (Mainen & Sejnowski 1996). At the cellular level, the dendritic complexity of 
layer V neurons derived from the primary motor cortex of female SLC7A11sut/sut mice 
was indistinguishable from sex-matched SLC7A11+/+ controls (Fig. 2.3C; p = 0.8603; 
two-way ANOVA). Conversely, neurons derived from male SLC7A11sut/sut mice had 
enhanced dendritic complexity as compared to SLC7A11+/+ sex-matched littermates 
(Fig. 2.3C; p < 0.0001) and in fact, were indistinguishable from SLC7A11sut/sut female 
mice (Fig. 2.3C; p = 0.4185). Interestingly, a sex-difference was uncovered in that 
SLC7A11+/+ males had decreased dendritic complexity as compared to SLC7A11+/+ 
females (Fig. 2.3C; p < 0.0001) (two-way ANOVA). While this data indicates a clear sex 
difference with respect to dendritic complexity in female and male SLC7A11+/+ mice on 
the C3H/HeSnJ background, it also indicates that loss of Sxc- in male mice rendered 
dendritic complexity more “female-like” overall. 
Quantification of primary, secondary, and tertiary neurite numbers and length 
revealed further sex differences: while no within-sex genotype differences were 
observed, the number of tertiary neurites in SLC7A11sut/sut male mice was enhanced as 
compared to SLC7A11sut/sut females (Fig. 2.4A; p < 0.05; two-way ANOVA with 
Bonferroni’s multiple comparisons). Moreover, the length of both primary (Fig. 2.4C; p = 
0.0210) and secondary (Fig. 2.4C; p = 0.0014) neurites was enhanced in females 
versus males (two-way ANOVA), and further classification of primary, secondary, and  
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Figure 2.3 Comparison of dendritic complexity between SLC7A11+/+ and 
SLC7A11sut/sut mice 
Photomicrographs of Golgi-Cox stained primary motor cortex (PM1) layer V pyramidal 
cells from naïve SLC7A11+/+ [+/+, n = 64 neurons (39M, 25F) from 7 mice (4M, 3F)] and 
SLC7A11sut/sut [sut/sut, n = 82 neurons (43M, 39F) from 9 mice (5M, 4F)] littermates 
from eight separate litters were reconstructed using Adobe Illustrator as depicted by 
representative tracings from (A) females or (B) males.  
C) The complexity of dendritic arborization in these neurons was explored by Sholl 
analysis in females and males. Each data point represents the mean number of 
crossings ± SEM. *Neurons derived from sut/sut male mice have enhanced dendritic 
complexity compared to +/+ littermate controls (p < 0.0001; two-way ANOVA with 
Bonferroni’s multiple comparisons). #Male +/+ neuronal complexity is also significantly 
decreased as compared to +/+ females as denoted by the # sign (p < 0.0001). 
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Figure 2.4 Neurite number and length analysis in female and male SLC7A11+/+ and 
SLC7A11sut/sut mice 
Neurite processes on reconstructed neurons from Figure 2.3 were quantified by NIH 
Image J analysis.  
A-B) Bars [black bar (SLC7A11+/+; +/+) and open bar (SLC7A11sut/sut; sut/sut)] represent 
the mean ± SEM number of (A) primary, secondary, or tertiary or (B) apical or basal 
neurites. No significant within-sex genotype differences were observed in the number of 
neurites at any order (1°, 2°, or 3°) or polarity (apical or basal) quantified (two-way 
ANOVA). However, sut/sut males have an increased number of 3° neurites as 
compared to female sut/sut mice as denoted by the asterisk (p < 0.05, Two-way ANOVA 
with Bonferroni’s multiple comparisons on log transformed data).   
C-D) Bars [black bar (+/+) and open bar (sut/sut)] represent the mean ± SEM length of 
(C) primary, secondary, or tertiary or (D) apical or basal neurites. No significant within-
sex genotype differences were observed in the length of neurites at any order (1°, 2°, or 
3°) or polarity (apical or basal) quantified (two-way ANOVA). #Females have increased 
1° (p = 0.0210) and 2° (p = 0.0014) order as well as basal (p = 0.0067) neurite lengths 
as compared to males (two-way ANOVA with Bonferroni’s multiple comparisons).  
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tertiary neurite polarity into apical or basal revealed enhanced basal neurite length in 
females as compared to males (Fig. 2.4D; p = 0.0067; two-way ANOVA). 
Evaluation of the neuronal cell body revealed that the cross-sectional soma area 
was similar in neurons derived from male SLC7A11+/+ and SLC7A11sut/sut littermates. 
However, an 18% reduction in cross-sectional soma area was revealed in female 
SLC7A11sut/sut as compared to SLC7A11+/+ sex-matched littermate controls (Fig. 2.5; 
335.6 ± 14.18 µm2 for SLC7A11+/+ and 273.7 ± 10.98 µm2 for SLC7A11sut/sut mice, mean 
± SEM; p < 0.01; two-way ANOVA with Bonferroni’s multiple comparisons). Once more, 
sex-differences between SLC7A11+/+ male and SLC7A11+/+ female mice were observed 
(Fig. 2.5; p < 0.01; two-way ANOVA with Bonferroni’s multiple comparisons), and loss of 
Sxc- in female mice rendered their cross-sectional soma area more “male-like” given 
that they were indistinguishable from SLC7A11sut/sut male mice (Fig. 2.5; two-way 
ANOVA with Bonferroni’s multiple comparisons).  
 
Cortical layer V pyramidal cell dendritic spine analysis 
The majority of fast excitatory synaptic activity occurs at ionotropic glutamate 
receptors residing on dendritic spines. Moreover, the spine structure-function 
relationship has been well-characterized, with increases and decreases in spine head 
width correlating with increases and decreases in glutamate receptors and thus, 
strengthening and weakening of synaptic efficacy, respectively (Matsuzaki et al 2001, 
Noguchi et al 2005). Herein, the head width and length of spines were used for 
categorical classification to determine the proportion of nascent (filopodia, long thin), 
immature (thin), or mature (stubby, mushroom, branched) dendritic spines  
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Figure 2.5 Soma analysis in female and male SLC7A11+/+ and SLC7A11sut/sut mice 
The cross sectional soma area of reconstructed neurons from Figure 2.3 were 
quantified by NIH Image J analysis. Bars [black bar (+/+) and open bar (sut/sut)] 
represent the mean soma area ± SEM in females (left) or males (right). *Neurons 
derived from female sut/sut mice have a decreased soma area compared to +/+ sex-
matched littermate controls as denoted by the asterisk (p < 0.01); two-way ANOVA with 
Bonferroni’s multiple comparisons). #Female +/+ neurons are also significantly different 
from male +/+ neurons ( #p < 0.01).   
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Figure 2.6 Comparison of dendritic spine density and morphology between 
SLC7A11+/+ and SLC7A11sut/sut mice 
Golgi-Cox stained dendritic spines located on secondary apical dendrites of primary motor 
cortex layer V pyramidal cells from naïve SLC7A11+/+ [+/+, n = 18 neurons (9M, 9F) from 6 
mice (3M, 3F)] and SLC7A11sut/sut [sut/sut, n = 17 neurons (8M, 9F) from 6 mice (3M, 3F)] 
littermates from seven separate litters were analyzed using the Risher et al. method as 
described in materials and methods. The spine density was determined by calculating the 
number of protrusions/µm of dendrite. 
A) Bars represent the mean number of spines/10 µm dendritic length ± SEM in +/+ or 
sut/sut female or male mice. No significant difference between female or male +/+ and 
sut/sut mice was observed in dendritic spine density in layer V pyramidal cells (two-way 
ANOVA on log-transformed data). Inset: Representative photomicrographs (60x) of 
secondary apical dendritic spines from Golgi-Cox stained +/+ and sut/sut female or male 
mice. 
B) Bars represent the mean percentage of spines ± SEM in female or male +/+ or sut/sut 
mice categorized as either mushroom, filopodia, stubby, branched, thin, or long thin. No 
significant within-sex genotype differences in spine typology were observed between +/+ 
and sut/sut mice (two-way ANOVA on arcsine transformed data). #Males have increased 
mushroom (p = 0.0261), stubby (p < 0.0001), and thin (p = 0.0060) spines as compared to 
females whereas females have increased filopodia (p < 0.0001) and long thin (p = 0.0242) 
spines as compared to males (two-way ANOVA on arcsine transformed data). 
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(Risher et al 2014). Assessment of secondary apical dendritic spines on cortical layer V 
pyramidal cells indicated that spine density was similar in both SLC7A11+/+ and 
SLC7A11sut/sut female and male mice (Fig. 2.6A, two-way ANOVA). Further categorical 
classification of these spines – facilitated by calculating the spine length to head-width 
ratios – revealed sex-differences, with male mice exhibiting an increased proportion of 
mature mushroom (p = 0.0261) and stubby (p < 0.0001) spines, as well as thin spines 
(p = 0.0060), as compared to female littermates (Fig. 2.6B; two-way ANOVA). 
Furthermore, female mice demonstrated an increased proportion of nascent filopodia (p 
< 0.0001) and long thin (p = 0.0242) spines as compared to males (Fig. 2.6B; two-way 
ANOVA). These genotype-independent sex-differences demonstrated that a greater 
proportion of male spines are classified into mature (versus nascent) categories as 
compared to females, suggesting that male spines may be strengthened overall as 
compared to females.  
Further analysis of the spine length and head width parameters used to derive 
the aforementioned classifications revealed that spine head widths were significantly 
decreased in female SLC7A11sut/sut mice as compared to SLC7A11+/+ sex-matched 
littermates (Fig. 2.7A-B; p < 0.0001; two-way ANOVA). The opposite occurred in males, 
wherein SLC7A11sut/sut male mice had increased spine head widths as compared to 
sex-matched SLC7A11+/+ controls (Fig. 2.7A-B; p < 0.0001; two-way ANOVA). Analysis 
of sex-differences revealed that spine head widths of SLC7A11+/+ females were 
enhanced as compared to SLC7A11+/+ males whereas SLC7A11sut/sut females were 
decreased as compared to SLC7A11sut/sut males (Fig. 2.7A-B; two-way ANOVA  
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Figure 2.7 Comparison of spine head width between SLC7A11+/+ and 
SLC7A11sut/sut mice 
The distribution of head width variables from SLC7A11+/+ [+/+; females, n = 4763; 
males, n = 5056) on 18 neurons (9F, 9M) from 6 mice (3M, 3F)] and SLC7A11sut/sut 
[sut/sut; females, n = 4430; males, n = 5355) on 17 neurons (9F, 8M) from 6 mice (3F, 
3M)] littermates used to derive length-to-width ratios in Figure 2.6 were compared.  
A and B) Top: Each data point [black circles (+/+) or gray circles (sut/sut)] represents 
the head width of a spine in female (open bars) or male (hatched bars) mice. Bars 
represent the mean spine head width for each genotype. Bottom: the distribution of 
variables in the above scatterplot were fit to a violin plot. *Sut/sut female mice have 
significantly decreased mushroom spine head widths as compared to +/+ littermate 
controls (p < 0.0001; two-way ANOVA performed on head widths [n = 9 
neurons/genotype]); the opposite effect was observed in males (p < 0.0001; two-way 
ANOVA [n = 8-9 neurons /genotype]). Within-genotype sex-differences are indicated by 
the # signs.  
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Figure 2.8 Comparison of spine length between SLC7A11+/+ and SLC7A11sut/sut 
mice 
The distribution of spine length variables from SLC7A11+/+ [+/+; females, n = 4763; 
males, n = 5056) on 18 neurons (9F, 9M) from 6 mice (3M, 3F)] and SLC7A11sut/sut 
[sut/sut; females, n = 4430; males, n = 5355) on 17 neurons (9F, 8M) from 6 mice (3F, 
3M)] littermates used to derive length-to-width ratios in Figure 2.6 were compared.  
A and B) Top: Each data point [black circles (+/+) or gray circles (sut/sut)] represents 
the spine length of spine in female (open bars) or male (hatched bars) mice. Bars 
represent the mean spine length for each genotype. Bottom: the distribution of variables 
in the above scatterplot were fit to a violin plot. *Sut/sut male mice have significantly 
increased mushroom spine length as compared to +/+ littermate controls (males, p < 
0.0001; two-way ANOVA performed on head widths [n = 8-9 neurons/genotype/sex]). 
Within-genotype sex-differences are indicated by the # signs. 
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with Bonferroni’s multiple comparisons). With respect to spine lengths, SLC7A11+/+ and 
SLC7A11sut/sut female mice were identical whereas SLC7A11sut/sut males had increased 
spine lengths as compared to SLC7A11+/+ sex-matched littermate controls (Fig. 2.8A-B; 
p < 0.0001; two-way ANOVA with Bonferroni’s multiple comparisons). Moreover, 
analysis of sex-differences indicated that male spine head lengths were decreased as 
compared to females (Fig. 2.8A-B; p < 0.0001; two-way ANOVA). Taken together, these 
results demonstrate that loss of Sxc- signaling results in a sex-dependent change in 
layer V cortical pyramidal cell spine head width, with decreases or increases occurring 
in SLC7A11sut/sut females or males, respectively, as compared to sex-matched littermate 
controls. 
 
Functional assessment of E/I balance in SLC7A11+/+ and SLC7A11sut/sut mice 
Increases in excitability have been associated with cellular morphological 
alterations including enhanced dendritic complexity (Klenowski et al 2016, Mainen & 
Sejnowski 1996), decreased soma size (Hsu et al 2012, Ye et al 2015), and increased 
spine head width (Zito et al 2009),. To determine whether the aforementioned 
morphological phenotypes affect E/I balance in SLC7A11sut/sut mice, the seizure 
threshold of female and male SLC7A11+/+ and SLC7A11sut/sut littermates was assessed 
using the GABAAR antagonist PTZ. Within minutes of an acute PTZ dose (42 mg/kg, 
i.p.), a hypomobility phenotype (seizure score = 1) was evoked in the vast majority of 
mice regardless of sex or genotype. Despite this initial similarity, the behavioral 
response of SLC7A11sut/sut mice progressed such that by the end of the 30 minute  
 
 72 
 
 
Figure 2.9 SLC7A11sut/sut mice are hyper-excitable 
Naïve female (n = 21) and male (n = 29) SLC7A11+/+ (+/+, total n = 50) and female (n = 
25) and male (n = 37) SLC7A11sut/sut (sut/sut, total n = 62) littermates were treated with 
a single dose of 42 mg/kg PTZ (i.p.). Seizure behavior was scored using a 5 point scale. 
Data were pooled from 16 independent experiments performed over 9 months.   
A) Individual seizure scores: Each data point [closed black circles (+/+) or open circles 
(sut/sut)] represents the maximal seizure score obtained by an individual mouse during 
a 30 min observation period. Horizontal lines represent the median seizure score for 
each genotype. *Sut/sut mice have a significantly greater seizure score than +/+ 
littermate controls (p = 0.0237; Mann-Whitney U Test).  
B) Convulsive index: Bars [black bar (+/+) and open bar (sut/sut)] represent the 
proportion (fraction within bars) of mice that experienced a convulsive seizure (seizure 
score ≥ 3) in A expressed as a % of total mice exposed to PTZ. *Sut/sut mice have a 
higher convulsive index compared to +/+ littermate controls (p = 0.0093; Fisher’s Exact 
Test).  
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Figure 2.10 Enhancement of acute PTZ-induced seizure activity in SLC7A11sut/sut 
mice differs by sex 
The distribution of variables from mice used to derive Figure 2.9 were grouped and 
analyzed separately by sex. 
A-B) Individual seizure scores: Each data point [closed black circles (+/+) or open 
circles (sut/sut)] represents the maximal seizure score obtained by individual female (A) 
or male (B) mice during a 30 min observation period. Horizontal lines represent the 
median seizure score for each genotype. Sut/sut female (p = 0.0030) but not male (p = 
0.6459) mice have a significantly greater seizure score than +/+ sex-matched littermate 
controls as denoted by the asterisk (Mann-Whitney U Test).  
C-D) Convulsive index: Bars [black bar (+/+) and open bar (sut/sut)] represent the 
proportion (fraction within bars) of mice that experienced a convulsive seizure (seizure 
score ≥ 3) in A (C) or B (D) as a % of total mice exposed to PTZ.  *Sut/sut female (p = 
0.0054) but not male (p = 0.4223) mice have a higher convulsive index compared to +/+ 
sex-matched littermate controls as denoted by the asterisk (Fisher’s Exact Test). n.s. 
denotes not-significant (p > 0.05).  
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Figure 2.11 Enhancement of acute PTZ-induced seizure activity in male 
SLC7A11sut/sut mice uncovered by using a lower dose 
Naïve male SLC7A11+/+ (+/+, total n = 46) and SLC7A11sut/sut (sut/sut, total n = 44) 
littermates were treated with a single dose of 35 mg/kg PTZ (i.p.). Seizure behavior was 
scored using a 5 point scale.  
A) Individual seizure scores: Each data point [closed black circles (+/+) or open circles 
(sut/sut)] represents the maximal seizure score obtained by individual mice during a 30 
min observation period. Horizontal lines represent the median seizure score for each 
genotype. Sut/sut male mice have a significantly greater seizure score than +/+ sex-
matched littermate controls as denoted by the asterisk (p = 0.0031, Mann-Whitney U 
Test).  
B) Convulsive index: Bars [black bar (+/+) and open bar (sut/sut)] represent the 
proportion (fraction within bars) of mice that experienced a convulsive seizure (seizure 
score ≥ 3) in A as a % of total mice exposed to PTZ.  *Sut/sut male mice have a higher 
convulsive index compared to +/+ sex-matched littermate controls as denoted by the 
asterisk (p = 0.0081, Fisher’s Exact Test). 
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observation period their median seizure score was significantly enhanced compared to 
SLC7A11+/+ littermates (Fig. 2.9A; p = 0.0237; Mann-Whitney U Test). Similarly, 
SLC7A11sut/sut mice demonstrated an enhanced convulsive seizure incidence with 
43.5% (27/62) achieving a seizure stage ≥ 3, compared to 20% (10/50) of SLC7A11+/+ 
mice (Fig. 2.9B; p = 0.0093; Fisher’s Exact Test). The mean latency to convulsive 
seizure, however, did not differ between genotypes (342.8 ± 59 and 387.5 ± 55 sec, 
mean ± SEM, for SLC7A11+/+ and SLC7A11sut/sut mice, respectively; p = 0.6500; 
unpaired t test).  
Stratification of the variables in Figure 2.9 by sex revealed that female (Fig. 
2.10A; p = 0.0030), but not male (Fig. 2.10B; p = 0.6459), SLC7A11sut/sut mice 
significantly contribute to this observed hyperexcitability (Mann-Whitney U Test). While 
female SLC7A11sut/sut mice had an elevated convulsive seizure incidence, with 14/25 
(56%) of mice achieving a seizure stage ≥ 3, compared to just 3/21 (14.3%) of 
SLC7A11+/+ mice (Fig. 2.10C; p = 0.0054; Fisher’s Exact Test), male SLC7A11+/+ and 
SLC7A11sut/sut mice had a similar convulsive seizure incidence (Fig. 2.10D; p = 0.4223; 
Fisher’s Exact Test). However, given that a greater proportion of male (7/29; 24.1%) 
versus female (3/21; 14.3%) SLC7A11+/+ mice had a convulsive seizure, we reasoned 
that males could have a lower seizure threshold overall that could mask our ability to 
detect a difference in excitability. To test this, male SLC7A11+/+ and SLC7A11sut/sut mice 
were administered a lower dose of PTZ (35 mg/kg, i.p.) and observed for behavioral 
seizure activity. Indeed, hyper-excitability in male SLC7A11sut/sut mice was uncovered at 
this dose, reflected by their enhanced seizure severity (Fig. 2.11A; p = 0.0031; Mann-
Whitney U Test) and convulsive seizure incidence (Fig. 2.11B; p = 0.0081; Fisher’s 
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Exact Test) as compared to SLC7A11+/+ sex-matched littermate controls. Taken 
together, the sex-independent decrease in SLC7A11sut/sut convulsive seizure threshold, 
unmasked by chemoconvulsant challenge, suggests that SLC7A11sut/sut mice have a 
shift in their E/I balance towards excitation as compared to SLC7A11+/+ sex-matched 
littermate controls.  
 
2.5 Discussion 
Glutamate transporters, such as the excitatory amino acid transporters (EAATs), 
have been demonstrated to be important in maintaining E/I balance [reviewed in 
(Danbolt 2001)]. Despite the well-characterized significance of EAAT signaling, whether 
and how Sxc--mediated cystine/glutamate exchange contributes to E/I balance has not, 
until now, been fully investigated in vivo. In this study, we provide the first evidence that 
sex-dependent morphological differences occur in both female and male Sxc- null mice 
in comparison to their wild-type littermate controls. These morphological changes occur 
in association with a sex-independent behavioral hyper-excitability phenotype in 
SLC7A11sut/sut mice manifest by a decrease in their acute PTZ convulsive seizure 
threshold. The latter observation demonstrates that Sxc- signaling contributes to the 
endogenous network activity that maintains brain E/I balance in vivo in both female and 
male mice. 
 Two parameters maintained by Sxc- – redox balance and glutamate signaling – 
could influence brain structure and, in turn, E/I balance. For example, mice null for the 
neuronal EAAT3 transporter have decreased brain GSH levels that occur in association 
with age-dependent brain atrophy (Aoyama et al 2006). Moreover, high frequency 
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stimulation at the hippocampal CA1 synapse results in dendritic spine growth (Engert & 
Bonhoeffer 1999), which is dependent on glutamate receptor (NMDA) activation 
(Maletic-Savatic et al 1999). Overall, there was no evidence of gross brain atrophy in 
most brain regions of female or male SLC7A11sut/sut mice as compared to SLC7A11+/+ 
sex-matched littermates. One exception was the thickness of the corpus callosum in 
SLC7A11sut/sut females – it was significantly decreased – as compared to SLC7A11+/+ 
littermates. As the largest inter-hemispheric connection in brain, the corpus callosum is 
important for integrating information through its primarily excitatory connections (Bloom 
& Hynd 2005). In fact, transection of the corpus callosum is a therapeutic option to 
thwart generalization of seizure activity in epileptic individuals (Bogen & Vogel 1962, 
Van Wagenen & Herren 1940). While callosal thinning could be a result of decreased 
myelination, and electroencephalographic and behavioral seizures have been reported 
in animal models of demyelination (Hoffmann et al 2008), it could also result from 
aberrant development and/or connectivity of callosal projection neurons (Fame et al 
2016). With respect to temporal lobe epilepsy, decreased thickness in the posterior and 
anterior callosal regions have been demonstrated, with anterior corpus callosum 
thickness positively correlating with epilepsy age of onset (Hermann et al 2003, Weber 
et al 2007). However, increased corpus callosum thickness at the midline has also been 
reported in epileptic individuals (Conlon & Trimble 1988). Furthermore, it remains 
uncertain as to whether changes in callosal thickness are cause or consequence of 
seizure activity, especially given that diffuse white matter changes are not restricted to 
the corpus callosum and have been reported to occur throughout the epileptic brain 
(Arfanakis et al 2002, Gross et al 2006, Scanlon et al 2013).   
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While gross structural abnormalities of entire brain regions – including the corpus 
callosum – can perturb E/I balance, so too can morphological changes occurring at the 
cellular level. For example, the complexity of dendritic arborization increases with neural 
activity (Redmond et al 2002, Sin et al 2002, Yu & Malenka 2003). Moreover, enhanced 
dendritic complexity occurs in association with increases in spontaneous excitatory 
postsynaptic current (EPSC) frequency (Klenowski et al 2016). While we saw no 
difference in dendritic complexity between female SLC7A11+/+ and SLC7A11sut/sut sex-
matched littermates, male SLC7A11sut/sut dendritic complexity was significantly 
enhanced as compared to SLC7A11+/+ sex-matched controls. Moreover, male 
SLC7A11sut/sut dendritic complexity was indistinguishable from that of female 
SLC7A11sut/sut mice, whereas SLC7A11+/+ male dendritic complexity was significantly 
reduced as compared to SLC7A11+/+ females. These sex-differences were further 
exemplified in examining primary, secondary, and basal neurite lengths, which were 
enhanced in females versus males. Together, these findings suggest that the enhanced 
complexity in SLC7A11sut/sut versus SLC7A11+/+ males may be a result of aberrant, 
tortuous morphometry versus increases in neurite length. These observed genotype-
dependent differences in male mice could plausibly underlie an E/I imbalance manifest 
by enhanced excitation in SLC7A11sut/sut as compared to SLC7A11+/+ sex-matched 
controls.  
  E/I balance is integrally related to cellular soma size as evidenced by results 
demonstrating increases in soma area enhance inhibitory input from perisomatic 
parvalbumin-positive interneurons (Ye et al 2015). Moreover, reductions in soma size 
occur in association with decreased inhibitory postsynaptic current (IPSC) frequency 
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(Hsu et al 2012) and increased seizure susceptibility (Hsu et al 2012, McLeod et al 
2013). Our results indicate that soma size in female SLC7A11sut/sut mice is significantly 
decreased as compared to SLC7A11+/+ sex-matched controls. However, this effect was 
sex-dependent, as the soma size of male SLC7A11sut/sut mice was indistinguishable 
from that of sex-matched SLC7A11+/+ controls. Interestingly, a sex-difference was 
uncovered in that SLC7A11+/+ males had soma sizes that were significantly smaller than 
SLC7A11+/+ female mice. Taken together, changes in SLC7A11sut/sut neuronal 
morphometry at the cellular level, including enhanced dendritic complexity in males and 
a reduction in soma area in females, could plausibly facilitate a physiological E/I 
imbalance, characterized by enhanced excitation, in SLC7A11sut/sut mice. 
 The vast majority of fast synaptic neurotransmission occurs at spine heads 
(Colonnier 1968), and increases or decreases in head width are associated with 
increases or decreases in glutamate receptor abundance, respectively (Matsuzaki et al 
2001). While the overall density of spines/µm was not altered between female or male 
mice of either genotype, male mice had an increased proportion of mature spines 
classified as mushroom or stubby and a concomitant decreased proportion of immature 
spines, classified as filopodia or long thin, as compared to female mice of either 
genotype, suggesting that, independent of genotype, male spines may be strengthened 
as compared to female spines. However, when comparing spine head widths of all 
dendritic protrusions, we found that head widths of spines measured in male 
SLC7A11+/+ mice were ≈7% smaller than female SLC7A11+/+ mice. Upon examination of 
within-sex genotype differences, we found that both spine head widths (≈4%) and spine 
lengths (≈11%) were enhanced in male SLC7A11sut/sut as compared to SLC7A11+/+ sex-
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matched mice. The former observation suggests that their spines have increased 
glutamate receptors (Matsuzaki et al 2001). However, an increase in spine lengths is 
associated with enhanced filtering of the signal received at the post synaptic density 
and thus, synaptic weakening (Araya et al 2006), and it is unclear what the overall 
functional effect of both increased spine head widths and spine lengths would be with 
regards to synaptic strength. Conversely, female SLC7A11sut/sut spine head widths were 
decreased by ≈8% as compared to SLC7A11+/+ littermates, and no changes in spine 
lengths were observed. While an increase in spine head widths in SLC7A11sut/sut male 
mice as compared to SLC7A11+/+ sex-matched littermates is consistent with their 
hyperexcitable phenotype, a decrease in spine head widths in SLC7A11sut/sut females is 
somewhat surprising, given that they too have a decreased convulsive seizure 
threshold. However, it is possible that a reduction in synaptic strength at excitatory 
pyramidal cell synapses in female SLC7A11sut/sut mice could be a compensatory 
response to a hyper-excitable circuit elicited by other changes – such as a reduction in 
soma size and inhibitory drive (Hsu et al 2012, McLeod et al 2013, Ye et al 2015). 
 Any of the aforementioned morphometric alterations could result in an E/I 
imbalance. Indeed, both female and male SLC7A11sut/sut mice exhibited increased 
seizure severity and convulsive seizure incidence as compared to SLC7A11+/+ sex-
matched littermate controls in response to a single dose of the chemoconvulsant PTZ. 
Thus, despite sex-dependent brain morphological differences, SLC7A11sut/sut mice 
exhibit a sex-independent functional hyper-excitability. These findings raise the 
intriguing possibility that morphological sex-differences serve to maintain E/I balance in 
brains of female and male wild-type mice, and these sex-differences are, at least in part, 
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maintained by Sxc- signaling. For instance, the decreased dendritic complexity in male 
versus female SLC7A11+/+ mice may be integral in dampening aberrant connectivity in 
males. In male mice, loss of Sxc- renders complexity more “female like”, and this occurs 
in association with hyper-excitability. With respect to soma size, the increased soma 
area in female versus male SLC7A11+/+ mice may be integral for females in maintaining 
an elevated level of somatic inhibitory input to thwart aberrant neural activity. In female 
mice, loss of Sxc- renders their soma area more “male like”, and this too occurs in 
association with hyper-excitability. That a null mutation in Sxc- eliminates morphological 
sex differences – and decreases convulsive seizure threshold – is suggestive that 
morphological sex differences exist to prevent adverse behavioral outcomes, such as 
an E/I imbalance. 
Taken together, our results are the first to detail a role for Sxc- in maintenance of 
cellular morphology.  Specifically, we found that female SLC7A11sut/sut mice with a null 
mutation in the substrate specific light chain of Sxc- demonstrate decreased corpus 
callosum thickness, cross-sectional soma area, and dendritic spine head widths as 
compared to SLC7A11+/+ sex-matched littermate controls. Conversely, male 
SLC7A11sut/sut mice exhibited enhanced dendritic complexity and spine head widths 
compared to SLC7A11+/+ mice. These sex-dependent morphological alterations occur  
in association with an E/I imbalance manifest by a decreased convulsive seizure 
threshold when provoked with the GABAAR antagonist PTZ. More broadly, these 
findings raise the intriguing possibility that morphological sex-differences serve to 
maintain E/I balance in brain, and these sex-differences are, at least in part, maintained 
by Sxc- signaling. 
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Chapter 3: Decreased epileptogenesis in mice lacking the system xc- 
transporter occurs in association with a reduction in AMPA receptor 
subunit GluA1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is near duplicate of the submitted manuscript:  
 
Sears, Sheila M.S., Hewett, James A., and Hewett, Sandra J. (2018) Decreased 
epileptogenesis in mice lacking the System xc- transporter occurs in association with a 
reduction in AMPA receptor subunit GluA1. Submitted.  
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3.1 Summary 
Although the cystine/glutamate antiporter System xc- (Sxc-) plays a permissive 
role in glioma-associated seizures, its contribution to other acquired epilepsies has not 
been determined. As such, the present study investigates whether and how Sxc- 
contributes to the PTZ chemical kindling model of epileptogenesis. Male SLC7A11sut/sut 
mice and their wild-type SLC7A11+/+ littermates were administered PTZ (i.p.) daily for up 
to 21 days (kindling paradigm). Seizure severity was scored on a five-point behavioral 
scale. Mossy fiber sprouting, cellular degeneration, and Sxc- light chain (xCT) 
messenger RNA (mRNA) was explored using Timm staining, thionin staining, or real-
time quantitative polymerase chain reaction (qPCR), respectively. Levels of reduced 
and oxidized glutathione and cysteine were determined via high performance liquid 
chromatography (HPLC). Plasma membrane protein levels of glutamate and GABA 
receptor subunits as well as the K+/Cl- co-transporter KCC2 were quantified in brains of 
SLC7A11+/+ and SLC7A11sut/sut mice via Western blot analysis. Our results demonstrate 
that repeated administration of PTZ produced chemical kindling in only 50% of 
SLC7A11sut/sut mice as compared to 82% of SLC7A11+/+ littermate control mice. Kindling 
did not result in any changes in xCT mRNA levels assessed in SLC7A11+/+ mice. No 
cellular degeneration or mossy fiber sprouting was discernible in either genotype. 
Except for a small, but significant, decrease in oxidized cysteine in the hippocampus, no 
other change in measured redox couples were determined in SLC7A11sut/sut mice. 
Cortical levels of the AMPA receptor subunit GluA1 were decreased in SLC7A11sut/sut 
mice as compared to SLC7A11+/+ littermates, whereas all other proteins tested showed 
no difference between genotypes. This study provides the first evidence that Sxc- 
signaling contributes to epileptogenesis in the PTZ kindling model of acquired epilepsy. 
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Further data indicate a reduction in AMPA receptor signaling could underlie the 
resistance to PTZ kindling uncovered in SLC7A11sut/sut mice. 
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3.2 Introduction 
System xc- (Sxc-) is a sodium-independent anionic amino acid antiporter 
comprised of two protein components linked via a disulfide bridge: xCT (encoded by 
SLC7A11), the light chain that confers substrate specificity, and 4f2hc (encoded by 
SLC3A2), the associated glycoprotein heavy chain that traffics xCT to the plasma 
membrane (Bassi et al 2001, Sato et al 1999). While xCT expression is inducible in a 
number of tissues, its constitutive expression is limited to the central nervous system 
(CNS) and lymphoid organs, including the thymus and spleen (Sato et al 2002, Taguchi 
et al 2007). Within the CNS, xCT is detected in most major brain regions with studies 
investigating its cellular source demonstrating it is predominantly of astrocytic origin 
(Ottestad-Hansen et al 2018, Pow 2001). 
Sxc- imports cystine (CySS) and exports glutamate (Glu) with 1:1 stoichiometry 
across the cellular plasma membrane (Bannai 1986). Early functional characterization 
of Sxc- established its fundamental physiological role as a cellular CySS supplier. 
Following Sxc--mediated uptake, CySS is rapidly reduced to cysteine (Cys), a critical 
component of many structural, catalytic, and regulatory domains of proteins and a 
precursor for the essential thiol antioxidant, glutathione (GSH) (Sato et al 1998). Cys is 
also directly exported from the cell via neutral amino acid transporters (Banjac et al 
2008). Thus, Sxc- regulates intracellular and extracellular thiol redox systems (Banjac et 
al 2008, Sato et al 1998). Additionally, several studies have determined that Sxc- 
contributes significantly to the ambient extracellular glutamate pool that bathes the CNS 
in vivo (De Bundel et al 2011, Massie et al 2011b, McCullagh & Featherstone 2014). 
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Alterations in redox homeostasis adversely affect neuronal synaptic plasticity 
(Almaguer-Melian et al 2000, Robillard et al 2011), stressing the importance of redox 
balance in the normal function of brain network activity. Additionally, glutamate released 
from astrocytes is known to modulate neuronal excitability and enhance synaptic 
strength [for review see (De Pitta et al 2016)]. Further, multiple studies demonstrate that 
changes in redox balance and/or extracellular glutamate levels could be permissive in 
generating ictal activity. For example, mice under chronic oxidative stress show 
increased incidence of spontaneous and handling-induced seizures, which occurs in 
association with decreased expression of the glial glutamate transporters (GLT-1 and 
GLAST) (Liang & Patel 2004). Diminished glutamate uptake in mice null for the 
glutamate transporters GLT-1 or GLAST occurs in association with spontaneous 
seizures or prolonged seizure duration in an amygdaloid kindling model, respectively 
(Tanaka et al 1997, Watanabe et al 1999). Moreover, increased Sxc--mediated 
cystine/glutamate exchange in glioma (Ye et al 1999) occurs in association with 
elevated glutamate levels (Ye & Sontheimer 1999), and pharmacological inhibition of 
Sxc- reduces peritumoral glutamate levels in human glioblastoma patients (Robert et al 
2015) as well as seizure frequency in glioma-bearing mice (Buckingham et al 2011). 
Whether Sxc- is involved in non-tumor associated seizure generation is not known, 
although xCT levels are upregulated in resected hippocampi from temporal lobe 
epileptics (Lewerenz et al 2014). Finally, male transgenic xCT null mice require an 
elevated dose of pilocarpine or KA to elicit behavioral seizures – in addition to 
demonstrating decreased seizure severity and mortality in response to an acute dose of 
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NMDA – suggesting that Sxc- signaling is permissive in generating acute seizure activity 
(De Bundel et al 2011). 
 The dual regulation of redox systems and glutamate homeostasis by Sxc- and the 
potential for alterations in such to regulate brain ictal activity prompted our interest in the 
possibility that this antiporter may also contribute to the aberrant changes that 
predispose the CNS to develop epilepsy. Thus, the overall goal of this study was to 
explore the contribution of Sxc- to epileptogenesis by comparing PTZ kindling in mice 
wild-type or null for the SLC7A11 gene.  
 
3.3 Materials and Methods 
3.3.1 Animals 
Mice were maintained in the AALAC accredited Laboratory Animal Resource 
facility of Syracuse University on a 12 hr light/dark schedule (7am/7pm). Standard 
mouse chow and water were provided ad libitum. Experiments were carried out using 
male mice (8-12 weeks at start of experimentation) in accordance with the National 
Institutes of Health guidelines for the use of experimental animals as approved by the 
Institutional Animal Care and Use Committee of Syracuse University. Purchased 
C57BL/6J mice [Jackson Laboratories (JAX) Stock #000664] were allowed to 
acclimatize to the facility for at least one week prior to any manipulations. Wild-type 
(SLC7A11+/+) and xCT mutant (SLC7A11sut/sut) mice were bred in-house from 
heterozygous (SLC7A11+/sut) breeding units (F1) that were obtained by crossing 
SLC7A11sut/sut male mice (JAX, Stock #001310) with SLC7A11+/+ female C3H/HeSnJ 
mice (JAX, Stock #000661). F2 SLC7A11+/sut progeny were also used as breeding units 
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for studies. Genotyping was performed via PCR analysis of tail genomic DNA samples: 
+/+ primers, 5'- GAA GTG CTC CGT GAA GAA GG -3' (forward), 5'- ATC TCA ATC 
CTG GGC AGA TG -3' (reverse); sut/sut primers, 5'- CCA CTG TTG TAG GTC AGC 
TTA GG -3’ (forward), 5'- CAG GAC CTG TGA ATA TGA TAG GG -3' (reverse). Mice 
were segregated by sex at weaning and placed two to three per cage such that at least 
one mouse of each genotype was represented. These breeding and housing strategies 
were employed to control for environmental differences, genetic background influences, 
and genetic drift. Gross morphological analysis of SLC7A11sut/sut and SLC7A11+/+ male 
mouse brains at 12 weeks of age revealed no significant differences (not shown). 
 
3.3.2 PTZ Kindling 
Five days prior to each study, mice were acclimated to handling by performing 
mock daily intraperitoneal (i.p.) injections, which consisted of inverting the mouse and 
rubbing its abdomen. They were also acclimatized to the procedure room for at least 
one hour on each day of injection. PTZ (Sigma Chemical Co., St. Louis, MO), made 
fresh daily, was dissolved in saline and filter sterilized. PTZ was administered i.p. in a 
volume of 10 ml/kg body weight. C3H/HeSnJ or C57BL/6J mice were dosed at 35 
mg/kg or 39 mg/kg, respectively, once daily for up to 21 days. The dose for C3H/HeSnJ 
and C57BL/6J mice was chosen following initial dose ranging studies to determine the 
PTZ seizure threshold [Supplementary Fig. S1 and (Claycomb et al 2011), respectively]. 
Following each injection, mice were monitored for 30 min and the time and severity of 
behavioral seizures scored and recorded by an observer blinded to genotype using a 
five-point modified Racine scale (0 - 4: 0 = no behavioral change; 1 = hypoactivity; 2 = 
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myoclonus; 3 = generalized convulsion with righting reflex; 4 = generalized convulsion 
with loss of righting reflex) [For full description see Table 1 (Racine 1972)]. Mice were 
deemed kindled after exhibiting convulsive seizures (≥ stage 3) on three consecutive 
days, after which PTZ injections were stopped. Ten days later, the permanence of the 
kindled state was assessed by rechallenging with PTZ. The percentage of permanently 
kindled mice was determined by dividing the number of animals with a maximum 
seizure score ≥ 3 by the total number of animals injected. It should be noted that six 
SLC7A11sut/sut mice were a priori excluded from the study as they responded to the first 
injection with a convulsive seizure (behavioral score ≥ 3) making any further reduction in 
seizure threshold elicited by the kindling protocol (vide supra) indeterminable.  
 
3.3.3 Real-Time Quantitative Polymerase Chain Reaction (q-PCR) 
Total RNA, isolated using TRIzol reagent (Invitrogen, Carlsbad, CA) from cortical 
or hippocampal tissue of PTZ-kindled, PTZ-non-kindled, or saline-injected C57BL/6J 
mice one day following the final injection with PTZ or saline, was subjected to first-
strand cDNA synthesis. cDNA was subjected to real-time quantitative polymerase chain 
reaction (qPCR) in a reaction containing mouse-specific primers for the system xc- light 
chain (xCT) (SLC7A11, Mm01292531_m1, Taqman Gene Expression Assays, Applied 
Biosystems, Foster City, CA) and the reference gene hypoxanthine guanine 
phosphoribosyl transferase (HPRT, Mm01545399_m1, Taqman Gene Expression 
Assays, Applied Biosystems, Foster City, CA) along with TaqMan Universal PCR 
MasterMix (Applied Biosystems, Foster City, CA). HPRT expression levels were stable 
under our experimental conditions. A serial dilution of cortical or hippocampal cDNA 
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demonstrated that the calculated slope of the line comparing ∆CT (CT value of xCT – CT 
value of HPRT) versus input cDNA was -0.007606 or -0.000905, respectively, and that 
the efficiency of both primers was >90% in either tissue. Reactions were performed in 
duplicate or triplicate using an Eppendorf Realplex2 under the following conditions: 50°C 
for 2 min and 95°C for 10 min followed by 40 amplification cycles (95°C for 15 sec and 
60°C for 1 min). Data analysis was performed using the comparative cycle threshold 
method (∆∆CT), where CT values of xCT were normalized to HPRT CT values from the 
same sample and compared to the calibrator CT values (saline controls) to determine 
the relative fold increase in xCT mRNA.  
 
3.3.4 Timm and Thionin Staining 
Mossy fiber sprouting, elucidated by Timm staining, was quantified in the 
supragranular layer of the dentate gyrus (DG) by an observer blinded to the 
experimental condition. Brain slices from PTZ kindled SLC7A11+/+ and SLC7A11sut/sut 
mice and saline-injected SLC7A11+/+ mice were sacrificed 16-17 days after kindling 
acquisition or cessation of saline injections by transcardial perfusion with a proprietary 
(FD Rapid TimmStain Kit; FD Neuro Technologies, Inc., Baltimore, MD) sodium sulfide-
containing perfusate (Perfusate A plus B), followed by 4% paraformaldehyde (PFA) in 
0.1 M phosphate buffer (PB). Following removal from the cranium, brains were post-
fixed in 4% PFA for 24 hr (4°C), transferred to a 30% sucrose solution in 0.1 M PB for 
72 hr (4°C), and then snap-frozen on dry ice in Optimal Cutting Temperature (O.C.T.) 
compound (Tissue-Tek, Torrance, CA) prior to storage at -80°C. Frozen brains were cut 
serially (≈-0.94 – -2.46 mm posterior to bregma) into 40 µm coronal sections, mounted 
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on gelatin-coated slides (FD Neuro Technologies, Inc., Baltimore, MD), air dried at room 
temperature for 24 hours, then stored in a light-protected box at -20°C. Timm staining 
was carried out per manufacturer’s instructions (FD Rapid TimmStain Kit) with the 
exception that the time in the silver nitrate developing solution (Solution A, B, C, and D) 
was extended to 55-70 min. Mossy fiber sprouting was quantified using a six-point 
rating scale (0-5) developed by Cavazos et al.(Cavazos et al 1991): 0 = no Timm 
granules; 1 = patchy distribution of sparse granules in supragranular layer; 2 = 
continuous distribution of granules in supragranular layer; 3 = continuous distribution of 
granules with patches of confluency in supragranular layer; 4 = prominent granules that 
form a dense, confluent laminar band in supragranular layer; 5 = prominent granules 
that form a dense, confluent laminar band in the supragranular layer that extend into the 
inner molecular layer. A Timm score for each mouse was determined by calculating the 
median of the scores assigned to the left and right DG at »-1.94 mm posterior to 
bregma. Tissue sections within 80 µm of those processed for Timm staining were 
thionin-stained (Sigma Chemical Co., St. Louis, MO) as we previously describe to 
assess for any neurodegeneration. All tissue analyses were performed on identically 
processed photomicrographs acquired using a DP73 digital color camera (Olympus, 
Tokyo, Japan) mounted on an Olympus IX50 inverted microscope (Olympus, Tokyo, 
Japan). 
 
3.3.5 Reduced/Oxidized Glutathione and Cysteine Measurements 
Fully anesthetized naïve SLC7A11+/+ or SLC7A11sut/sut mice were perfused 
transcardially with ice-cold phosphate buffered saline (PBS, 1x). Hippocampal and 
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cortical tissue were rapidly dissected and snap-frozen separately in liquid nitrogen. The 
concentrations of reduced and oxidized glutathione (GSH and GSSG) and cysteine 
(Cys and CySS) were determined via high performance liquid chromatography (HPLC) 
by the Emory-Children’s Pediatric Biomarkers Core facility.  
 
3.3.6 Immunoblotting  
3.3.6.1 Plasma membrane protein isolation: 
Naïve SLC7A11+/+ or SLC7A11sut/sut mice were perfused transcardially with ice-
cold 1x PBS under full anesthesia. Bilateral hippocampi and cortices were dissected, 
snap frozen in liquid nitrogen separately, and stored at -80°C prior to use. Plasma 
membrane proteins were isolated from pooled hippocampi (2-5 mice/sample) or bilateral 
cortices (one mouse/sample) using an aqueous two-phase separation method as per 
manufacturer’s instructions (Plasma Membrane Protein Extraction Kit, Abcam, 
Cambridge, U.K.). Isolated proteins were suspended in 0.5% Triton X-100 in PBS. 
Samples were stored at -80°C until immunoblotting. Protein concentrations were 
quantified using the BCA assay kit (Pierce, Rockford, IL).  
 
3.3.6.2 Gel electrophoresis and protein detection 
Protein samples (7.5 µg) were separated by 8% SDS-PAGE under reducing 
(10mM dithiothreitol) and chaotropic (8M urea) conditions followed by electrophoretic 
transfer to a PVDF membrane (Bio-Rad; Hercules, CA). Membranes were blocked for 
one hr at room temperature (Odyssey® blocking buffer, LI-COR Biosciences; Lincoln, 
NE) then probed overnight (4°C) with the following antibodies: anti-Na+/K+ ATPase α1 
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mouse monoclonal antibody (1:750; Abcam; RRID: AB_306023); anti-GluA1 rabbit 
polyclonal antibody (1:750; Abcam; RRID:AB_2113447); anti-GluA2 rabbit polyclonal 
antibody (1:750; Abcam; RRID:AB_2232655); anti-GluN1 rabbit monoclonal antibody 
(1:750; Cell Signaling; RRID: AB_1904067); anti-GluN2A rabbit polyclonal antibody 
(1:750; Cell Signaling; RRID: AB_2112295); anti-GluN2B rabbit polyclonal antibody 
(1:750; Cell Signaling; RRID: AB_1264223); anti-GABAARα1 rabbit polyclonal antibody 
(1:3000; Abcam; RRID: AB_732498); anti-K+/Cl- co-transporter (KCC2) rabbit polyclonal 
antibody (1:750; Abcam; RRID: AB_881571). Species-specific secondary antibodies 
labeled with spectrally distinct IRDye® fluorescent dyes (LI-COR Biosciences, Lincoln, 
NE) were used to detect primary antibodies (1 hr at 25°C) (1:10,000 dilution). Results 
were recorded on a LI-COR ODYSSEY® Fc Imaging system (LI-COR Biosciences; 
Lincoln, NE) and protein levels quantified using Image Studio 3.1 (LI-COR Biosciences; 
Lincoln, NE). Each protein was normalized to the Na+/K+ ATPase levels contained in 
each lane. The signal intensity pertaining to the amount of hippocampal or cortical 
protein per lane (7.5 µg) was determined to be in the linear range for each antibody at 
their respective dilution (data not shown). 
 
3.3.7 Statistical Analysis 
All statistical analyses were performed using GraphPad Prism (Version 6.0.1, 
Graphpad Software, Inc., La Jolla, CA). Curves depicting kindling acquisition as a 
function of time were compared using a log-rank test. Two-way ANOVA or unpaired t 
test was used to compare seizure latencies, mouse weight, and the concentrations of 
reductants/oxidants. Proportions indicating the percent of mice convulsing were 
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compared using a Fisher’s exact test. The Mann-Whitney U test was used to compare 
Timm scores. Prior to parametric analysis, qPCR data were transformed to the 
geometric means whereas immunoblot data was log transformed (y = log(y+1)) and 
compared using one-way ANOVA or an unpaired t test, respectively. In all cases, 
significance was set at p < 0.05.  
 
3.4 Results  
Kindling acquisition, maintenance and mortality 
Irrespective of the mouse’s genotype, the rate of kindling steadily increased over 
the 21-day dosing paradigm (Fig. 3.1A) with the mean latency to kindle being 10.3 ± 1.1 
and 11.4 ± 1.2 days for SLC7A11+/+ and SLC7A11sut/sut mice, respectively (p = 0.54, 
unpaired t test). Although the latency to convulsive seizure on each of the three 
consecutive days leading up to and inclusive of the kindled state was similar between 
SLC7A11+/+ and SLC7A11sut/sut littermates (Fig. 3.1B; p = 0.40, two-way ANOVA), 
kindling acquisition was significantly reduced in SLC7A11sut/sut (9/18; 50%) as compared 
to SLC7A11+/+ (22/27; 81.5%) (Fig. 3.1A; p = 0.02, log-rank test).  
Permanency of the kindled state, determined by rechallenge with PTZ ten days 
after the third convulsion, was neither 100% for either genotype nor statistically 
significant between genotypes with only 82% of the SLC7A11+/+ (18/22) and 78% of 
SLC7A11sut/sut (7/9) responding to the PTZ challenge with a seizure score of ≥ 3 (p = 
1.00, Fisher’s exact test). The latency to convulsion upon rechallenge also did not differ  
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Figure 3.1 Comparison of PTZ kindling acquisition and convulsive seizure latency 
between SLC7A11+/+ and SLC7A11sut/sut mice 
SLC7A11+/+ (+/+; closed circles, n = 27) and SLC7A11sut/sut (sut/sut; open circles, n = 
18) mice were administered 35 mg/kg PTZ (i.p.) once daily for 21 days or until the 
mouse became kindled. Five separate experiments were performed over 24 months.  
A) Kindling acquisition: Each data point represents the percentage of mice kindled each 
day over the 21 day paradigm, which was determined by dividing the number of animals 
defined as kindled (see methods) by the total number of animals injected. Fractions 
represent the proportion of mice kindled at the end of the protocol. The rate and 
proportion of SLC7A11sut/sut mice that kindled is significantly decreased as compared to 
SLC7A11+/+ littermate controls as denoted by the large and small asterisk, respectively 
(*p = 0.02, log-rank test; #p = 0.047, Fisher’s exact test).  
B) Convulsive seizure latency: Each data point [closed black circles (+/+) or open 
circles (sut/sut)] represents the latency to convulsion (behavioral score ≥ 3) of a single 
mouse for each of the three consecutive convulsions (depicted as Convulsion 1-3) that 
led to its kindled state. Bars represent the mean latency to convulsive seizure for each 
genotype. Kindled SLC7A11+/+ and SLC7A11sut/sut mice have similar convulsive seizure 
latencies (p = 0.40, two-way ANOVA).  
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between the genotypes (431 ± 45 vs. 416 ± 51 s for SLC7A11+/+ vs. SLC7A11sut/sut, 
respectively; p = 0.85, unpaired t test). 
Of note, no mortality occurred in either group during the kindling paradigm. Mice 
that completed the paradigm exhibited an average weight loss of 0.28 g. However, the 
final weight of kindled mice did not differ between genotypes (25.2 ± 0.4 vs. 23.9 ± 0.5 g 
for SLC7A11+/+ and SLC7A11sut/sut, respectively), nor did these differ from that of non-
kindled mice (23.2 ± 1.1 vs. 24.4 ± 0.5 g for SLC7A11+/+ and SLC7A11sut/sut, 
respectively, two-way ANOVA). 
 
xCT mRNA levels 
To determine whether the kindling phenotype was associated with an increase in 
xCT expression, we measured hippocampal and cortical xCT mRNA levels in kindled, 
non-kindled, and saline-injected SLC7A11+/+ mice via quantitative PCR one day 
following the final PTZ or saline injection. Neither hippocampal nor cortical xCT mRNA 
expression levels of kindled mice differed from non-kindled or saline-administered 
control mice (Figure 3.2), suggesting that basal levels of Sxc- are sufficient to facilitate 
kindling.  
 
Histological analysis of injury and axonal sprouting 
Sixteen to seventeen days following PTZ-kindling, brains were examined for 
signs of overt cellular degeneration. Thionin-staining of brain slices revealed that the 
cortex (not shown) and principal layers of the hippocampal formation (Fig. 3.3A, E, I),  
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Figure 3.2 PTZ kindling phenotype is not associated with alterations in xCT 
mRNA 
SLC7A11+/+ mice on a C57BL/6J background were administered 39 mg/kg PTZ once 
daily for 21 days or until kindled. Mice receiving vehicle (saline) were injected in parallel. 
A) The left hippocampus and (B) left cortex were harvested 24 hours following the final 
injection of PTZ or vehicle and xCT mRNA assessed via qPCR. Data are expressed as 
mean ± SEM fold change in xCT mRNA compared with vehicle-injected controls. No 
significant between-group differences in xCT mRNA expression in hippocampus (p = 
0.84) or cortex (p = 0.26) was found as determined by one-way ANOVA. N = 4-5 each 
per treatment group.  
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Figure 3.3 PTZ kindling phenotype is not associated with cellular degeneration 
Representative photomicrographs of thionin-stained coronal brain sections ≈ -1.82 mm 
posterior to bregma: (A-D) vehicle (saline)-injected SLC7A11+/+ (+/+; n = 3), (E-H) 
kindled SLC7A11+/+ (+/+; n = 4), and (I-L) kindled SLC7A11sut/sut (sut/sut; n = 2) brain 
sections. Images represent the hippocampal formation (A, E, I; 8x), CA1 (B, F, J; 20x), 
CA3 (C, G, K; 20x), or the DG (D, H, L; 20x). 
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Figure 3.4 PTZ kindling phenotype is not associated with increased mossy fiber 
sprouting 
A-F) Representative photomicrographs of Timm stained hippocampal formation ≈ -1.94 
mm posterior to bregma: (A-B) vehicle (saline)-injected control SLC7A11+/+ (+/+; n = 3), 
(C-D) kindled SLC7A11+/+ (+/+; n = 4) (C-D), and (E-F) kindled SLC7A11sut/sut (sut/sut; n 
= 2). Images represent the hippocampal formation (A, C, E; 8X) and the DG (B, D, F; 
40X). Boxes in A, C, and E depict the region of the DG assessed for mossy fiber 
sprouting. 
G) Each closed circle represents the Timm score (see methods) of a single mouse 
determined by calculating the median of the scores assigned to the right and left DG 
(40x) at ≈ -1.94 mm bregma. Open bars represent the median Timm score for each 
group. There was no significant difference in mossy fiber sprouting between vehicle-
injected SLC7A11+/+ and kindled SLC7A11+/+ mice as determined by the Mann-Whitney 
U test (p = 0.69).  
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including the CA1 (Fig. 3.3B, F, J), the CA3 (Fig. 3.3C, G, K), and the dentate gyrus 
(DG; Fig. 3.3D, H, L) of kindled mice appeared grossly normal and intact irrespective of 
genotype. The lack of degeneration was confirmed in adjacent sections using Fluoro 
Jade C and a 4’,6-Diamidino-2-Phenylindole, Dilactate (DAPI) counterstain (data not 
shown). Aberrant sprouting of DG granule cell axons, known as mossy fiber sprouting, 
is a common feature in temporal lobe epilepsy and is found in some, but not all, rodent 
models of epileptogenesis. PTZ-kindled SLC7A11+/+ mice, maintained on a C3H/HeSnJ 
background, had few mossy fiber synaptic terminals as evidenced by little to no Timm 
granules in the supragranular layer of the DG that were comparable in number to those 
quantified in saline-treated control mice (Fig. 3.4; median Timm score = 0.75 vs. 1, 
respectively; p = 0.69, Mann Whitney U test). SLC7A11sut/sut kindled mice also showed 
little to no change in mossy fiber sprouting (Fig 3.4; median Timm score = 1). Thus, 
alterations in mossy fiber sprouting cannot explain the reduction in kindling acquisition 
in SLC7A11sut/sut as compared to SLC7A11+/+ mice.  
 
Redox signaling 
Cys derived from Sxc- import of CySS is the rate-limiting substrate for the 
production of the low molecular weight thiol GSH and contributes to the Cys/CySS 
redox couple across the cell plasma membrane (Banjac et al 2008, Dringen 2000, Lu 
2009). To determine whether loss of Sxc- resulted in a redox imbalance in SLC7A11sut/sut 
brains, the hippocampal and cortical levels of reduced and oxidized GSH (GSH and 
GSSG) and Cys (Cys and CySS) were measured and compared to levels measured  
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Figure 3.5 Comparison of redox couples in SLC7A11+/+ and SLC7A11sut/sut mice 
The concentration of reduced and oxidized glutathione (GSH and GSSG) or cysteine 
(Cys and CySS) was determined by high performance liquid chromatography (HPLC) in 
hippocampus (A-B) or cortex (C-D) of naïve SLC7A11+/+ (+/+; n = 8-10) and 
SLC7A11sut/sut (sut/sut; n = 10) littermates. Bars represent the mean ± SEM fold-change 
over control (+/+, set to one) of the concentration of hippocampal or cortical GSH (A, C; 
left bars), GSSG (A, C; right bars), Cys (B, D; left bars), or CySS (B, D; right bars). 
Comparisons between individual levels of reduced or oxidized GSH or Cys were made 
using an unpaired t test on raw data. An asterisk (*) represents a significant between 
group difference (p = 0.002).  
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Figure 3.6 Comparison of plasma membrane protein expression in SLC7A11+/+ 
and SLC7A11sut/sut mice 
Plasma membrane protein levels in hippocampus or cortex derived from SLC7A11+/+ 
(+/+) or SLC7A11sut/sut (sut/sut) littermates were compared using Western blot analysis 
(see methods). Representative Western blots of +/+ and sut/sut hippocampal plasma 
membrane proteins are shown in (A). Each data point [closed black circles (+/+; n = 7-9) 
or open circles (sut/sut; n = 5-9) represents the level of hippocampal (B) or cortical (C) 
protein following normalization to their respective loading control (i.e., Na+/K+ ATPase 
levels). Bars indicate the mean fold change over control (+/+), which was set to one. 
Hippocampal or cortical plasma membrane protein expression levels were compared 
using an unpaired t test on log-transformed data. An asterisk (*) represents a significant 
between group difference (p = 0.01).  
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from SLC7A11+/+ tissues. Neither hippocampal nor cortical GSH (Fig. 3.5A left; p = 0.74; 
Fig. 3.5C left; p = 0.28, unpaired t test) nor GSSG (Fig. 3.5A right; p = 0.34; Fig. 3.5C 
right; p = 0.12, unpaired t test) levels were different between SLC7A11+/+ and 
SLC7A11sut/sut mice. Cortical levels of Cys were also similar between the genotypes 
(Fig. 3.5D left; p = 0.80, unpaired t test), while there was a small, but non-significant, 
increase in CySS (Fig. 3.5D right; p = 0.12, unpaired t test). Notably, in the 
hippocampus, the level of CySS was significantly decreased in SLC7A11sut/sut mice as 
compared to SLC7A11+/+ littermate controls (Fig. 3.5B right; p = 0.002, unpaired t test), 
while Cys levels were unchanged (Fig. 3.5B left; p = 1.00, unpaired t test). 
 
Plasma membrane protein expression levels 
Finally, we assessed cortical and hippocampal surface expression of AMPA 
(GluA1, GluA2), NMDA (GluN1, GluN2A, and GluN2B), and GABA (GABAARα1) 
receptor subunits, as well as, the K+/Cl- co-transporter (KCC2) (Figure 3.6), as 
aberrations in plasma membrane levels of each has been associated with abnormal 
neuronal synchronization (Kelley et al 2016, Mathern et al 1998, Raol et al 2006). 
Western blot analysis of this suite of plasma membrane proteins revealed no change in 
expression levels between SLC7A11+/+ and SLC7A11sut/sut littermates in the 
hippocampus (Fig. 3.6A,B). Of note, cortical levels of the AMPA receptor subunit GluA1 
were significantly decreased in SLC7A11sut/sut mice as compared to SLC7A11+/+ 
littermate controls (Fig. 3.6C; p = 0.01, unpaired t test on log transformed data). No 
other cortical plasma membrane proteins were altered in SLC7A11sut/sut as compared to 
SLC7A11+/+ littermate controls (Figure 3.6C).  
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3.5 Discussion  
By virtue of its localization to astrocytes and its role in regulating thiol redox 
systems as well as ambient extracellular glutamate levels, Sxc- (cystine/glutamate 
antiporter) contributes importantly to CNS homeostasis. In fact, astrocytic transporters, 
in general, regulate brain excitatory/inhibitory (E/I) balance by providing neurons with 
energy substrates, by maintaining ion homeostasis, and by removing excess 
neurotransmitters from the extracellular space. Dysfunction in any one of these activities 
can facilitate epileptogenesis [reviewed in (Eid et al 2018)]. In this study, we now 
provide evidence that Sxc- signaling contributes to epileptogenesis in the PTZ-kindling 
model of acquired epilepsy (Figure 3.1). These findings complement studies 
demonstrating an incontrovertible role for Sxc- in glioma-associated epilepsy in both 
mice and man (Buckingham et al 2011, Robert et al 2015).  
While Sxc- has been found to be upregulated in glioma(Yuen et al 2012), we do 
not find any changes in xCT mRNA expression in PTZ-kindled mice as compared to 
vehicle-injected controls (Figure 3.2), suggesting that basal levels of Sxc- are sufficient 
to facilitate PTZ-kindling. Given the lack of reliable commercial antibody for xCT 
(personal observations and (Van Liefferinge et al 2016)), we cannot rule out the 
possibility that enhanced transporter trafficking (as has been described in human glioma 
cells in vitro (Chase et al 2013)) or increased transporter kinetics (as demonstrated in 
rat striatum in vivo) occurs in wild-type mice (Baker et al 2002). However, present data 
suggests that in vivo glutamatergic tone — maintained in large part by non-vesicular 
release of glutamate by Sxc- (De Bundel et al 2011, Massie et al 2011b, McCullagh & 
Featherstone 2014) — may be enough to dysregulate excitatory signaling in wild-type 
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mice, as we previously documented in an in vitro paradigm of hypoglycemic neuronal 
cell death (Thorn et al 2015). Leading credence to this interpretation are the findings 
that a reduction in GABAergic inhibition (Kapur et al 1989a, Kapur et al 1989b) and an 
increase in extracellular glutamate and glutamate receptor levels (Li et al 2000, 
Schröder et al 1993) are associated with PTZ-kindling in rodents. Conversely, a 
decrease in ambient, extracellular glutamate levels has been reported in mice lacking 
Sxc- (De Bundel et al 2011, Massie et al 2011b, McCullagh & Featherstone 2014). This, 
together with the reduction in cortical GluA1 AMPA receptor subunit protein expression 
found herein (Figure 3.6), suggests that glutamatergic signaling may be hypo-functional 
in the SLC7A11sut/sut mouse brain in a manner sufficient to reduce PTZ-kindling. In 
keeping with this idea, long-term potentiation (LTP), which is observed at glutamatergic 
excitatory synapses in hippocampus and cortex, is also reduced in SLC7A11sut/sut mice 
(Li et al 2012). However, it should be noted that enhanced synaptic GluA1 expression 
has been reported in the CA1 region of the hippocampus of transgenic xCT null mice 
(Williams & Featherstone 2014), although we found no change in global hippocampal 
GluA1 levels in SLC7A11sut/sut mice (Figure 3.6). It is difficult to compare these two 
studies as our plasma membrane measurements include all hippocampal subregions 
and would capture receptors of both synaptic and extrasynaptic origin. Nevertheless, a 
global plasma membrane reduction in cortical GluA1 is interesting given evidence from 
animal models that block of AMPA receptor signaling is anti-epileptogenic (Kodama et 
al 1999, Namba et al 1994). 
Sxc--mediated CySS import has been demonstrated to be fundamental in 
maintaining the extracellular and intracellular redox balance (e.g., GSH/GSSG and 
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Cys/CySS) at least in vitro where growth of xCT deficient cells is dependent upon the 
addition of a reducing agent (Sato et al 2005). Interestingly, dysregulation of glutathione 
homeostasis is associated with impairment of synaptic strength (Almaguer-Melian et al 
2000, Robillard et al 2011) and thus represents another possible explanation for the 
resistance of SLC7A11sut/sut mice to PTZ-kindling. However, SLC7A11sut/sut mice have 
normal Cys, GSH and GSSG levels in hippocampal and cortical tissue, although 
hippocampal CySS levels were found to be significantly decreased (Figure 3.4). Our 
data are in agreement with other studies in transgenic xCT nulls showing normal 
hippocampal GSH levels as compared to wild-type mice (De Bundel et al 2011). To our 
knowledge, this study is the first to measure the concentration of GSH in cortex as well 
as brain cyst(e)ine levels in a mouse null for Sxc-. Taken in toto, current and previous 
data in both transgenic xCT nulls and SLC7A11sut/sut mice suggest these animals must 
employ compensatory mechanisms (e.g., EAAT3 or the alanine-cysteine-serine 
transporter [ASCT1/2] as alternative Cys transporters) to sustain GSH levels in vivo.  
Finally, epileptogenic network sensitization and its resultant E/I imbalance is 
associated with synaptic reorganization, particularly when hilar neurons in the dentate 
gyrus are lost (Buckmaster & Dudek 1997, Cavazos & Sutula 1990). This reorganization 
includes reactive synaptogenesis of granule cell mossy fibers, whose targets have been 
demonstrated to include both excitatory (Scharfman et al 2003) and inhibitory (Sloviter 
et al 2006) neurons. However, we found no cellular loss in the hippocampus or cortex of 
PTZ-kindled mice of either genotype (Figure 3.3). We also did not observe any 
significant hippocampal mossy fiber sprouting in any group tested, indicating that this 
structural alteration was not necessary for kindling development. These results are not 
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unprecedented as previous studies show that rats (Osawa et al 2001) and guinea pigs 
(Mohapel et al 2000) kindle in the absence of mossy fiber sprouting. Moreover, 
suppression of reactive sprouting in rats (Longo & Mello 1997) and mice (Buckmaster & 
Lew 2011) has been demonstrated to be ineffective in preventing epileptogenic 
neuronal sensitization following chemically-induced status epilepticus.  
In sum, our results demonstrate that SLC7A11sut/sut mice have a reduction in 
PTZ-kindling acquisition that occurs in association with decreased GluA1 levels. Given 
the permissiveness of Sxc- signaling to epileptogenesis — both glioma- (Buckingham et 
al 2011, Robert et al 2015) and PTZ-induced (this study) — we postulate that inhibition 
of astrocyte Sxc- may represent an alternative therapeutic strategy to modulate 
excessive glutamatergic signaling in individuals predisposed to developing epilepsy.  
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Chapter 4: KA-mediated alterations in excitability in system xc- null 
mice differ according to dosing paradigm. 
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4.1 Summary  
 Sxc- null (SLC7A11sut/sut) mice exhibited hyper-excitability (Chapter 2) or hypo-
excitability (Chapter 3) following acute or chronic dosing with PTZ, respectively, which 
induces seizure activity indirectly via disinhibition. In this chapter, the model-
dependency of these findings was explored using KA, a glutamate receptor agonist that 
directly elicits excitation. Female and male SLC7A11sut/sut and SLC7A11+/+ littermates 
were injected with KA once (acute paradigm) or repeatedly (escalated dosing paradigm) 
and the resulting seizure severity scored on a nine-point behavioral scale. Following the 
elevated dosing paradigm, brains of SLC7A11+/+ and SLC7A11sut/sut mice were 
evaluated for hippocampal cellular degeneration or for plasma membrane protein levels 
of glutamate and GABA receptor subunits using Fluoro jade C staining or Western blot 
analysis, respectively. Our results demonstrate that SLC7A11sut/sut mice exhibit 
behavioral hyper-excitability following acute KA administration. In contrast, repeated 
administration of KA in the elevated dosing paradigm elicits behavioral hypo-excitability 
in SLC7A11sut/sut mice, a response opposite to that observed in the vast majority of 
SLC7A11+/+ littermates who entered into a period of unremitting convulsive seizure 
activity (status epilepticus). The repeated KA dosing paradigm elicited neural 
degeneration in a subset of both SLC7A11+/+ and SLC7A11sut/sut littermates. However, 
the hippocampal sub-region predominantly affected differed by genotype, with the CA3 
or CA1 sub-region demonstrating degeneration in SLC7A11sut/sut or SLC7A11+/+ 
littermates, respectively. Cortical levels of the GABA receptor subunit GABAARa were 
increased in SLC7A11sut/sut mice that became hypo-mobile by the end of the repeated 
dosing paradigm as compared to SLC7A11sut/sut mice that entered into status 
epilepticus. No between-genotype differences were found in plasma membrane proteins 
tested following the repeated KA dosing protocol. These results extend findings in 
Chapters 2 and 3 and indicate that positive or negative excitability alterations elicited in 
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SLC7A11sut/sut mice via acute or repeated/chronic chemoconvulsant administration, 
respectively, are not model dependent.  
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4.2 Introduction  
System xc- (Sxc-) is a heteromeric amino acid antiporter that exports glutamate 
and imports cystine with 1:1 stoichiometry (Bannai & Kitamura 1980, Sato et al 1999). In 
most tissues, including the central nervous system (CNS), cystine import through Sxc- is 
necessary for the synthesis and maintenance of the cellular antioxidant, glutathione 
(GSH). This, along with the cysteine/cystine (Cys/CySS) redox cycle, also influenced by 
Sxc- activity, contributes to the intracellular/extracellular redox homeostasis (Banjac et al 
2008, Sato et al 2005). Sxc- is also an important contributor to the ambient extracellular 
glutamate levels that bathe the CNS in vivo (Augustin et al 2007, Baker et al 2002, De 
Bundel et al 2011, Massie et al 2011b, Melendez et al 2005). Studies addressing the 
cellular source of this glutamate conclude that it is astrocyte-derived (Augustin et al 
2007, Grosjean et al 2008, Warr et al 1999). 
Data presented in Chapter 2 of this dissertation demonstrated that SLC7A11sut/sut 
mice ─ who harbor a natural mutation in exon 12 of SLC7A11, rendering them null for 
the Sxc- substrate specific light chain xCT (Chintala et al 2005) ─ are more excitable 
(i.e., have lower convulsive seizure thresholds) than SLC7A11+/+ littermate control mice 
following acute challenge with the GABAA receptor antagonist PTZ (Fig 2.9). Despite 
this, SLC7A11sut/sut mice show behavioral signs of hypoexcitability upon chronic 
administration of PTZ. Specifically, data presented in Chapter 3 established that 
repeated daily injections of a kindling dose of PTZ ultimately leads to a permanent 
decrease in the threshold of excitability in SLC7A11+/+ mice (i.e., mice become kindled), 
whereas the percent SLC7A11sut/sut mice that kindle over the same 21 days is 
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significantly lower (Fig 3.1). These data suggest that Sxc- activity modulates synaptic 
strength in vivo in a context-dependent manner. 
In contrast to our findings using PTZ – whereby excitation results from 
endogenous glutamate signaling – transgenic xCT null mice on a C57BL/6 background 
appear to have an elevated seizure threshold in response to three pharmacologically 
distinct chemoconvulsants (De Bundel et al 2011). Specifically, xCT null mice require an 
elevated dose of either the muscarinic acetylcholine agonist, pilocarpine, or the 
glutamate receptor agonist, KA, to elicit the same behavioral seizure response as wild-
type controls (De Bundel et al 2011). Furthermore, this study demonstrated that xCT 
null mice exhibit decreased seizure severity and mortality, as well as increased latency 
to seize, in response to a systemic injection of the glutamate receptor agonist NMDA 
(De Bundel et al 2011). Thus, contrary to our findings using the SLC7A11sut/sut mice in 
the acute PTZ paradigm (Chapter 2), these results suggest that xCT null mice on the 
C57BL/6 background have an elevated seizure threshold.  
The goal of this study was to determine if our findings using PTZ in the 
SLC7A11sut/sut mice were model-dependent. As such, the susceptibility of SLC7A11+/+ 
and SLC7A11sut/sut littermates to seizures evoked by acute or repeated administration of 
the glutamate receptor agonist KA was explored. Whether KA induced neural 
degeneration or altered plasma membrane protein expression levels was also explored 
given the association of these phenotypes with KA-mediated excitoxic cell death (Nadler 
et al 1980) or neuronal synaptic strength, respectively (Mathern et al 1998, Raol et al 
2006). 
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4.3 Materials and Methods  
4.3.1 Animals 
Mice were maintained in the AALAC accredited Laboratory Animal Resource 
facility of Syracuse University on a 12 hr light/dark schedule (7am/7pm). Standard 
mouse chow and water were provided ad libitum. Experiments were carried out using 
male and female mice (8-12 weeks old) in accordance with the National Institutes of 
Health guidelines for the use of experimental animals as approved by the Institutional 
Animal Care and Use Committee of Syracuse University. Wild-type (SLC7A11+/+) and 
xCT mutant (SLC7A11sut/sut) mice were bred in-house from heterozygous (SLC7A11+/sut) 
breeding units (F1) that were obtained by crossing SLC7A11sut/sut male mice (JAX, 
Stock #001310) with SLC7A11+/+ female C3H/HeSnJ mice (JAX, Stock #000661). F2 
SLC7A11+/sut progeny were also used as breeding units for studies. Genotyping was 
performed via PCR analysis of tail genomic DNA samples: +/+ primers, 5'- GAA GTG 
CTC CGT GAA GAA GG -3' (forward), 5'- ATC TCA ATC CTG GGC AGA TG -3' 
(reverse); sut/sut primers, 5'- CCA CTG TTG TAG GTC AGC TTA GG -3’ (forward), 5'- 
CAG GAC CTG TGA ATA TGA TAG GG -3' (reverse). Mice were segregated by sex at 
weaning and placed two to three per cage such that at least one mouse of each 
genotype was represented. These breeding and housing strategies were employed to 
control for environmental differences, genetic background influences, and genetic drift 
(Barnwell et al 2009, Pick & Little 1965).  
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4.3.2 KA dosing paradigms  
Changes in in vivo network excitability were provoked in SLC7A11+/+ and 
SLC7A11sut/sut mice by injection of KA (Abcam, Cambridge, U.K.). Mice were acclimated 
to handling by performing mock daily intraperitoneal (i.p.) injections five days prior to 
each study, which consisted of inverting the mouse and rubbing its abdomen. They 
were also acclimatized to the procedure room for at least one hour prior to 
experimentation. The KA injection solution (1 – 1.5 mg/mL) was prepared fresh on day 
of use in 0.05M phosphate buffered saline (PBS) and filter sterilized prior to i.p. 
administration.  
4.3.2.1 Acute Dose 
SLC7A11+/+ or SLC7A11sut/sut mice were injected once with KA (12 mg/kg, males; 
15 mg/kg, females) in a volume of 10 ml/kg body weight. Following the injection, mice 
were monitored for 30 min and the time and severity of behavioral seizures scored and 
recorded by an observer blinded to genotype using a nine-point modified Racine scale 
as described below. All mice received 5mg/kg diazepam (i.p., dissolved in 0.9% saline 
containing 40% propylene glycol) 60 min after dosing to arrest any ongoing seizure 
activity. 
4.3.2.2 Escalating Dose 
The escalating dosing paradigm was initiated by injecting SLC7A11+/+ or 
SLC7A11sut/sut mice with a loading dose of 10 mg/kg KA in a volume of 10 ml/kg body 
weight. Booster doses of 2.5 mg/kg KA were administered 30, 60, 90, 120, and 150 min 
later (see below) in a volume of 2.5 ml/kg body weight. Mice were continuously 
monitored throughout the 240 min paradigm and the time and severity of behavioral 
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seizures scored and recorded by an observer blinded to genotype using a nine-point 
modified Racine scale as described in Section 4.3.2.3 (Table 4.1). All mice received 
5mg/kg diazepam (i.p., dissolved in 0.9% saline containing 40% propylene glycol) 240 
min after the initial dose of KA to arrest any on-going seizure activity. 
 
 
 
 
 
 
 
 
 
4.3.2.3 Quantification of KA-induced Seizure Behavior 
Behavioral seizure scores were recorded for each mouse by an observer blinded 
to genotype to ensure unbiased scoring (see Table 4.1 below). Scores ≤ 4 = non-
convulsive seizures; scores ≥ 5 = clonic/convulsive seizure. 
 
 
 
 
 
 
 
TIME (min) 
KA 
0 30 60 90 150 
10 2.5 
TREATMENT (mg/kg) 
120 
2.5 2.5 2.5 2.5 
240 
Diazepam 
5 
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Table 4.1: Descriptive KA-induced Seizure Scoring System  
 
Table adapted from descriptions in (Ferraro et al 1999, Pitkanen 2006, Racine 1972).  
 
 
 
Seizure 
Score 
Abbreviated 
Description 
Detailed 
Description 
0 Normal behavior 
Normal ambulation/exploration: sniffing, rearing, grooming, eating, digging, 
and climbing are common. Unless sleeping, mice will rarely be motionless for 
more than a few seconds. 
1 Hypomobility and hypoactivity 
Overall behavior will be dominated by bouts (> 10 sec in duration) of staring 
and motionlessness that may be interrupted by brief sniffing or ambulation. 
2 Hyperactivity 
Hyperactivity includes excessive unidirectional rotations, escape-like 
behavior, and running with an abnormal gait. This generally follows periods of 
hypoactivity. 
3 
Repeated 
twitching or  
myoclonus 
Animal with normal posture exhibiting two or more brief (≤ 2 sec) myoclonic 
twitches of head, tail or axial musculature. Twitching of whiskers and facial 
movements are apparent. 
4 Rearing without clonus 
Animal adopts a posture with prominent kyphosis. Head bobbing or nodding 
may occur, but movement is not clonic. 
5 Rearing with clonus 
Similar to score 4 with addition of clonic movement of one or both 
paws/forelimbs. Animal may transiently lose balance but never falls on side. 
Continuous clonic movements lasts  ≤ 10 min. 
6 
Generalized 
seizure with 
righting reflex 
Animals start showing generalized convulsive seizures but will not lose their 
righting reflex. Convulsive seizures rarely last longer than 1 min. 
7 
Generalized 
seizure with loss 
of righting or 
violent jumping 
Similar to score 6, but animal will fall on side for ≥5 seconds due to hind and 
forelimb clonus. Animal may barrel roll or violently jump (popcorn) and run 
around cage. 
8 
Status 
Epilepticus, 
continuous 
generalized 
seizure activity 
Sustained score 5-7 seizures for ≥ 20 min. Typically, score 5 seizures evolve 
to score 6-7 and resolve back to score 5 without any intervening periods of 
absent convulsive seizure activity or lesser seizure scores. Clonic seizures 
involving loss of posture may proceed uninterrupted for tens of minutes. 
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4.3.3 Histology  
SLC7A11+/+ or SLC7A11sut/sut mice administered 22.5 mg/kg KA (escalated 
dosing paradigm) were sacrificed 72 hr later by transcardial perfusion and fixation with 
ice-cold 1x PBS and 4% paraformaldehyde (PFA) in PBS. Following removal from the 
cranium, brains were post-fixed in 4% PFA in PBS for 24 hr (4°C), transferred to a 20% 
sucrose solution for 24 hr (4°C), and then snap-frozen on dry ice in Optimal Cutting 
Temperature (O.C.T.) compound (Tissue-Tek, Torrance, CA) prior to storage at -80°C. 
Frozen brains were cut serially (≈-0.94 – -2.46 mm posterior to bregma) into 14 µm 
coronal sections, mounted on SuperFrost Plus slides (Fisher Scientific, Houston, TX), 
air dried at room temperature for 24 hours, and then stored at -20°C until processing. 
4.3.3.1 Thionin staining 
Frozen sections were removed from -20°C and initially incubated in a descending 
ethanol series of 70% (five min) and 50% (one min) ethanol followed by a one min rinse 
in deionized (DI) water prior to incubation in 0.5% thionin (Sigma Chemical Co., St 
Louis, MO) for 10 min. Slides were rinsed in DI water 2x for one min each followed by 
serial dehydration in absolute ethanol (70%, 95%, 100%, 100%; one min each). Ethanol 
was cleared with xylenes (2x for one or three min each), after which coverslips were 
mounted using Permount mounting media.  
4.3.3.2 Fluoro Jade C staining 
Tissue sections within 168 µm of those processed for thionin staining were 
Fluoro Jade C stained (AAT Bioquest, Sunnyvale, CA). Frozen sections were removed 
from -20°C and dried at 50-60°C for 25-30 min. Samples were initially incubated with 
basic alcohol solution (1% NaOH in absolute ethanol) for 5 min followed by 70% ethanol 
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for 2 min and a 2 min rinse in deionized (DI) water. Sections were then placed in 0.06% 
potassium permanganate for 10 min, rinsed in DI water for 2 min, and then placed in 
0.0001% Fluoro Jade C in 0.1% acetic acid for 10 min. Samples were rinsed in DI water 
3X for 1 min each, dried on a slide warmer at 50-60°C, and images captured with a 
Zeiss Axio Imager A2 microscope equipped with epifluorescence and an AxioCam MRc 
digital camera (Carl Zeiss, Germany). Following image acquisition, samples were 
cleared with xylenes and mounted with DPX mounting media. All images were 
processed identically using Zen Microscope and Imaging Software (Carl Zeiss, 
Germany, RRID: SCR_013672) and Microsoft PowerPoint. 
 
4.3.4 Immunoblotting 
4.3.4.1 Plasma membrane protein isolation 
A separate cohort of SLC7A11+/+ or SLC7A11sut/sut mice having undergone the 
escalating KA dosing paradigm were perfused transcardially with ice-cold 1x PBS under 
full anesthesia within 5-25 min of diazepam injection. Cortices were dissected, snap 
frozen in liquid nitrogen, and stored at -80°C prior to use. Plasma membrane proteins 
were isolated from bilateral cortices (one mouse/sample) using an aqueous two-phase 
separation method as per manufacturer’s instructions (Plasma Membrane Protein 
Extraction Kit, Abcam, Cambridge, U.K.). Isolated proteins were suspended in 0.5% 
Triton X-100 in PBS. Samples were stored at -80°C until immunoblotting. Protein 
concentrations were quantified using the BCA assay kit (Pierce, Rockford, IL).  
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4.3.4.2 Gel electrophoresis and protein detection 
Protein samples (7.5 µg) were separated by 8% SDS-PAGE under reducing 
(10mM dithiothreitol) and chaotropic (8M urea) conditions followed by electrophoretic 
transfer to a PVDF membrane (Bio-Rad; Hercules, CA). Membranes were blocked for 
one hr at room temperature (Odyssey® blocking buffer, LI-COR Biosciences; Lincoln, 
NE) then probed overnight (4°C) with the following antibodies: anti-Na+/K+ ATPase α1 
mouse monoclonal antibody (1:750; Abcam; RRID: AB_306023); anti-GluA1 rabbit 
polyclonal antibody (1:750; Abcam; RRID:AB_2113447); anti-GluA2 rabbit polyclonal 
antibody (1:750; Abcam; RRID:AB_2232655); anti-GluN1 rabbit monoclonal antibody 
(1:750; Cell Signaling; RRID: AB_1904067); anti-GABAARα1 rabbit polyclonal antibody 
(1:3000; Abcam; RRID: AB_732498). Species-specific secondary antibodies labeled 
with spectrally distinct IRDye® fluorescent dyes (LI-COR Biosciences, Lincoln, NE) 
were used to detect primary antibodies (1 hr at 25°C) (1:10,000 dilution). Results were 
recorded on a LI-COR ODYSSEY® Fc Imaging system (LI-COR Biosciences; Lincoln, 
NE) and protein levels quantified using Image Studio 3.1 (LI-COR Biosciences; Lincoln, 
NE). Each protein was normalized to the Na+/K+ ATPase (males) or total protein 
(females) levels contained in each lane. The signal intensity pertaining to the amount of 
cortical protein per lane (7.5 µg) was determined to be in the linear range for each 
antibody at their respective dilution (data not shown).  
 
4.3.5 Statistical analysis 
All statistical analyses were performed using GraphPad Prism (Version 6.0.1, 
Graphpad Software, Inc., La Jolla, CA). Acute seizure severity and proportions 
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indicating the percent of mice convulsing were compared using a Mann-Whitney U test 
and Fisher’s exact test, respectively. An unpaired t test with Welch’s correction was 
used to compare latency to seizure. Curves depicting the median seizure scores over 
time were compared using a comparison of fit test, while individual seizure scores over 
time were compared using the Kruskal-Wallis test. Kaplan Meier survival curves were 
compared using the Mantel-Cox log-rank test. Prior to parametric analysis, immunoblot 
data was log transformed (y = log(y+1)) and compared using two-way ANOVA. In all 
cases, significance was set at p < 0.05.  
 
4.4 Results  
 
Acute KA-induced seizure severity  
The behavioral seizure severity in response to a single acute dose of KA (12-15 
mg/kg) was compared in SLC7A11+/+ and SLC7A11sut/sut mice. Irrespective of genotype 
or sex, within minutes of receiving the dose of KA, all mice exhibited a decrease in 
spontaneous locomotor activity (seizure score = 1). This behavior was often followed by 
hypermobility, manifest by excessive pacing, climbing, or unilateral rotations (seizure 
score = 2), or sporadic myoclonic twitches (seizure score = 3). In a subset of mice, 
behavioral seizures progressed to a kyphosis, or hunchback, posture (seizure score = 
4). The majority of SLC7A11sut/sut (19/20), and a subset of SLC7A11+/+ mice (4/17), 
progressed to behavioral clonic or convulsive seizures manifest by kyphosis with 
forelimb clonus (seizure score = 5), a generalized convulsion (seizure score = 6), or a 
generalized convulsion with loss of righting reflex and/or violent jumping (seizure score  
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Figure 4.1 Comparison of acute KA-induced seizure activity in SLC7A11+/+ and 
SLC7A11sut/sut mice 
Male (n = 6) and female (n = 11) SLC7A11+/+ (+/+, total = 17) and male (n = 7) and 
female (n = 13) SLC7A11sut/sut (sut/sut, n = 20) littermates were treated with a single 
dose of either 12 mg/kg (males) or 15 mg/kg (females) KA (i.p.). Seizure behavior was 
scored using a 9 point scale as described in the materials and methods. Data were 
pooled from 6 independent experiments performed over 2 months.   
A-C) Individual seizure scores: Each data point [closed black circles (+/+) or open 
circles (sut/sut)] represents the maximal seizure score obtained by an individual mouse: 
(A) male and females combined, (B) females, or (C) males only during a 30 min 
observation period. Horizontal lines represent the median seizure score for each 
genotype. SLC7A11sut/sut mice have significantly greater seizure severity as compared 
to SLC7A11+/+ littermate controls (*p = 0.0002, **p < 0.0001; Mann-Whitney U Test).  
B) Convulsive index: Bars [closed black bar (+/+) and open bar (sut/sut)] represent the 
proportion (fraction within bars) of mice that experienced a clonic seizure (seizure score 
≥ 5) in A (D), B (E), or C (F) expressed as a % of total mice exposed to KA. 
SLC7A11sut/sut mice have a higher clonic index compared to SLC7A11+/+ littermate 
controls as denoted by the asterisk(s) (*p = 0.0210, **p = 0.0005, ***p < 0.0001; Fisher’s 
Exact Test).  
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Figure 4.2 Comparison of convulsive seizure latency between SLC7A11+/+ and 
SLC7A11sut/sut mice 
The latency to convulsion of SLC7A11+/+ (+/+, n= 4; 2M, 2F) and SLC7A11sut/sut (sut/sut, 
n = 19; 7M, 12F) mice that achieved a score of ≥ 5 in Figure 4.1 is graphed.  
A-C) Each data point [closed black circles (males) or open circles (females)] represents 
the latency to convulsion (behavioral score ≥ 5) of a single mouse during the 30 min 
observation period: (A) combined males plus females, (B) females, or (C) males only. 
Bars represent the median latency for each genotype. SLC7A11sut/sut mice have a 
decreased convulsive seizure latency as compared to SLC7A11+/+ littermate controls as 
denoted by the asterisk (A only; *p = 0.0346, Unpaired t test with Welch’s correction).  
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= 7). A fraction of SLC7A11sut/sut mice exhibited unremitting clonic/convulsive seizure 
activity as evidenced by a score of 5, 6, or 7 for ³ 20 min and as such, these mice were 
assigned a score of 8 (status epilepticus).  
The median seizure score in female and male SLC7A11sut/sut mice was 
significantly greater than that of SLC7A11+/+ littermate controls (Fig. 4.1A p < 0.0001; 
Mann-Whitney U test). Stratification of this data by sex revealed that female (Fig. 4.1B; 
p = 0.0002) but not male (Fig. 4.1C; p = 0.1142) SLC7A11sut/sut mice have significantly 
enhanced seizure severity as compared to SLC7A11+/+ sex-matched littermate controls 
at their respective KA doses (Mann Whitney U test). Furthermore, a decreased 
convulsive seizure threshold was evident in the SLC7A11sut/sut mice, with 95% (19/20) 
reaching a seizure stage ≥ 5, compared to 23.5% (4/17) of SLC7A11+/+ mice (Fig. 4.1D; 
p < 0.0001; Fisher’s exact test). This effect, however, was sex-independent, with 92.3% 
of female and 100% of male SLC7A11sut/sut mice experiencing a clonic seizure as 
compared to 18.2% of female and 33.3% of male SLC7A11+/+ sex-matched littermate 
controls (Females, Fig. 4.1E, p = 0.0005; Males, Fig. 4.1F, p = 0.0210; Fisher’s exact 
test). Finally, the mean latency to clonus was decreased in combined female and male 
SLC7A11sut/sut mice as compared to SLC7A11+/+ littermate controls (Fig. 4.2A; 265 ± 57 
and 302 ± 45 sec, mean ± SEM, for SLC7A11+/+ and SLC7A11sut/sut mice, respectively, 
p = 0.0346, unpaired t-test with Welch’s correction). It is also noteworthy that the latency 
to clonic seizure was reduced in SLC7A11sut/sut versus sex-matched SLC7A11+/+ female 
(Fig. 4.2B; 1044 ± 148.5 s in SLC7A11sut/sut vs. 1493 ± 171 s in SLC7A11+/+, mean ± 
SEM) and male (Fig. 4.2C; 1444 ± 122.6 s in SLC7A11sut/sut vs. 1711 ± 37.5 s in  
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Figure 4.3 Comparison of SLC7A11+/+ and SLC7A11sut/sut seizure severity in the 
escalating KA dosing paradigm 
 
Male (n = 12) and female (n =16) SLC7A11+/+ (+/+, total n = 28) and male (n = 13) and 
female (n = 12) SLC7A11sut/sut (sut/sut, total n = 25) littermates underwent the escalating 
KA dose treatment paradigm and behavioral responses were scored using a 9-point 
scale as described in the materials and methods. Data were pooled from 9 independent 
experiments performed over 4 months.  
A-C) Time Course: The shaded area represents the 150 min interval in which KA was 
administered. Each data point [closed black circles (+/+) or open circles (sut/sut)] 
represents the median maximal seizure score obtained: (A) females and males 
combined, (B) females, or (C) males only for each 10 min interval of the 240 min 
treatment paradigm. Green linear regression lines are fitted from the last kainate dose (t 
= 150 min) to the end of the protocol (t = 240 min). Slope of the SLC7A11sut/sut line is 
significantly different from slope of the SLC7A11+/+ line as denoted by the asterisk (p < 
0.0001; Comparison of fit test). 
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Figure 4.4 Comparison of individual SLC7A11+/+ and SLC7A11sut/sut mouse seizure 
severity in the escalating KA dosing paradigm 
The individual seizure scores of mice administered KA in Figure 4.3 were compared.  
A-C) Individual seizure scores: Each data point [closed black circles (+/+) or open 
circles (sut/sut)] represents the median seizure score obtained by an individual mouse: 
(A) females and males combined, (B) females, or (C) males only calculated from the 
maximal seizure score obtained over the six 10 min intervals contained in each quartile 
(Q1-Q4). Bars represent the median seizure score for each genotype calculated using 
the median score from all animals. SLC7A11sut/sut mice have significantly lower seizure 
severity in the final 60 min quartile (Q4) of the four hour KA dosing paradigm as 
compared to SLC7A11+/+ littermate controls as denoted by the asterisk(s) (*p < 0.01, **p 
< 0.001, ***p < 0.0001; Kruskal-Wallis test). 
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SLC7A11+/+, mean ± SEM) littermates, although the sample sizes preclude a sufficiently 
powered statistical comparison. 
 
Seizure severity in mice administered an escalating dose of KA  
To further explore changes in excitability, mice were administered an escalating 
dose of KA (22.5 mg/kg over 150 min) (Claycomb et al 2012). Similar to behavioral 
seizure activity elicited in the acute paradigm, a profound hypomobility was observed in 
in all mice regardless of genotype or sex within minutes of the initial 10 mg/kg dose of 
KA. As the dosing protocol progressed over the first hour, the median maximal seizure 
score (MMSS) in the SLC7A11sut/sut mice reached a score of 5 (kyphosis with forelimb 
clonus) compared to a score of 4 (kyphosis) in SLC7A11+/+ littermate controls (Fig. 
4.3A). However, by the second hour of the protocol (t = 120 min), the behavior of 
SLC7A11sut/sut mice was indistinguishable from their SLC7A11+/+ littermate controls (Fig. 
4.3A). Interestingly, in the 90 min following the final KA dose (t = 150-240 min), the 
MMSS trend lines fit to seizure scores in SLC7A11+/+ and SLC7A11sut/sut mice began to 
diverge (green lines on Fig. 4.3A, p < 0.0001, comparison of fit test). Upon receiving the 
final dose of KA at t = 150 min, seizure activity in SLC7A11+/+ mice escalated such that 
the MMSS reached status epilepticus (seizure score = 8) by the final hour of the 
protocol. Unexpectedly, SLC7A11sut/sut mice exhibited a striking decrease in behavioral 
seizure severity within the final hour of the protocol dominated by immobility (seizure 
score = 1) in the majority of mice. Of note, the aforementioned seizure behaviors 
occurred independent of sex, with both female (Fig. 4.3B) and male (Fig. 4.3C) 
SLC7A11sut/sut mice exhibiting hypomobility in the final quartile of the paradigm as 
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compared to SLC7A11+/+ sex-matched littermate controls, which were consistently in 
status epilepticus.  
A comparison of the MMSS of individual mice in each quartile of the paradigm 
further demonstrated the divergence in seizure activity between SLC7A11+/+ and 
SLC7A11sut/sut mice in the final quartile of the escalating dose protocol. While the 
median MMSS of the population of male and female (Fig. 4.4A), female (Fig. 4.4B), or 
male (Fig. 4.4C) SLC7A11+/+ mice was at a seizure score = 8 in the fourth quartile, the 
median MMSS of the SLC7A11sut/sut mice was at a seizure score = 1 (Females and 
males, Fig. 4.4A, p < 0.0001; Females, Fig. 4.4B, p < 0.01; Males, Fig. 4.4C, p < 0.001; 
Kruskal-Wallis test).  
 
Incidence of status epilepticus (SE) and fatality in escalated dosing paradigm. 
The disparity in behavioral seizure activity induced by an escalating dose of KA 
was further exemplified by examining the incidence of status epilepticus in quartile four, 
which was three times greater in SLC7A11+/+ [85.2% (23/27)] as compared to 
SLC7A11sut/sut mice [28% (7/25)] (Fig. 4.5A; p < 0.0001; Fisher’s exact test). This effect 
was also sex-independent, with 81.3% of female and 91% of male SLC7A11+/+ mice 
experiencing status epilepticus as compared to 33.3% of female and 23.1% of male 
SLC7A11sut/sut sex-matched littermate controls (Females, Fig. 4.5B, p = 0.0189; Males, 
Fig. 4.5C, p = 0.0013; Fisher’s exact test).   
 In toto, 23% (12/53) of mice administered an escalating dose of KA died over the 
course of the four-hour paradigm, with all but one of the deaths occurring in the final 
hour after cessation of the 150 min dosing period (Fig. 4.6). Notably, the majority of 
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deaths occurred in SLC7A11+/+ mice, with just 64.3% (18/28) of SLC7A11+/+ as 
compared to 92% (23/25) of SLC7A11sut/sut mice surviving the paradigm (Fig. 4.6A; p = 
0.0137, Mantel-cox log-rank test). This effect was driven by a decreased incidence of 
death in SLC7A11sut/sut male mice relative to SLC7A11+/+ sex-matched controls; 92.3% 
(12/13) of SLC7A11sut/sut mice survived the paradigm as compared to 58.3% (7/12) of 
SLC7A11+/+ mice (Fig. 4.6C; p = 0.0402; Mantel-cox log-rank test). A similar decrease 
in KA-induced mortality, although statistically insignificant (Fig. 4.6B; p = 0.1374, 
Mantel-cox log-rank test), was observed in SLC7A11sut/sut female mice.  
 
KA-induced hippocampal neural degeneration occurs in different sub-regions in 
SLC7A11+/+ and SLC7A11sut/sut mice. 
A subset of SLC7A11+/+ and SLC7A11sut/sut mice dosed with 22.5 mg/kg KA (Fig. 
4.3A) were sacrificed 72 hr post-seizure initiation and brains were processed for thionin 
or Fluoro-Jade C staining. All of the tissue analyzed was derived from SLC7A11+/+ (Fig. 
4.7A, 5 females, 3 males) or SLC7A11sut/sut (Fig. 4.7B, 4 females, 1 male) mice that 
achieved behavioral seizure scores of 6 (generalized convulsion) or 7 (generalized 
convulsion with loss of righting reflex and/or violent jumping) over the course of the 
dosing paradigm. Despite their behavioral seizure similarities, the hippocampal neural 
degeneration in SLC7A11+/+ and SLC7A11sut/sut mice occurred with striking sub-region 
specificity. Though the incidence of neural degeneration occurred in a similar fraction of 
SLC7A11+/+ [37.5% (3/8; 2 males, 1 female)] and SLC7A11sut/sut [60% (3/5; 1 male, 2 
females)] mice (p = 0.5921; Fisher’s exact test), degeneration in the SLC7A11+/+ mice  
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Figure 4.5 Effect of SLC7A11 disruption on incidence of status epilepticus SE in 
the escalating KA paradigm. 
A-C) Bars represent the proportion (fraction within bars) of SLC7A11+/+ [+/+, n = 27 
(11M, 16F)] and SLC7A11sut/sut [sut/sut, n = 25, (13M, 12F)] mice that experienced a 
seizure score = 8 (SE) in the final 60 min quartile of the four hour KA dosing paradigm. 
*Indicates significant between group difference (*p = 0.0189, **p = 0.0013, ***p < 
0.0001; Fisher’s exact test). 
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Figure 4.6 Effect of SLC7A11 disruption on mortality in the escalating KA 
paradigm. 
A-C) Kaplan-Meier survival curves up to 72 hr following initial KA dose for SLC7A11+/+ 
[+/+, n = 28 (12M, 16F)] and SLC7A11sut/sut [sut/sut, n = 25, (13M, 12F)] (A) females and 
males combined, (B) females, or (C) males are graphed. Each data point represents the 
time at which individual mice died during the KA dosing protocol or over the following 72 
hr. Fractions represent the proportion of mice that survived the 240 min KA paradigm 
(shaded region). *Indicates significant between group difference (*p = 0.0402, **p = 
0.0137; Mantel-Cox log-rank test). 
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Figure 4.7 Comparison of cellular degeneration in hippocampus of SLC7A11+/+ 
and SLC7A11sut/sut mice exposed to the escalating KA dose paradigm 
A cohort of SLC7A11+/+ and SLC7A11sut/sut mice responding to the escalated KA dosing 
paradigm with a seizure score ≥ 6 were sacrificed 72 hr later by transcardial perfusion 
and fixation with 4% PFA. Brains were removed and coronal sections of 14 μm 
thickness were taken at 28 μm intervals spanning the hippocampal formation. 
A-B) Representative photomicrographs of (A) SLC7A11+/+ (+/+, n = 8) and (B) 
SLC7A11sut/sut (sut/sut, n = 5) brain sections stained with (a-d) thionin or (e-h) Fluoro-
Jade C. Photomicrographs represent the hippocampal formation ≈ -1.2 to -1.9 anterior 
to posterior from bregma (a, e; 4X); the CA1 (b, f; 10X); the CA3 (c, g; 10X); and the 
dentate gyrus (DG) (d, h; 10X).  
C) Incidence of hippocampal histological damage: Bars represent the proportion 
(fraction within bars) of SLC7A11+/+ (+/+, black bar) and SLC7A11sut/sut (sut/sut, blue 
bar) mice with degenerating cells in the hippocampal formation sub-regions (CA1, CA3, 
or DG) as indicated by positive Fluoro-Jade C staining. 
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occurred primarily in the hippocampal CA1 sub-region whereas degeneration was 
limited to area CA3 in SLC7A11sut/sut mice (Fig. 4.7C). This was demonstrated by 
pyknosis or green fluorescence predominating in the CA1 (Fig. 4.7Ab and Fig. 4.7Af) or 
CA3 (Fig. 4.7Bc and Fig. 4.7Bg) of SLC7A11+/+ or SLC7A11sut/sut mice, respectively. 
 
Plasma membrane protein expression levels 
Despite receiving 22.5 mg/kg KA over the course of the escalating dosing 
paradigm, the majority of SLC7A11sut/sut mice exhibited profound hypo-excitability 
(seizure score = 1) in the fourth quartile of the protocol, a behavioral state polar 
opposite to SLC7A11+/+ littermate controls who entered into behavioral status 
epilepticus (seizure score = 8). Given that aberrations in plasma membrane levels of 
AMPA (GluA1, GluA2), NMDA (GluN1), or GABA (GABAARα) receptor subunits are 
associated with abnormal neuronal synchronization (Kelley et al 2016, Mathern et al 
1998, Raol et al 2006), we measured cortical plasma membrane expression levels of 
this suite of proteins to investigate whether alterations in such could underlie the 
behavioral hypo-excitability observed in the majority of SLC7A11sut/sut mice.  
As such, comparisons were made between cortical plasma membrane proteins derived 
from naïve SLC7A11+/+ and SLC7A11sut/sut mice as well as mice of each genotype that 
entered into a state of KA-induced hypomobility (MMSS = 1) or status epilepticus 
(MMSS = 8) in the final quartile of the escalating dose paradigm. Western blot analysis 
revealed no change in female and male SLC7A11+/+ and SLC7A11sut/sut GluA1 (Fig. 
4.8A), GluA2 (Fig. 4.8B), GluN1 (Fig. 4.8C), or GABAARa (Fig. 4.8D) expression levels 
(two-way ANOVA with Tukey’s multiple comparisons). Moreover,  
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Figure 4.8 Comparison of plasma membrane protein expression in SLC7A11+/+ 
and SLC7A11sut/sut mice 
Plasma membrane protein levels in cortex derived from female and male SLC7A11+/+ 
(+/+) or SLC7A11sut/sut (sut/sut) littermates naïve to any treatment (ctrl) or mice 
exhibiting hypo-mobility [KA (1)] or status epilepticus [KA (8)] in the final quartile of the 
four hour escalating dose paradigm were compared using Western blot analysis (see 
methods). Each data point [closed black circles (+/+; n = 8) or open circles (sut/sut; n = 
8) represents the level of cortical (A) GluA1, (B) GluA2, (C) GluN1, or (D) GABAARa 
protein following normalization to their respective loading control (i.e., Na+/K+ ATPase 
levels or total protein) and subsequent normalization to +/+ controls. Bars indicate the 
mean fold change from control (+/+), which was set to one. Cortical plasma membrane 
protein expression levels were compared using a two-way ANOVA on log-transformed 
data.  
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Figure 4.9 Comparison of plasma membrane protein expression in female 
SLC7A11+/+ and SLC7A11sut/sut mice 
Plasma membrane protein levels in cortex derived from female SLC7A11+/+ (+/+) or 
SLC7A11sut/sut (sut/sut) littermates naïve to any treatment (ctrl) or mice exhibiting hypo-
mobility [KA (1)] or status epilepticus [KA (8)] in the final quartile of the four hour 
escalating dose paradigm were compared using Western blot analysis (see methods). 
Each data point [closed black circles (+/+; n = 4) or open circles (sut/sut; n = 4) 
represents the level of cortical (A) GluA1, (B) GluA2, (C) GluN1, or (D) GABAARa 
protein following normalization to their respective loading control (i.e. total protein 
levels) and subsequent normalization to +/+ controls. Bars indicate the mean fold 
change from control (+/+), which was set to one. Representative Western blots of +/+ 
and sut/sut cortical plasma membrane proteins are shown beside their respective 
graphs. Cortical plasma membrane protein expression levels were compared using a 
two-way ANOVA on log-transformed data.  
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Figure 4.10 Comparison of plasma membrane protein expression in male 
SLC7A11+/+ and SLC7A11sut/sut mice 
Plasma membrane protein levels in cortex derived from male SLC7A11+/+ (+/+) or 
SLC7A11sut/sut (sut/sut) littermates naïve to any treatment (ctrl) or mice exhibiting hypo-
mobility [KA (1)] or status epilepticus [KA (8)] in the final quartile of the four hour 
escalating dose paradigm were compared using Western blot analysis (see methods). 
Each data point [closed black circles (+/+; n = 4) or open circles (sut/sut; n = 4) 
represents the level of cortical (A) GluA1, (B) GluA2, (C) GluN1, or (D) GABAARa 
protein following normalization to their respective loading control (i.e., Na+/K+ ATPase 
[NKA] levels) and subsequent normalization to +/+ controls. Bars indicate the mean fold 
change from control (+/+), which was set to one. Representative Western blots of +/+ 
and sut/sut cortical plasma membrane proteins are shown above their respective 
graphs. Cortical plasma membrane protein expression levels were compared using a 
two-way ANOVA on log-transformed data. An asterisk (*) represents a significant 
between group difference (p < 0.05).  
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stratification of this data by sex revealed a similar trend in female SLC7A11+/+ as 
compared to SLC7A11sut/sut sex-matched littermates, who also demonstrated similar 
levels of GluA1, GluA2, GluN1, and GABAARa protein levels (Fig. 4.9; two-way ANOVA 
with Tukey’s multiple comparisons). Interestingly, while glutamate receptor subunits 
were similar between male SLC7A11+/+ and SLC7A11sut/sut sex-matched littermates 
regardless of treatment (Fig. 4.10A-C), male SLC7A11sut/sut mice that became 
hypomobile by the end of the four-hour protocol demonstrated elevated GABAARa 
expression levels as compared to male SLC7A11sut/sut mice that entered into status 
epilepticus (Fig. 4.10D, p < 0.05, two-way ANOVA with Tukey’s multiple comparisons). 
 
4.5 Discussion 
Results presented in Chapter 2 demonstrated that SLC7A11sut/sut mice have a 
decreased seizure threshold upon administration of an acute dose of PTZ. Despite this, 
SLC7A11sut/sut mice were less susceptible to PTZ-kindling (Chapter 3), suggesting that 
Sxc- contributes to E/I balance in a context-dependent manner. The present chapter 
extends these findings by demonstrating that alterations in excitability observed in 
SLC7A11sut/sut mice were generalizable to acute and elevated KA dosing seizure 
paradigms.  
KA induces excitatory activity by binding to both AMPA receptors as well as its 
own cognate receptors (Vincent & Mulle 2009). In response to an acute systemic dose 
of KA, a significantly greater number of female and male SLC7A11sut/sut mice 
experienced a clonic or convulsive seizure as compared to SLC7A11+/+ littermates, 
indicating that they have a decreased KA-induced seizure threshold. While these results 
support our initial studies using the GABAAR antagonist PTZ (Chapter 2), they are in 
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contrast with results reported by De Bundel et al demonstrating that transgenic xCT null 
(xCT-/-) mice on a C57BL/6 background require a significantly greater dose of KA to 
elicit behavioral clonus, and thus have an increased seizure threshold, as compared to 
xCT+/+ littermate controls (De Bundel et al 2011). Given that both the xCT-/- and 
SLC7A11sut/sut mice are xCT null (Chintala et al 2005, De Bundel et al 2011, McCullagh 
& Featherstone 2014), the reason for the discrepancy in findings is not immediately 
clear. However, it may be accounted for by differences in experimental paradigms. In 
De Bundel et al, continuous intravenous infusion of chemoconvulsant resulted in rapid 
behavioral seizure onset such that clonic seizures were evoked in xCT+/+ and xCT-/- 
mice by the time 58.1 or 75.6 mg/kg KA was infused, respectively (De Bundel et al 
2011). However, it is difficult to attribute behavioral activity to a given dose when the 
dose is continuously changing, and it is possible that 58 mg/kg KA could elicit clonus in 
both xCT+/+ and xCT-/- mice, but xCT-/- mice have an increase in clonic seizure latency. 
While the clonic latencies were not calculated in De Bundel et al, keeping the weight of 
an animal constant, the rapid infusion rate (150 µl/min) utilized in this protocol would 
result in a dose of 58.1 mg/kg by »77 sec versus a dose of 75.6 mg/kg by »100 
seconds, which were the doses that evoked clonic seizures in xCT+/+ or xCT-/- mice, 
respectively. Whether this change represents a significant difference in latency to 
clonus (77 versus 100 sec) is uncertain. Despite the discrepancy between the De 
Bundel et al study and our own, the present findings in this chapter parallel the results 
seen using the GABAAR antagonist PTZ (Chapter 2), and provide further evidence that 
SLC7A11sut/sut mice have a decreased acute seizure threshold.  
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Interestingly, repeated administration of KA in the elevated dosing paradigm 
revealed the opposite behavioral results; regardless of sex, the majority of 
SLC7A11sut/sut mice became profoundly hypomobile as compared to SLC7A11+/+ 
littermate controls in the final quartile of the dosing protocol. Given the acute hyper-
excitability observed in the SLC7A11sut/sut mice, it is tempting to speculate that the 
hypomobility seen in the latter portion of the escalating dose paradigm is simply due to 
excessive excitation and a resultant comatose post-ictal state. However, this does not 
appear to be the case, as this type of hypo-activity is usually associated with death and 
the SLC7A11sut/sut mice exhibiting hypomobility in the final quartile fully recover – with 
diazepam administration ostensibly superfluous in some mice (S. Sears personal 
observations). In fact, SLC7A11sut/sut mice have significantly decreased mortality overall 
as compared to SLC7A11+/+ littermate controls in this paradigm.    
In the final quartile of the elevated dosing paradigm, SLC7A11sut/sut mice 
exhibited a significantly decreased incidence of status epilepticus as compared to 
SLC7A11+/+ mice. KA-induced behavioral convulsions are typically associated with 
structural alterations, as excessive depolarization can result in cell death (Olney et al 
1974), and cell populations in the CA3 sub-region of the hippocampal formation have 
been demonstrated to be particularly vulnerable to KA-induced degeneration (Nadler et 
al 1980). However, mouse strain differences with respect to KA-induced degeneration 
do exist (Schauwecker 2003). As such, a subset of mice that attained a seizure score ³ 
6 were examined for overt hippocampal cellular degeneration. Interestingly, 
degeneration was not pervasive in every mouse examined, though of the mice that did 
exhibit cell loss, the hippocampal sub-region affected was strikingly genotype specific 
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with the CA1 and CA3 region exhibiting neural degeneration in SLC7A11+/+ and 
SLC7A11sut/sut mice, respectively. Although xCT is expressed throughout the 
hippocampal formation, Ottested-Hansen and colleagues recently demonstrated that 
xCT protein levels are greatest in the stratum lacunosum moleculare (SLM) and the 
molecular layer of the dentate gyrus (DG) (Ottestad-Hansen et al 2018). Interestingly, 
afferent projections from the entorhinal cortex (EC) terminate in both of these layers 
(Amaral et al 2007). This gives rise to the intriguing possibility that afferent EC 
projections to the SLM, together with Sxc- signaling, promotes neural degeneration in 
the CA1 hippocampal sub-region, and that lack of Sxc- thwarts this degeneration. 
Although the DG molecular layer is relatively cell-free – containing granule cell dendrites 
and inhibitory basket cells (Amaral et al 2007) – it is possible that afferent EC 
projections, together with Sxc- signaling, promotes basket cell-mediated inhibitory drive 
onto granule cells, thus thwarting over-activation of their CA3 synaptic targets and 
preventing KA-mediated CA3 cell death. Conversely, lack of Sxc- signaling in the 
molecular layer of SLC7A11sut/sut mice could render DG granule cells hyper-active, thus 
underlying the enhanced neural degeneration of their CA3 synaptic partners. 
Regardless of the underlying mechanism, the sub-region specific differences in 
SLC7A11+/+ and SLC7A11sut/sut mice neural degeneration elicited by an elevated dose 
of KA suggest that Sxc- signaling regulates hippocampal circuitry. Nevertheless, 
hippocampal sub-region notwithstanding, the incidence of KA-induced cellular 
degeneration was similar in either genotype. Taken together, although not completely 
comparable to the chronic 21-day PTZ-kindling paradigm (Chapter 3), the behavioral 
hypo-excitability observed in response to an elevated KA dosing protocol in the present 
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chapter is qualitatively similar, suggesting that loss of Sxc- increases seizure threshold 
in response to repeated/chronic chemoconvulsant administration. 
The increased synaptic drive elicited by repeated chemoconvulsant 
administration could plausibly engage homeostatic synaptic scaling mechanisms to 
allow stabilization of neuronal firing rate (Christie & Jahr 2008, Turrigiano 2008, 
Turrigiano et al 1998). This process is largely accomplished through the addition and 
subtraction, respectively, of ionotropic AMPA (O’Brien et al 1998, Turrigiano et al 1998, 
Wierenga et al 2005), NMDA (Mu et al 2003, Rao & Craig 1997, Watt et al 2000) or 
GABAA (Kilman et al 2002, Stellwagen et al 2005) receptors at the postsynaptic 
membrane. As such, we compared glutamate and GABAA receptor levels in cortical 
plasma membrane of naïve or KA-treated SLC7A11+/+ and SLC7A11sut/sut mice. Out of 
all of the receptors investigated, the only difference observed was in GABAARa levels: 
male, but not female, SLC7A11sut/sut mice that attained a MMSS = 1 (hypomobility) in 
the final quartile of the escalated dosing paradigm had increased GABAARa levels as 
compared to sex-matched SLC7A11sut/sut mice that reached a MMSS = 8 (status 
epilepticus). However, neither KA-treated group significantly differed from naïve 
SLC7A11sut/sut mice nor from naïve or KA-treated SLC7A11+/+ sex-matched controls. 
These results give rise to the intriguing possibility that KA-administration resulting in a 
slight increase in GABAARa expression in the SLC7A11sut/sut mice confers diminished 
excitatory seizure activity – a behavioral state evident in the majority of SLC7A11sut/sut 
mice – whereas a slight decrease in GABAARa expression does the opposite. However, 
these findings do not rule out the possibility that the changes detected in plasma 
membrane are driven by alterations in extrasynaptic (Brickley & Mody 2012) versus 
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synaptic GABAARs, and it will be important to determine whether GABAAR-dependent 
inhibitory postsynaptic currents (IPSCs) are functionally enhanced in the KA-treated 
male SLC7A11sut/sut mice with a fourth quartile MMSS = 1. Nevertheless, it is plausible 
that the fourth quartile hypo-excitability observed in SLC7A11sut/sut male mice is driven 
by an increase in plasma membrane GABAARa expression. The mechanism conferring 
behavioral hypo-excitability in female SLC7A11sut/sut mice requires further investigation. 
Finally, the idea that this phenotype (behavioral hypo-excitability) is sex-independent yet 
could be driven by sex-dependent differences (altered GABAAR expression in males 
versus unknown mechanism(s) in females) is perhaps unsurprising given results 
described in Chapter 2 of this dissertation, whereby a sex-independent hyperexcitable 
phenotype occurred in association with sex-dependent cellular morphological changes.   
Taken together, our results demonstrate that SLC7A11sut/sut mice have a 
decreased convulsive seizure threshold in response to acute KA administration whereas 
an elevated dosing paradigm using the same chemoconvulsant results in SLC7A11sut/sut 
behavioral hypoactivity as compared to SLC7A1+/+ littermate controls. These results 
suggest that Sxc- contributes to E/I balance in a context-dependent manner. Moreover, 
KA-induced behavioral hypo-excitability in male SLC7A11sut/sut mice occurs in 
association with increased GABAARa levels, suggesting that a change in GABAergic 
function could underlie this phenotype. Whether this alteration in GABAARa protein 
levels confer a functional change in males, and the exact mechanism by which loss of 
Sxc- signaling confers fourth quarter behavioral hypo-excitability in female mice, requires 
further experimentation.  
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Chapter 5: Discussion, conclusions, and future directions  
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5.1 Main findings 
The goal of this dissertation was to elucidate whether and how System xc- (Sxc-) 
signaling contributes to the excitatory/inhibitory (E/I) balance in brain. The main findings 
of this dissertation are that (1) loss of Sxc- in SLC7A11sut/sut mice renders them hyper-
excitable in response to acute administration of two pharmacologically distinct 
chemoconvulsants, PTZ or KA. Furthermore, baseline hyper-excitability in 
SLC7A11sut/sut mice occurs in association with morphological alterations at the gross, 
cellular, and sub-cellular level, as well as with alterations in plasma membrane 
glutamate receptor subunit expression and brain redox status, any or all of which could 
underlie the behavioral responses elucidated. (2) Despite acute hyper-excitability in 
response to either PTZ or KA, chronic/repeated dosing with these same 
chemoconvulsants elicits a polar opposite response – behavioral hypo-excitability – in 
SLC7A11sut/sut mice as compared to SLC7A11+/+ littermate controls.  
 
5.2 Acute hyper-excitability in Sxc- null mice occurs in association with 
morphological, redox, and plasma membrane protein alterations  
Findings presented in this dissertation demonstrate a sex-independent hyper-
excitability phenotype uncovered in SLC7A11sut/sut mice via administration of two 
pharmacologically distinct chemoconvulsants, PTZ or KA. SLC7A11sut/sut mice are 
viable, fertile, do not display spontaneous seizure activity, and, other than a subtle grey 
coat color, particularly apparent in juvenile mice three to four weeks of age, are 
indistinguishable from their C3H/HeSnJ SLC7A11+/+ littermates [personal observations 
and (Chintala et al 2005, Lane 1988)]. Despite their overt similarities to SLC7A11+/+ 
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controls, the behavioral hyper-excitability in SLC7A11sut/sut mice upon acute 
chemoconvulsant administration is indicative of a brain E/I imbalance.  
Previous characterization of male xCT transgenic null mice on a C57BL/6 
background revealed increased spontaneous and evoked miniature excitatory 
postsynaptic currents (mEPSCs) and synaptic AMPA receptor expression levels in 
hippocampal CA1 (Williams & Featherstone 2014). These findings, if true in the 
SLC7A11sut/sut mice, could explain the increased susceptibility to chemoconvulsant-
induced acute seizure activity (Croll et al 1999, Greenwood et al 2009). However, 
neither male (Chapter 3, Fig. 3.6) nor female (Supplementary Fig. S4) SLC7A11sut/sut 
mice have increased levels of plasma membrane glutamate receptors. In fact, the 
AMPA receptor subunit GluA1 is decreased in cortical plasma membrane of male 
(Chapter 3, Fig. 3.6) and hippocampal plasma membrane of female (Supplementary 
Fig. S4) SLC7A11sut/sut mice as compared to SLC7A11+/+ sex-matched littermate 
controls. However, our plasma membrane measurements capture receptors of both 
synaptic and extrasynaptic origin, as well as receptors in all hippocampal and cortical 
sub-regions. Thus, in order to determine if post-synaptic membranes are strengthened 
in SLC7A11sut/sut mice, dendritic spine head width – which correlates with glutamate 
receptor abundance – was measured in cortical layer V pyramidal cells. In agreement 
with findings demonstrating increased synaptic strength in male xCT transgenic null 
mice (Williams & Featherstone 2014), spine head widths in male SLC7A11sut/sut mice 
are increased as compared to SLC7A11+/+ sex-matched littermate controls (Chapter 2, 
Fig. 2.7). Thus, despite a reduction in total cortical plasma membrane GluA1 levels in 
SLC7A11sut/sut male mice, synaptic strength – as measured by spine head width – was 
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enhanced, which could plausibly underlie the acute hyper-excitability in SLC7A11sut/sut 
males. Surprisingly, results in female mice demonstrated the opposite: spine head 
widths of SLC7A11sut/sut mice were significantly decreased as compared to SLC7A11+/+ 
sex-matched littermate controls (Chapter 2, Fig. 2.7). However, these findings do not 
rule out the possibility of changes to hippocampal synapses, which, unfortunately, were 
precluded from our analysis due to the complexity and density of Golgi-Cox stained 
neurons in the hippocampal formation. To further understand how these morphological 
changes translate functionally – and to explore hippocampal synapses – an instructive 
next step would be to record (miniature) excitatory postsynaptic potentials [(m)EPSPs]) 
from whole-cell patch-clamped neurons in order to precisely and quantitatively detect 
changes in quantal content and/or postsynaptic glutamate receptors that could underlie 
a shift in E/I balance towards excitation. 
To explore further mechanisms underlying hyper-excitability in SLC7A11sut/sut 
mice, two additional lines of inquiry, cellular morphology and redox balance, were 
investigated in this dissertation. With respect to morphology, the work presented herein 
uncovered that (1) sex-differences in cellular morphology exist in SLC7A11+/+ mice on 
the C3H/HeSnJ background and (2) within-sex morphological alterations were 
uncovered that could plausibly contribute to genotype-dependent differences in E/I 
balance. With regards to the first finding, our results indicate that soma size is 
significantly increased in female SLC7A11+/+ as compared to male SLC7A11+/+ mice on 
the C3H/HeSnJ background (Chapter 2, Fig. 2.5). To our knowledge, this is the first 
account of sex-differences in cortical layer V neuronal soma size reported in mouse. 
Functionally, it is unclear why a sex-difference in soma size exists. However, loss of 
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Sxc- lends credibility to one possibility: sex morphological differences exist to prevent 
functional differences (De Vries 2004). This idea seems plausible given that loss of Sxc- 
in female SLC7A11sut/sut mice leads to a reduction in soma area – which itself is 
associated with decreased inhibition (Hsu et al 2012, Ye et al 2015) – and occurs in 
association with increased behavioral excitability (decreased acute seizure threshold). 
As such, an increase in soma area in SLC7A11+/+ females as compared to SLC7A11+/+ 
males may be important in maintaining an elevated acute seizure threshold in female 
SLC7A11+/+ mice. Of note, a slight decrease in SLC7A11+/+ male versus female acute 
seizure threshold was uncovered in Chapter 2 (Fig. 2.10), and as such, male mice 
required a lower acute PTZ (or KA) dose to uncover an E/I imbalance in SLC7A11sut/sut 
mice. Whether or not soma size is integrally linked to maintenance of E/I balance in 
females requires further investigation, including characterizing the abundance and 
strength of perisomatic inhibitory synapses using immunohistochemistry and 
electrophysiology, respectively.     
 If soma size correlates with E/I balance in female SLC7A11+/+ and SLC7A11sut/sut 
mice, does the same hold true for males? Our results indicate that soma size is similar 
in male SLC7A11+/+ and SLC7A11sut/sut sex-matched littermate controls. However, our 
results demonstrate that dendritic complexity is significantly decreased in SLC7A11+/+ 
male as compared to female mice on the C3H/HeSnJ background (Chapter 2, Fig. 2.3). 
Once again, to our knowledge, this is the first report of sex-differences in cortical layer V 
dendritic complexity in mouse. Furthermore, loss of Sxc- in male mice increases 
dendritic complexity as compared to SLC7A11+/+ sex-matched littermates, such that 
their complexity is indistinguishable from female mice (Chapter 2, Fig. 2.3). Thus – 
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similar to soma size – these findings raise the intriguing possibility that morphological 
sex-differences in dendritic complexity exist to maintain functional E/I balance. Given 
that enhanced dendritic complexity is associated with increased excitability (Klenowski 
et al 2016, Mainen & Sejnowski 1996), it is tempting to speculate that an increase in 
cortical dendritic complexity underlies the decreased seizure threshold in SLC7A11sut/sut 
male mice. Whether this morphological change is associated with enhanced neuronal 
excitability, such as increases in EPSC frequency or repetitive spikes, will require 
electrophysiological confirmation.  
 Given that Sxc--mediated cystine import provides cells with the rate-limiting 
substrate (cysteine) for synthesis of the thiol antioxidant GSH, we also explored whether 
alterations in levels of reduced and oxidized glutathione (GSH and GSSG) or cysteine 
(cysteine and cystine) could account for an E/I imbalance in SLC7A11sut/sut mice. 
Interestingly, the brains of SLC7A11sut/sut females (Supplementary Fig. S2), but not 
males (Chapter 3, Fig. 3.5), are under oxidative stress as demonstrated by elevated 
cortical GSSG and hippocampal cystine levels compared to sex-matched SLC7A11+/+ 
littermate controls. Given that increased levels of oxidants can decrease seizure 
threshold (Liang & Patel 2004), the cysteine prodrug N-acetylcysteine (NAC) was 
administered to female SLC7A11sut/sut mice and seizure threshold determined 
(Supplementary Fig. S3). Our results indicate that NAC administration over eight days 
does not increase SLC7A11sut/sut seizure threshold as compared to vehicle-administered 
SLC7A11sut/sut littermate controls, suggesting that the decreased acute seizure threshold 
in female SLC7A11sut/sut mice is not due to a redox imbalance. A potential caveat to this 
study includes the length of NAC administration, which may not have been extensive 
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enough to restore brain redox status. However, oral supplementation of NAC for seven 
days at the same dose used by our laboratory has been demonstrated to elevate brain 
thiol content in the excitatory amino acid transporter 3 (EAAC1) null mouse (Berman et 
al 2011). Conversely, in the case of the SLC7A11sut/sut mice, a balanced redox status 
may be required throughout development in order to properly establish E/I balance, 
especially if redox state influences other downstream effectors that ultimately confer E/I 
balance. One plausible example of redox status affecting E/I balance indirectly is 
through soma size: during periods of decreased protein synthesis, net loss of cellular 
protein results in somatic atrophy (Franklin & Johnson 1998). Interestingly, under 
periods of oxidative stress, shunting of cysteine from its role as a macromolecular 
building block to its incorporation into antioxidants, including GSH, is upregulated in 
order to confer cellular protection (Ratan et al 1994). As such, it is conceivable that a 
redox imbalance in female SLC7A11sut/sut mice facilitates cysteine shunting from protein 
synthesis to GSH synthesis, resulting in a reduction in soma size – and an associated 
decrease in inhibitory tone – and ultimately leading to a decrease in seizure threshold. A 
logical future direction is to administer NAC to female SLC7A11sut/sut mice throughout 
development, including in utero via dietary supplementation to the dam, to determine if 
this rescues cell body size and/or seizure threshold to that of SLC7A11+/+ sex-matched 
littermate controls.  
  
5.3 Delayed hypo-excitability in Sxc- null mice  
Despite hyper-excitability elicited in response to an acute dose of 
chemoconvulsant, SLC7A11sut/sut mice show behavioral signs of hypoexcitability upon 
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chronic administration of PTZ (Chapter 3, Fig. 3.1) or repeated administration of KA 
(Chapter 4, Fig. 4.3). Specifically, repeated daily injections of an initially sub-convulsant 
dose of PTZ ultimately leads to a permanent decrease in the threshold of excitability in 
SLC7A11+/+ mice (i.e., mice become kindled), whereas the percent SLC7A11sut/sut mice 
that kindle over the same 21 days is significantly lower (Chapter 3, Fig. 3.1). Similarly, 
SLC7A11+/+ mice attain status epilepticus (seizure score = 8) after repeated dosing with 
KA, whereas SLC7A11sut/sut mice become hypomobile (seizure score = 1) (Chapter 4, 
Fig. 4.3). These data suggest that Sxc- activity modulates synaptic strength in vivo in a 
context-dependent manner. 
In Chapter 3, PTZ-kindling was explored in male mice only, as the low seizure-
threshold in SLC7A11sut/sut females precluded our ability to carry out a kindling protocol 
(data not shown). Post-kindling, our results indicate that mossy fiber sprouting and 
cellular degeneration are unlikely to contribute to the decreased incidence of PTZ-
kindling in SLC7A11sut/sut mice, as neither reactive synaptogenesis nor cell loss were 
observed in mice of either genotype. Rather, it was postulated in Chapter 3 that 
decreased PTZ-kindling in SLC7A11sut/sut mice may be a result of hypo-glutamatergic 
signaling given that glutamate levels (McCullagh & Featherstone 2014) and basal 
plasma membrane expression levels of the glutamate receptor subunit GluA1 (Chapter 
3, Fig. 3.6) are diminished in male SLC7A11sut/sut mice. However, morphological 
parameters presented in Chapter 2 indicate that, despite decreased plasma membrane 
GluA1 levels, cortical synapses may indeed be strengthened in male mice given their 
increased dendritic spine head widths (Chapter 2 Fig. 2.7). These contradictory results 
could be explained by the fact that plasma membrane protein expression levels are not 
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indicative of synaptic protein levels as they incorporate receptors expressed in both 
synaptic and extrasynaptic regions. As such, it will be necessary to perform ex vivo 
electrophysiological brain slice recordings to directly measure synaptic strength in 
SLC7A11sut/sut mice.   
Chronic excitation elicited by PTZ-kindling (Kapur et al 1989a, Kapur et al 1989b, 
Schröder et al 1993) or status epilepticus (Friedman et al 1994, Goodkin et al 2005, 
Grooms et al 2000, Naylor et al 2013) is associated with alterations in neurotransmitter 
receptor mRNA or protein expression levels, with increases in glutamate receptor 
subunits GluN1 and GluA1 (Naylor et al 2013, Schröder et al 1993) or decreases in 
GluA2 (Grooms et al 2000) and GABAergic receptors (Goodkin et al 2005, Kapur et al 
1989a, Kapur et al 1989b) demonstrated. In order to determine whether alterations in 
repeated/chronic chemoconvulsant administration provoked changes in receptor 
expression levels, we assessed levels of glutamate (GluA1, GluA2, and GluN1) and 
GABA (GABAARa) receptor subunits in plasma membrane following repeated KA 
administration, chosen because the paradigm is complete after 240 min and likely 
provides qualitatively the same data as the 21-day PTZ-kindling paradigm. While no 
changes in glutamate or GABAA receptor subunits between female or male SLC7A11+/+ 
or SLC7A11sut/sut mice were detected, we did find that the behavioral response of male 
SLC7A11sut/sut mice within the final quartile of the dosing paradigm correlated with 
GABAARa expression levels: SLC7A11sut/sut males that became hypomobile had 
significantly increased plasma membrane GABAARa protein levels as compared to 
SLC7A11sut/sut males that entered into status epilepticus (Chapter 4, Fig. 4.10). Whether 
increases or decreases in GABAARa expression underlies male SLC7A11sut/sut 
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behavioral hypomobility or status epilepticus, respectively, requires further 
experimentation. Moreover, this change was not detected in female SLC7A11sut/sut mice 
(Chapter 4, Fig. 4.9), and the mechanism underlying their behavioral hypo-excitability in 
the face of repeated KA administration remains unexplained.     
The within-genotype change in GABAARa expression in male SLC7A11sut/sut 
mice notwithstanding, receptor expression levels are overwhelmingly similar in 
SLC7A11+/+ and SLC7A11sut/sut mice following the repeated KA dosing paradigm. 
However, just as with basal plasma membrane protein expression levels discussed 
earlier, a caveat to this study is plasma membrane measurements do not exclusively 
measure synaptic receptors. Thus, measuring synaptic activity via electrophysiology or 
measuring synaptic protein expression via immunohistochemistry will be important next 
step(s) in determining whether alterations in synaptic protein levels account for 
SLC7A11sut/sut behavioral hypo-excitability in the repeated/chronic chemoconvulsant 
dosing paradigms.  
  
5.4 Working model(s) to explain the dichotomy  
Synaptic scaling: Neurons detect fluctuations in extracellular glutamate levels 
and/or in synaptic drive and autonomously adjust the strength of their synapses up or 
down to stabilize firing via a process known as homeostatic synaptic scaling (Christie & 
Jahr 2008, Turrigiano 2008, Turrigiano et al 1998). This is largely accomplished through 
the addition and subtraction, respectively, of ionotropic AMPA receptors at the 
postsynaptic membrane (Turrigiano et al 1998, Wierenga et al 2005), although this can 
only occur within a modifiable range (Rioult-Pedotti et al 2007, Rioult-Pedotti et al 
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2000). For example, scaling-up of AMPA receptors to a “ceiling” results in an occlusion 
of processes dependent upon postsynaptic AMPA receptor membrane insertion, such 
as long-term potentiation (LTP) (Li et al 2016). Interestingly, hippocampal LTP is 
diminished in SLC7A11sut/sut mice and genetically engineered xCT nulls show deficits in 
hippocampal-dependent spatial learning – a process dependent upon postsynaptic 
AMPA receptor membrane insertion (De Bundel et al 2011, Li et al 2012). Moreover, 
both kindling-induced plasticity (Cain 1989, Goddard & Douglas 1975) and status 
epilepticus (Naylor et al 2013, Rice & DeLorenzo 1998, Rice et al 1998) share common 
mechanisms with LTP, including the insertion of postsynaptic glutamate receptors 
(Naylor et al 2013), a long-lasting increase in response to a constant stimulus (Cain 
1989), and the dependency of this response on NMDAR activation (Rice & DeLorenzo 
1998). Moreover, status epilepticus, and its subsequent epileptic sensitization, impaired 
performance of rats in the Morris water maze, suggesting that status epilepticus-
induced neuronal sensitization and learning share common mechanisms (Rice et al 
1998).  
Given that enhanced expression of synaptic AMPA receptors has been 
demonstrated in the hippocampus of transgenic xCT null mice (Williams & Featherstone 
2014), and that SLC7A11sut/sut males (but not females) have increased dendritic spine 
head widths as compared to SLC7A11+/+ littermate controls (Chapter 2, Fig. 2.7), it is 
tempting to speculate that male mice null for Sxc- may have AMPA receptors scaled-up 
to the apex of their modifiable range. This endogenous “scaling-up” in male 
SLC7A11sut/sut mice, perhaps a result of diminished ambient extracellular glutamate 
levels (De Bundel et al 2011, Massie et al 2011b, McCullagh & Featherstone 2014), 
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could explain their decreased acute seizure threshold. Conversely, repeated/chronic 
chemoconvulsant administration in a system already at the “ceiling” of its modifiable 
range could cause homeostatic scaling-down of glutamate receptors, explaining the 
reduced excitability of SLC7A11sut/sut mice in the PTZ-kindling and repeated KA-dosing 
paradigm. Given that enhanced dendritic spine head width was observed in cortical 
neurons derived from male – but not female – SLC7A11sut/sut mice, if the 
aforementioned mechanisms are driving the dichotomous excitability in SLC7A11sut/sut 
mice, they may be sex-dependent and present exclusively in males. In line with this, 
decreased ambient glutamate levels – that could plausibly evoke an endogenous 
“scaling-up” of glutamate receptors – have been reported in male (De Bundel et al 2011, 
Massie et al 2011b, McCullagh & Featherstone 2014) but not female (Borra et al 2014) 
Sxc- null mice. However, it should be noted that glutamate measurements were carried 
out in the striatum in SLC7A11sut/sut female mice (Borra et al 2014), and our dendritic 
spine head measurements were limited to the cortex (Chapter 2, Fig. 2.7). As such, it 
remains plausible that reduced glutamate levels or increased spine head width exist in 
other brain regions in female Sxc- null mice, especially given that Sxc- appears to 
contribute to ambient extracellular glutamate levels in a brain-region dependent manner 
(McCullagh & Featherstone 2014).  
 Redox balance: Alternatively, the dichotomous changes in excitability evoked by 
acute or repeated chemoconvulsant stimulus could be a result of a redox imbalance in 
SLC7A11sut/sut mice. Glutamate transporters and the NMDA receptor possess redox-
sensing properties that regulate their activity (Aizenman et al 1989, Köhr et al 1994, 
Sullivan et al 1994, Trotti et al 1997). Moreover, manganese superoxide dismutase 
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(SOD2+/-) mice with chronic mitochondrial oxidative stress have a decreased KA-
induced seizure threshold (Liang & Patel 2004). Given that female (but not male) 
SLC7A11sut/sut brains have elevated levels of oxidized GSH and cysteine, it is tempting 
to speculate that their reduced acute seizure threshold is a result of a redox imbalance.   
Furthermore, LTP is diminished in GSH-deficient rodents (Almaguer-Melian et al 
2000, Robillard et al 2011), and normalizing GSH levels can restore LTP (Robillard et al 
2011). These findings stress the importance of redox balance in the regulation of 
synaptic plasticity. Given the mechanistic similarities between LTP and the sustained 
excitation elicited by chemoconvulsants in vivo (Cain 1989, Goddard & Douglas 1975, 
Naylor et al 2013, Rice & DeLorenzo 1998, Rice et al 1998), it is plausible that a redox 
imbalance could thwart the progression of PTZ-kindling or KA-induced status epilepticus 
in SLC7A11sut/sut mice, thus explaining their hypo-excitability in these models. As a 
redox imbalance was observed in female (Supplementary Fig. S2) – but not male 
(Chapter 3, Fig. 3.5) – SLC7A11sut/sut mice, if the aforementioned mechanisms are 
driving the dichotomous excitability in SLC7A11sut/sut mice, they may be sex-dependent 
and present exclusively in females. 
 
5.5 Astrocytic maintenance of E/I balance  
As discussed in Chapter 1, there is now indisputable evidence, stemming from both 
transcriptome and immunohistochemical analyses, that astrocytes are the primary cell 
types expressing Sxc- in the mature brain in vivo (Ottestad-Hansen et al 2018, Pow 
2001, Zhang et al 2014). As the most numerous glial subtype in the CNS, astrocytes 
perform a number of well-characterized homeostatic support functions, including 
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maintenance of perivascular homeostasis and blood brain barrier integrity (Alvarez et al 
2013, Mathiisen et al 2010), K+ buffering (Orkand et al 1966), supplying neurons with 
energy substrates (Pellerin et al 1998) and neurotransmitter precursors (Bak et al 
2006), and glutamate uptake via EAATs [reviewed in (Danbolt 2001)]. With respect to 
the latter, astrocytic EAAT1 or EAAT2 knock-out mice demonstrate prolonged seizure 
duration in an amygdala kindling model (Watanabe et al 1999) or spontaneous 
electroencephalographic seizures (Tanaka et al 1997), respectively, highlighting the 
potent ways in which astrocytes regulate synaptic transmission. Additionally, more 
recent evidence implicates astrocytes in the positive and negative regulation of CNS 
synaptogenesis through their release of soluble factors such as thrombospondins 
(TSPs)-1 and -2 (Christopherson et al 2005), Hevin and SPARC (Kucukdereli et al 
2011), and glypicans 4 and 6 (Allen et al 2012). While the aforementioned functions 
render astrocytes capable of modulating synaptic transmission indirectly, astrocytes 
also play an active role at the synapse by both responding to (Ding et al 2013, Murphy-
Royal et al 2015) and releasing (Allen et al 2012, Guthrie et al 1999, Malarkey & 
Parpura 2008, Schell et al 1995, Schmitt et al 2012) neurotransmitters. Moreover, 
astrocytes are capable of modulating both Hebbian and homeostatic synaptic plasticity 
through their release of the NMDA receptor co-agonist, D-serine (Henneberger et al 
2010) and the cytokine TNF-a (Stellwagen & Malenka 2006), respectively.  
In light of the multitude of ways in which astrocytes participate in CNS activity, the 
findings presented in this dissertation support a growing theme for astrocytic 
transporters – including Sxc- – in maintenance of E/I balance. Given that elevated KA 
dosing induced hippocampal neural degeneration in a sub-region dependent manner in 
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SLC7A11sut/sut and SLC7A11+/+ littermate controls, our results also implicate Sxc- 
signaling in maintenance of hippocampal circuitry (Figure 4.7). Nevertheless, it is 
important to reiterate that the SLC7A11sut/sut mice used in this study harbor a global 
natural null mutation in the SLC7A11 gene. Given that Sxc- is predominantly astrocytic it 
is tempting to speculate that the results herein are a result of astrocytic Sxc- signaling.  
However, the cell type specificity of the observations reported in this dissertation will be 
necessary to confirm using an astrocyte conditional SLC7A11 null mouse. 
  
5.6 Future directions 
While the results presented in this dissertation demonstrate that Sxc- signaling 
regulates E/I balance in a context dependent manner, several future directions remain. 
Clearly, the dichotomy that was uncovered – that SLC7A11sut/sut mice are hyper-
excitable or hypo-excitable depending on the chemoconvulsant dosing paradigm – is an 
interesting finding that warrants further investigation. Electrophysiological brain slice 
recordings from naïve mice, as well as from mice exposed to the repeated/chronic 
chemoconvulsant dosing paradigms described herein, should be made in order to 
understand physiological parameters – including both inhibitory and excitatory post-
synaptic currents – driving neuronal activity that were potentially missed by our plasma 
membrane protein analysis. Electrophysiological slice recordings will also be informative 
to understand how the observed morphological alterations affect cell firing capacity. 
Furthermore, although our results indicate that NAC supplementation in female 
SLC7A11sut/sut mice – whose brains are under oxidative stress – does not increase their 
acute PTZ seizure threshold, a future direction includes supplementation with NAC 
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throughout their lives in order to thwart changes that might occur early in development 
that confer an E/I imbalance. Additionally, developmental NAC supplementation, as well 
as its continued supplementation throughout the repeated/chronic dosing paradigms, 
would be an interesting study to pursue in both females and males in order to determine 
if hypo-excitability observed therein is a result of oxidative stress. Finally, as mentioned 
above, in order to confirm the cell type specificity of the findings presented in this 
dissertation, it would be necessary to confirm our findings using an astrocyte conditional 
SLC7A11 null mouse. 
  
5.7 Significance 
The purpose of this dissertation research was to investigate whether and how 
Sxc- signaling contributes to E/I balance in vivo. This line of inquiry was of interest given 
that an E/I imbalance is implicated in numerous neurological disorders (Gao & Penzes 
2015, Nelson & Valakh 2015) and disease states (Foerster et al 2013, Fritschy 2008, 
Lai et al 2014, Ren et al 2018, Snyder et al 2005). The findings presented herein that 
loss of Sxc- thwarts the progression of excitability upon repeated/chronic 
chemoconvulsant application, including in a model of epileptogenesis, suggests that 
inhibition of Sxc- signaling may be a therapeutic option in individuals suffering from an 
E/I imbalance, such as those prone to develop epilepsy as a result of traumatic brain 
injury or glioblastoma. However, these results should be interpreted with caution given 
that loss of Sxc- also results in acute hyper-excitability. Thus, whether the acute hyper-
excitability phenotype uncovered in SLC7A11sut/sut mice is a result of a developmental 
change or whether acute pharmacological inhibition of Sxc- elicits a similar acute hyper-
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excitability needs to be determined prior to consideration of Sxc- targeting as a 
therapeutic option for individuals suffering an E/I imbalance.  
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Supplementary Figures 
 
 
Supplemental Figure S1: Acute PTZ dose response curve in female and male 
SLC7A11+/+ and SLCA11sut/sut mice 
(A) Male SLC7A11+/+ (+/+; n = 3-29) and SLC7A11sut/sut (sut/sut; n = 3-37) or (B) female 
SLC7A11+/+ (+/+; n = 3-21) and SLC7A11sut/sut (sut/sut; n = 3-26) littermates were 
administered a single dose of PTZ (i.p.), after which behavior was monitored for 20-30 
min. Seizure severity was scored using a 5-point scale as described in Chapter 2 
materials and methods. Dose of PTZ (25-63 mg/kg) is expressed as log [PTZ], M. 
Symbols represent the mean maximal seizure score for +/+ (closed black circles) and 
sut/sut (open circles) mice during the 30 min observation period.  
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Supplemental Figure S2: Effect of SLC7A11 disruption on hippocampal and 
cortical reduced/oxidized glutathione and cysteine levels in female mice 
Naïve female SLC7A11+/+ (+/+; n = 5) and SLC7A11sut/sut (sut/sut; n = 6) littermates were 
sacrificed by transcardial perfusion with ice-cold phosphate buffered saline and the left 
(A-F) hippocampus or (G-L) cortex rapidly dissected and snap-frozen in liquid nitrogen. 
The concentration of reduced and oxidized glutathione (GSH and GSSG) or cysteine 
(Cys and CySS) was determined by high performance liquid chromatography (HPLC) as 
described in Chapter 3 Materials and Methods. GSH, GSSG, Cys, and CySS levels 
were compared using an unpaired t test whereas GSH/GSSG or Cys/CySS ratios were 
compared using a Mann Whitney U test.   
A-L) Bars [black bar (+/+) and open bar (sut/sut)] represent the mean µmoles/g tissue ± 
SEM of GSH (A and G), GSSG (B and H), Cys (D and J), CySS (E and K), or the ratio 
of GSH/GSSG (C and I) or Cys/CySS (F and L) in (A-F) hippocampus or (G-L) cortex. 
*Sut/sut female mice have a decreased hippocampal Cys/CySS ratio (p = 0.03; Mann-
Whitney U test) and elevated GSSG levels (p = 0.01; unpaired t test) as compared to 
+/+ littermate controls. 
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Supplemental Figure S3: Female SLC7A11sut/sut hyper-excitability is not rescued 
by administration of N-acetylcysteine 
Naïve female SLC7A11sut/sut (sut/sut) littermates were administered 2-3 mg/ml of the 
cysteine prodrug N-acetylcysteine (NAC) (n = 9) or vehicle (water) (n = 9) ad libitum for 
eight days. On days 4-8, animals were acclimated to handling by performing mock daily 
intraperitoneal (i.p.) injections which consisted of inverting the mouse and rubbing its 
abdomen. On day nine, mice received a single dose of 42 mg/kg PTZ (i.p.). Seizure 
behavior was scored using a 5-point scale as described in Chapter 2 Materials and 
Methods. Data were pooled from three independent experiments performed over three 
months.  
A) Seizure Scores: Each data point represents the maximal seizure score obtained by 
an individual female mouse during a 30 min observation period. Horizontal lines 
represent the median seizure score for each treatment. Seizure severity was compared 
using the Mann-Whitney U test.  
B) Convulsive index: Bars represent the proportion (fraction within bars) of mice that 
experienced a convulsive seizure (seizure score ≥ 3) in A expressed as a % of total 
mice exposed to PTZ. Convulsive incidence was compared using Fisher’s Exact test. 
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Supplementary Figure S4: Comparison of plasma membrane protein expression 
in female SLC7A11+/+ and SLC7A11sut/sut mice 
Plasma membrane protein levels in hippocampus or cortex derived from female 
SLC7A11+/+ (+/+) or SLC7A11sut/sut (sut/sut) littermates were compared using Western 
blot analysis exactly as described for male mice in Chapter 3 Materials and Methods. 
Each data point [closed black circles (+/+; n = 7-9) or open circles (sut/sut; n = 5-9) 
represents the level of hippocampal (B) or cortical (C) protein following normalization to 
their respective loading control (i.e., Na+/K+ ATPase levels). Bars indicate the mean fold 
change over control (+/+), which was set to one. Hippocampal or cortical plasma 
membrane protein expression levels were compared using an unpaired t test on log-
transformed data. An asterisk (*) represents a significant between group difference (p = 
0.0160).  
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Fellowship awarded to attend the ISN-JNC Flagship School ($900 + full-board 
accommodation) in Alpbach, Austria by the International Society of Neurochemistry-
Journal of Neurochemistry (ISN-JNC). 
 
September 2016   
  
   
Best Graduate Student Poster Presentation, Neuroscience Research Day, Syracuse 
University 
 
April 2016   
   
Travel fellowship recipient ($1100), awarded by the Syracuse University Graduate 
Student Organization ($600) and Neuroscience Program ($500) to attend the 47th 
Annual American Society for Neurochemistry meeting in Denver, CO.  
 
March 2016   
  
   
Travel fellowship recipient ($350), awarded to attend the 45th Annual Society for 
Neuroscience meeting in Chicago, IL by the Biology Department, Syracuse University.  
 
October 2015   
  
   
Admitted into the Women in Science and Engineering Future Professionals 
Program (WiSE-FPP), Syracuse University 
 
8/2015 - 8/2017   
   
Attendee of "Workshop in Surgical Techniques in the Laboratory Mouse," held by 
the Jackson Laboratories in Paris, France.  
 
6/24–6/27/2014   
   
Dean’s List, University of California, Santa Barbara.  
 
2008/2012           
Publications    
Schaefer N, Rotermund C, Blumrich E, Lourenco M, Joshi P, Hegemann R, Jamwal S, Ali N, Garcia Romero 
Ezra, Sharma S, Ghosh S, Sinha J, Loke H, Jain V, Lepeta K, Salamian A, Sharma M, Golpich M, Nawrotek K, 
Kumar P, Shahidzadeh S.M., Piermartiri T, Amini E, Pastor V, Wilson Y, Adeniyi P, Datusalia A, Vafadari B, 
Saini V, Suarez-Pozos Edna, Kushwah N, Fontanet P, Turner A. (2017). The malleable brain: plasticity of neural 
circuits and behavior – A review from students to students. Journal of Neurochemistry. 142 (6): 790-811.  
Shahidzadeh, S.M., Hewett, JA, and Hewett, SJ. Decreased epileptogenesis in mice lacking the System xc- 
transporter occurs in association with a reduction in AMPA receptor subunit GluA1. Submitted.     
Shahidzadeh, S.M., Hewett, JA, and Hewett, SJ. Sex differences in redox environment and neuronal 
morphology occur in association with enhancement of excitability in system xc- null mice. In prep.  
         
Presentations    
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Invited talks 
      
"Altered brain excitability in system xc- null mice", Mclaughlin Research Institute, Great 
Falls, Montana  
 March 2018 
     
"Altered CNS excitability in system xc- null mice uncovered using the kainic acid model 
of status epilepticus", Astrocyte-neuron regulation of excitatory signaling workshop at 
the American Society for Neurochemistry meeting in Denver, Colorado.  
March 2016   
  
  
   
Posters       
Shahidzadeh S.M., Hewett J.A., Hewett S.J. Sex differences in redox environment and neuronal morphology 
occur in association with enhancement of excitability in system xc- null mice. Presented at the American Society 
for Neurochemistry Meeting in Riverside, CA. March 2018.    
Shahidzadeh S.M., Hewett J.A., Hewett S.J. Altered neuronal excitability in system xc- null mice in vivo 
uncovered by chemoconvulsant challenge. Presented at the International Society for Neurochemistry Biennial 
Meeting in Paris, France. August 2017. 
   
Shahidzadeh S.M., Hewett J.A, Hewett S.J. System xc- null mice are resistant to pentylenetetrazole kindling. 
Presented at the Society for Neuroscience Meeting in San Diego, CA. November 2016.    
Shahidzadeh S.M., Hewett J.A, Hewett S.J. Altered CNS excitability in system xc- null mice uncovered using 
the kainic acid model of status epilepticus. Presented at the American Society for Neurochemistry Meeting in 
Denver, CO. March 2016.    
Shahidzadeh S.M., Hewett J.A, Hewett S.J. Role of system xc- in the pentylenetetrazole model of temporal lobe 
epilepsy. Presented at the Society for Neuroscience Meeting in Chicago, IL. October 2015. 
         
Teaching Experience    
Lecturer, Biology Department, Syracuse University, Syracuse, NY 
“Synaptic Plasticity” Advanced Neuroscience course. Syracuse University. (2017-2018, yearly). 
“The Blood Brain Barrier” Advanced Neuroscience course. Syracuse University. (2015-2017, yearly).    
Teaching Assistant, Biology Department, Syracuse University, Syracuse, NY 
Introduction to Biology (BIO 121); two semesters. (Fall 2013/2014). 
Anatomy and Physiology I and II (BIO 216); two semesters. (Spring 2014/fall 2015). 
Biology of Adaptive Behavior (BIO 414); one semester. (Spring 2015). 
Developmental Biology (BIO 504); two semesters. (Spring 2016/17). 
Cell Biology (BIO 327); one semester. (Fall 2016). 
Advanced Neuroscience (BIO 407/607); three semesters. (Spring 2015/16/17). 
         
University Service    
Ad hoc Reviewer, Brain Research, (May 2017 – Present).    
Ad hoc Reviewer, Neurochemistry International, (February 2018 – Present).    
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Graduate Representative, Graduate Recruitment Committee, Biology Department at Syracuse University  
(May 2016 – May 2017).    
Graduate Scientific Member, Institutional Animal Care and Use Committee (IACUC) at Syracuse University 
(June 2016 – September 2018).     
Vice President, Biology Graduate Student Organization (BGSO), Syracuse University (2014 – 2016).    
Vice President, National Society of Collegiate Scholars, UCSB Chapter (2010-2012). 
         
Professional Training    
Postdoctoral Tenure-Track Boot Camp, sponsored by Women in Science and Engineering at Syracuse 
University. June 2018.    
Future Professoriate Program (FPP) Workshop, sponsored by Syracuse University FPP, White Eagle 
Conference Center, New York. May 2017.    
Astrocyte-Neuron Regulation of Excitatory Signaling Workshop, the 47th ASN meeting, Denver.   March 
2016.    
Neurobiology of Disease Workshop, the 44th SfN meeting, Washington, DC. November 2014.    
Workshop on Surgical Techniques in the Laboratory Mouse, The Jackson Laboratory, Paris, Fr. June 
2014.  
         
Professional Associations     
Member, American Society for Neurochemistry, 2016 - Present      
Member, International Society for Neurochemistry, 2016 - Present    
Member, Institutional Animal Care and Use Committee, 2016 - Present     
Member, Women in Science and Engineering Future Professionals Program, 2015 - Present    
Member, Society for Neuroscience, 2014 - Present     
Member, Biology Graduate Student Organization, 2013 - Present    
National Society of Collegiate Scholars, UCSB Chapter, 2010 – 2012    
Psi Chi National Honor Society in Psychology, UCSB Chapter, 2010 – 2012 
 
Technical Skills    
Animal behavioral studies including the kainic acid model of status epilepticus, pentylenetetrazole kindling 
model of epileptogenesis, and chemoconvulsant induced acute seizures. 
   
Transcardial perfusion of rodents and tissue (brain) sectioning.    
Histochemical staining and stereological analysis; Golgi-Cox stain, Timm stain, Nissl stain, and Fluorojade-C 
stain.    
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Primary cell culture (purified neurons and astrocytes).    
q-PCR, Western blot, and immunohistochemistry    
Skilled in major professional software (Word, PowerPoint, Excel, EndNote, Photoshop) as well as GraphPad 
Prism, Adobe Illustrator, and ImageJ (NIH). 
 
 
